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Abstract
Recent advances in ’omics technologies and the development of new compu-
tational techniques have greatly contributed to the identification of factors
influencing the onset and progression of many common diseases. Yet, despite
this great success, it is unlikely that the independent analysis of these data
will elucidate the complex web of mechanisms involved in disease develop-
ment. To enhance our knowledge of disease aetiology, new approaches for
linking the large amount of available data need to be developed.
As a step towards this goal, the aim of this thesis is to investigate and
develop novel statistical methods for the integrative analysis of ’omic data.
In particular, in this project we analyse genomic and metabolomic data in
relation to the health outcomes in three study populations. To investigate
how genetic and metabolic variables act as risk factors in the development of
complex disorders, we have developed three novel analytical methodologies,
namely ’Differential Network’, ’GEMINi: GEnome Metabolome Integrated
Network analysis’ and ’Variance and Covariance regression’ and illustrate
their use on real data sets.
The results demonstrate the applicability of the new methodologies to
identify key molecular changes undetectable with standard approaches. The
approaches introduce here have the potential of providing insight into the
biological basis of phenotypic variation and aid the generation of new hy-
potheses about molecular control and regulation in the context of systems
biology.
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Summary
The major goal for modern biomedicine is to elucidate the complex web of
interactions through which genes and their products, in combination with
environmental factors, influence the onset and progression of many complex
disorders. The knowledge of mechanisms is expected to be translated into
clinical settings to improve prediction of individuals’ disease risk and develop
better and more personalized treatments for complex diseases.
The development of high throughput technologies for assaying molecu-
lar characteristics of biological systems has been transforming biomedical re-
search for the past decade. Molecular profiling technologies such as single nu-
cleotide polymorphism (SNP) arrays, gene expression microarrays and high-
throughput metabolomics provide a wealth of information about molecular
changes underlying diseases development. For example, SNP datasets have
aided the identification of genetic variants strongly associated with the risk of
disease development. Similarly, the rapidly developing field of metabolomics
has made remarkable progress in understanding metabolic changes as re-
sponse to genetic modifications and environmental stimuli.
While separated analysis of these different types of data has provided
valuable information, it is unlikely that considering these data sets indepen-
dently will uncover the complex web of biological mechanisms involved in
disease development. To enhance our knowledge of mechanisms involved in
disease aetiology, as well as facilitate the prediction of (patho)physiological
status more accurately, systems-based approaches for analysing biological
data is becoming crucial.
As a step towards this goal, the aim of this thesis is to investigate and
develop novel statistical methods for the integrative analysis of metabolomic
and genomic data. In particular, in this project we analyse and combine
genetic and metabolic information in relation to the health outcomes in the
17
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three study populations. We begin by examining the genetic basis of varia-
tions in serum metabolite levels. For that purpose, three different statistical
approaches, namely, single-SNP, multiple-SNP and multiple responses, are
applied. Secondly, we investigate the use of changes in molecular associ-
ations to identify key differences between (patho)physiological states. We
present a novel statistical approach for the differential analysis of molecular
associations and illustrate its application in the context of diabetic dyslipi-
demias. Thirdly, we apply the differential network approach to an integrative
genome-metabolome analysis and investigate the potential use of variations
in association between different molecules as an alternative phenotype to
uncover genetic variants involved in complex biological processes. We re-
fer to this statistical analysis as GEMINi: GEnome Metabolome Integrated
Network analysis. Finally, we propose to employ Bayesian hierarchical mod-
els to investigate changes in mean levels and variances of metabolic traits as
response to environmental stimuli. We further investigate changes in corre-
lation between metabolites in relation to these covariates.
Following these integrative approaches, we expect to uncover hidden as-
pects of the combined genetic and metabolic variables’ contribution to the
development of complex disorders. This will aid the generation of new hy-
potheses about molecular control and regulation in the context of systems
biology.
Main Achievements of This Thesis
In this research project, we introduce three novel analytical methodologies
for the comprehensive analysis of metabolic data in combination with SNP
data. Their application is shown on real data sets. They can be summarized
as follows:
The Differential Network approach is a formal statistical method for
the differential analysis of molecular associations via network representation.
GEMINi: GEnome Metabolome Integrated Network analysis is a novel
analytical approach which exploits differences in molecular associations to
uncover genetic variants involved in phenotype variation.
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The Variance and Covariance regression is a new analytical proce-
dure based on Bayesian hierarchical models that allows the investigation of
continuous changes in mean level, variance and correlation of metabolic traits
in relation to covariates.
Thesis Outline
Chapter 1 - Genomics and Metabolomics: In this chapter we pro-
vide an introduction to the two main areas of research covered by this the-
sis: Genomics and Metabolomics. We review basic definitions and key con-
cepts used in the area of research. Moreover, applications of genomics and
metabolomics in biomedical research are reviewed.
Chapter 2 - Data Sets: In this chapter we describe the materials used
in this thesis. Firstly, we present the three study populations investigated
in this thesis. Brief description of the data collection and design is also pro-
vided. The two types of ’omic data investigated in this work are described
in this chapter. Details of analytical platforms experimental design and pro-
tocols are also covered. Moreover, we provide a biological background of the
main metabolites investigated.
Chapter 3 - Statistical Methods in Genome-Wide analysis: In
this introductory chapter we focus on investigating the genetic basis of serum
metabolite traits. Consequently, three different statistical approaches for
genome-wide association analysis, namely, single-SNP, multiple-SNP and
multiple responses, are applied.
Chapter 4 - Differential Networks: Here, we investigate the use of
changes in molecular association to identify key differences between (patho)
physiological states. We present a novel statistical approach for the dif-
ferential analysis of molecular associations. Firstly, a simulation study is
performed with the aim of assessing the performance of the proposed differ-
ential networks at identifying differences in molecular associations between
20
two different groups. Subsequently, we show the application of the differen-
tial network approach in the context of diabetic dyslipidemias.
Chapter 5 - GEnome Metabolome Integrated Network analysis:
In this chapter, we apply the differential network approach to an integrative
genome-metabolome analysis and investigate the potential use of variations
in association between different molecules as an alternative phenotype to un-
cover genetic variants involved in complex biological processes. We refer to
this statistical analysis as GEMINi: GEnome Metabolome Integrated Net-
work analysis.
Chapter 6 - Variance and covariance regression: In this chapter,
the focus is on investigating continuous changes in metabolic traits as re-
sponse to pathogenic stimuli. In particular, we propose to employ Bayesian
hierarchical models to investigate changes in mean levels, variance and corre-
lation of metabolic traits in relation to covariates. To illustrate our approach
we investigate changes in urinary metabolic traits in response to cadmium
exposure, a toxic environmental pollutant.
Chapter 7 - Conclusions and future work: In the last chapter we
draw conclusions on the results obtained in the thesis and we outline some
possible future research directions.
Chapter 1
Genomics and Metabolomics
In this chapter we provide an overview of the two main areas of research
covered by this thesis: Genomics and Metabolomics. A full review of the
entire field of genomics and metabolomics is beyond the scope of this project,
therefore the aim of this chapter is to provide a brief review of key concepts
and methodological aspects underlying these two research areas. Current
applications of genomics and metabolomics to the study of complex traits and
diseases will be covered in more detail, highlighting some of their strengths
and limitations. In the last part of this chapter we present a number of
examples that illustrate how by integrating metabolomics with genomics,
studies can gain in power and provide a deeper understanding of mechanisms
underlying complex traits.
1.1 Genomics
Genomics is a relatively new scientific discipline which focuses on the global
analysis of genes, examining not only the role but also the interplay between
genes and the interaction of genes with the organism’s environment. The
field of genomics is a very broad area of research ranging from structural
genomics to functional genomics. In this thesis we focus on genome-wide
association studies (GWAS) and their application to elucidate the genetic
structure of human complex traits.
21
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1.1.1 The human genome
The term genome refers to the complete set of the genetic material of an
organism, which is essential for its correct functioning and survival. In hu-
mans, each copy of the genome is constituted of approximately 3 billion base
pairs (bp) of deoxyribonucleic acid (DNA), stored in 23 chromosome pairs
in the cells’ nucleus. An individual inherits one chromosome per pair from
the mother and the other copy from the father. In addition to the nuclear
DNA, there is also a small proportion of circular DNA (cDNA) stored in
mitochondria, which is inherited only from the female line.
The information carried in the DNA is stored as a code made up of
chemical building blocks called nucleotides. Nucleotides are made of three
components: a phosphate group, a sugar group and one of four types of
nitrogenous bases known as adenine (A), thymine (T), guanine (G) and cy-
tosine (C) (Figure 1.1.a). The most common form of DNA consists of two
twisted strands that run in opposite directions to each other, so-called the
double helix (1) (Figure 1.1.b). The base-pairing rules in this form of DNA
specify that adenine pairs with thymine and guanine pairs with cytosine
(Figure 1.1.a). The DNA sequences that contain instructions to code for a
particular protein (amino acid sequences) or with a particular function (e.g.
regulatory) are called genes, which are unevenly distributed across the chro-
mosomes (Figure 1.1.c).
The specific location of a gene or DNA sequence in a chromosome is
known as locus. Genes are divided into two types of DNA sequence: exons
and introns. An exon is the portion of DNA in a gene that codes for proteins
whereas intron refers to the gene sequence that do not code for proteins.
It is estimated that the number of protein-coding genes is about 20,000 to
25,000, which represents around the 1.5% of whole genome (2). Although the
majority of this genetic material has no known biological function, much of
it is expected to be involved in transcriptional and translational regulatory
functions (3).
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Figure 1.1: A graphic illustrating the topographical levels of human
genome. From a) nucleotide sequence progressively folding as b) DNA double
helix, c) genes, d) chromosome and finally the e) genome in the cells’ nucleus.
Figure taken and modified from Riverside Health System’s webside. (Original
URL: http://www.riversideonline.com/health reference/Tools/DS00549.cfm)
1.1.2 Human genetic variations
While the human genome is largely similar among different individuals -
99.9% of one individual DNA sequence is identical to that of another indi-
vidual - there are still a few variations. The genomes of two non-related
subjects are estimated to differ about 1 in every 1,200-1,500 bases (4). There
are, therefore, more than three million differences between different individ-
uals’ genomes. Each version of a DNA sequence in a given locus is called
an allele. The complete set of alleles (genetic makeup) of an individual is
defined as a genotype.
Genetic variations can be introduced into our genome through two main
events: recombination and mutation. Recombination is the major force for
generating genetic variation. It is a common phenomenon through which
two chromosomes exchange segments of nucleotide sequence, resulting in the
production of a new DNA molecule. This shuﬄing of alleles varies between
individuals and across different locations within the human genome (5). The
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second most important force that generates genetic variations is genetic mu-
tation. A mutation occurs when the nucleotide sequence of a DNA molecule
is altered. It can occur at random regions across the entire genome at any
time and in any body cell. The estimated rate of mutation in humans is 2.5−8
per nucleotide site per generation (6). Mutations can be classified according
to their phenotypic effect as silent or functional mutations. The majority of
mutations are functionally silent, that is, no phenotypic effect is observable
(7). This can happen either because a mutation has occurred in a non-coding
or non-regulatory region with no biological function or because the variation
in DNA sequence does not impair the final amino acid sequence. On the
other hand, when a functional mutation occurs, it is usually associated with
phenotypic changes such as morphological, biochemical, loss/gain of func-
tion. A single mutation can have a large effect (e.g. lethal mutation), but
in most of the cases, phenotypic changes are based on the accumulation of
multiple mutations with only small effects.
Genetic variants can also be discussed in terms of the frequency of their
minor allele (less frequent allele) as common or rare variants in a specific
population. The term ‘common genetic variants’ is generally taken to mean
genetic variants with a minor allele frequency (MAF) of 5% or more in a
population. The most common type of variants are single nucleotide poly-
morphisms (SNP). This type of genetic variant represents the substitution
of a single nucleotide by another (Figure 1.2.a). It is estimated that SNPs
make up about 90% of all human genetic variation and occur every 100 to
300 bases. Since the human genome has approximately 3 billion base pairs, it
has been estimated that there are approximately 11 million SNPs across the
entire genome, of which 7 million have a MAF> 5% (8). Other types of mu-
tations are structural variations (macromutations) which are rarer than SNPs
but alter a larger region in the genome. Examples of structural variations are
deletions (Figure 1.2.b), duplications (Figure 1.2.c), inversion (Figure 1.2.d),
substitution (Figure 1.2.e) and translocation (Figure 1.2.f) of large blocks of
DNA sequence. A form of structural genetic variation that has increasingly
gained attention in genetic studies is copy number variation (CNV)(9).
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Figure 1.2: A graphical representation of genetic variations. Top panel
represents the difference between two DNA molecules at a single base-pair location.
Bottom panel illustrates a number of structural variations including deletions,
duplications, inversions, substitution and translocations of large blocks of DNA
sequence. Image taken and modified from National Human Genome Research
Institute glossary.
1.1.3 The structure of variations in the human genome
Due to their abundance, the most commonly used variants are SNPs. Most
SNPs are exploited as genetic markers, that is, genetic variants strongly as-
sociated with the true causative genetic variant. The statistical measure that
defines association between genetic variants is called linkage disequilibrium
(LD) (10). Specifically, LD describes a phenomenon through which some
combinations of alleles occur together more often than expected by chance,
based on their allele frequencies in the population. This phenomenon occurs
either because there is a low recombination rate between two loci or be-
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cause one (or both) of the alleles arose recently (11). The linear combination
of closely linked alleles (generally at adjacent locations) on a chromosome
and transmitted together are known as haplotypes. Overall, the genome LD
structure can be summarized as a series of regions within which alleles are in
strong LD (cold recombination spots) separated by short discrete regions of
very low LD (hotspots). In regions of low recombination frequencies, there
is a limited number of haplotypes (haplotype blocks) (12).
The information provided by LD and haplotype blocks can be used to
generate genetic maps of variants were genotyped SNPs act as direct proxies
to other untyped but highly correlated SNPs.
1.1.4 Genome-wide association studies
During the last decade there has been considerable effort devoted to the
identification of genetic variants that underlie complex phenotypes. With
the development of high throughput genotyping technology and SNPs refer-
ence maps (13, 14, 15, 16), the genome-wide association (GWAS) approach
has become a powerful tool to investigate the genetic basis of complex traits
(17). In GWAS studies typically hundreds of thousands of genetic variants
are scanned across the entire genome of thousands of individuals to find
genetic regions that are associated with a trait of interest. An important
feature of GWAS studies is that they follow a hypothesis-free design, that is,
all SNPs are assessed for association without focusing on loci whose biology
suggests that a relationship to trait is likely.
The GWAS method relies on the assumption that common variants (with
MAF > 5%) are strong candidates for being responsible for most of the ge-
netic contribution to complex traits variability, each of them exerts a small-
to-modest effect size (“Common Disease-Common Variant” hypothesis).
However, the question of whether disease risk can be explained by these
common variants, detectable by GWAS, or is mainly determined by more
rare variants with frequency lower than 1% , still remains unanswered (18).
The power to detect genetic variants with weak effect sizes is contingent
upon a number of factors which include the sample size of the study pop-
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ulation, genome coverage and the strength of LD between the markers and
causal variants. The application of appropriate statistical approaches can
also have important impact on the detection of significant SNP-phenotype
associations. While a number of statistical methods have been proposed for
analysing genome-wide data, the per-SNP-per-phenotype approach still dom-
inates the literature. Based on this approach, association between genetic
variants and a trait of interest is tested considering only one SNP at a time.
SNPs that do not pass the cut-off for significance are discarded. Those SNPs
that show a significant association with the traits are generally tested again
in an independent dataset. The SNPs that remain significantly associated
with the trait are taken as potentially causal variants or if not, at least as a
proxy for the true causal variant. Under the univariate approach each tested
SNP constitutes a separate hypothesis test, therefore the statistical signifi-
cance threshold needs to be corrected to reduce the chance a false positive.
The most accepted threshold for significance in GWAS is P < 5×10−8 which
is equivalent to a per-test α = 0.05 after a Bonferroni correction for 1 million
independent tests (19). With the application of such a stringent cut-off for
significance, very strong association between genetic variants and the traits
under study should be identified.
Since the first GWAS study published in 2005 (20), more than 200 com-
plex diseases and traits have been studied by GWAS and hundreds of genetic
variants have been identified (21). In Figure 1.3 we show a graphical rep-
resentation of genetic variants identified by GWAS for obesity and type 2
diabetes (T2DM).
Despite the success of GWAS at identifying genetic variants associated
with complex traits, the major challenge now is how to translate these results
into clinical settings. It is important to bear in mind that currently GWAS
studies only provide information about statistical association between a ge-
netic variant and the trait of interest which does not necessarily infer causal
relationship to the outcome. Several strategies have been proposed to im-
prove the biological interpretation of GWAS findings. One approach that
is gaining popularity is the use of molecular phenotypes such as metabolic
profiling in combination with GWAS. It has been suggested that detecting
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Figure 1.3: Graphical representation of genetic variants identified by
GWAS for obesity and type 2 diabetes (T2DM). Genetic variants as-
sociated with the traits of interest are shown by their location on each of the
23 human chromosomes. Image was taken and modified from National Human
Genome Research Institute: Catalogue of published Genome-Wide association
studies (http://www.genome.gov/gwastudies/).
genetic variants associated with molecular phenotypes may provide more
detailed information about the specific mechanism involved in disease de-
velopment, generating in this way a causal link between genes and disease
traits.
1.2 Metabolomics
Metabolomics (22), also known as metabonomics (23) or metabolic profiling,
is defined as the comprehensive, qualitative and quantitative study of the
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repertoire of small molecules. Specifically, metabolomic research combines
the application of spectroscopic technology with multivariate statistics to
investigate the metabolic composition of cells, tissues or biofluids as well as
to gain an overall understanding of how metabolites levels change in response
to genetic and environmental stimuli. During the last decade, metabolomics
has grown in popularity and has been applied in a wide range of research
areas. In biomedical science, metabolomics has been demonstrated to be a
valuable tool to elucidate mechanisms underlying disease development.
1.2.1 The human metabolome
Metabolites (biomolecules less than 1.5 kDa in size) are the intermediate
and end products of all cellular activities and play critical roles for the cor-
rect functioning of the cell. They act as building blocks of many cellular
components (e.g. phospolipids), provide energy (e.g. triglyceride) and play
active roles in cell signalling and regulation. The full suite of small-molecule
metabolites to be found in a biological sample (cell, tissues, or fluids) in a
particular physiological or developmental state is known as the metabolome
(22). The metabolome of an organism - its metabolic composition, concen-
tration and fluxes - is closely related to and highly affected by its genotype,
physiological state and environment (Figure 1.4). Because variations at any
level of the biological system are reflected as changes at the metabolic level,
the metabolome represents the most integrative profile of biological state. As
result, the analysis of the metabolome serves as a link to investigate inter-
actions between the genotype and phenotype as well as to provide a direct
read-out of the physiological status of organisms.
1.2.2 Analysis of the metabolome
Due to the large diversity of biochemical species (e.g. ionic inorganic, hy-
drophilic carbohydrates, hydrophobic lipids) that form the metabolome and
differences in composition between biosamples, it is not currently possible to
analyse the entire metabolome using a single analytical method. The most
commonly used analytical techniques for data acquisition in metabolomics
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Figure 1.4: Graphical representation of flow from the genetic code
(DNA) to metabolites. The environment and DNA affect the end products
and influence health disease states. Figure reprinted by permission from Macmillan
Publishers Ltd: Neuropsychopharmacology, Kaddurah-Daouk, R. and Krishnan,
K. R., Metabolomics: A Global Biochemical Approach to the Study of Central
Nervous System Diseases, copyright (2009) (24))
are Mass Spectrometry (MS) and Nuclear Magnetic Resonance (NMR). The
principles and properties of these two techniques are very different, how-
ever they are also complementary instruments and are often used in parallel.
MS is based on the principle of ions separation according to their mass-to-
charge ratio and is a very powerful method for screening large number of
metabolites with great sensitivity, providing a great metabolome coverage.
MS generally requires cleaning and separation steps prior to analysis, which is
usually done using high-performance liquid or gas chromatography. Nuclear
Magnetic Resonance (NMR) spectroscopy is an non-destructive analytical
technique used for determining the content of a sample as well as its molec-
ular structure, both in vitro or in vivo. NMR-based metabolomics is used
to detect metabolites that contain atomic nuclei with a nuclear spin, that is,
atomic nuclei that resonate (spin) when an external magnetic field is applied.
Example of these compounds are 1H, 13C, 15N. Protons (1H) are one of the
most used nuclei for NMR magnetic spectroscopy because they are present
in nearly all naturally occurring compounds.
Broadly speaking, analytical approaches for metabolomic analysis can
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be placed in two main categories - targeted and untargeted. Untargeted
metabolomics is used for the global analysis of all metabolites in a sam-
ple including known or unknown compounds. The main aim is to achieve
specific fingerprints or metabolic patterns that differentiate samples from dif-
ferent biological origins or treatments. Targeted metabolomics on the other
hand focuses on the identification and quantification of a selected group of
pre-defined metabolites, that belong to a specific class of compounds such
as carbohydrates or amino acids. Because such a set of targeted metabolites
are chemically known, it is possible to quantify their absolute concentra-
tions by comparing the biosample spectrum to internal standard compound.
Once the compounds have been identified and quantified, classical statisti-
cal methods such regression models or correlation analysis can be applied to
draw biological conclusions.
1.2.3 Exploring complex traits through metabolomics
Many complex disorders, such as cancer or kidney diseases, manifest them-
selves as abnormal patterns of metabolic profiles. Such alterations can oc-
cur during the early stages of disease development, even decades before
they manifest as clinical phenotype. Hence the identification of disease-
related metabolic changes can serve as an early diagnostic tool as well as
to determine individuals predisposed to a specific disorder. To date, there
have been a number of studies that have used metabolomic data to identify
diseases-specific molecular mechanisms (25, 26, 27). Since applications of
metabolomics are numerous, here we only provide some examples of metabolo-
mics applied to the study of two common metabolic disorders, type 2 diabetes
and obesity which are the main clinical phenotypes investigated in this thesis.
Metabolomics applied to diabetes research
Type 2 diabetes mellitus (T2DM) is a heterogeneous metabolic disorder
known to be caused by a complex combination of genetic and lifestyle factors
(28). Patients clinically diagnosed with T2DM present increased levels of
fasting glucose in blood and a relative insulin resistance/insulin deficiency.
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In addition, individuals with T2DM often exhibit abnormal patterns of serum
metabolites. Association between altered levels of lipids (dyslipidemias) and
T2DM has been known for many years (29). More recently, the application of
advanced lipoprotein profiling such as NMR spectroscopy of plasma have re-
vealed alterations in particle size and lipids composition of certain lipoprotein
subclasses in relation to T2DM-related disorders. Garvey et al. (2003) (30)
investigated the effect of insulin resistance on lipoprotein metabolism using
NMR-based lipoprotein subclasses. This study demonstrated the association
between insulin resistance and accumulation of atherogenic lipoprotein par-
ticles, including increased levels of large VLDL, small LDL and small HDL.
Such abnormalities in lipoprotein subclasses have been reported even at pre-
diabetic state. Festa et al. (2005) (31) studied lipoproteins subfractions
measured by NMR in 830 nondiabetic individuals at baseline (31). A spe-
cific pattern of abnormalities in lipoprotein subclasses, which includes size
and compositional changes in VLDL and HDL subclasses, was identified for
those prediabetic subjects who developed diabetes when compared with sub-
jects who stayed nondiabetic. More recently, the relationship between glucose
tolerance and lipoprotein profiles has been investigated in a large population-
based study which included a total of 9399 Finnish men (normoglycemic and
newly diagnosed T2DM patients) (32). Association between abnormal glu-
cose metabolism and increased levels of all VLDL subclass particles (with the
exception of very small VLDL particles) was found. In addition, decrease in
levels of large HDL particles and increased concentration of small HDL were
found in T2DM patients after adjustment for total triglyceride and HDL-C
concentrations.
In addition to diabetes dyslipidemias, there is an increasing interest in un-
derstanding the relationship between branched-chain amino acids (BCAAs)
and T2DM-related disorders. The first metabolomic study that drew atten-
tion to the potential role of BCAAs in diabetes was performed by Newgard et
al. (2009) (33). Based on a targeted metabolomic analysis on obese and lean
individuals, a distinctive metabolic signature, which related to variations in
BCCAS, was identified in obese subjects. These metabolic changes, which
correspond with increased levels of valine, isoleucine and leucine, showed high
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correlation with insulin resistance. More recently increased concentrations
of three branched amino acids and two aromatic amino acids (phenylalanine,
tyrosine, valine, isoleucine, leucine) were found in individuals who developed
T2DM when compared to individuals who did not develop T2DM (34).
Metabolomics applied to obesity research
Obesity, defined as an excessive body fat accumulation, is a multifactorial
metabolic disorder which results from an imbalance between a positive energy
intake and a negative energy expenditure. Obesity - especially central obesity
- is known to be strong risk factor for the development of cardiometabolic
disorders such as insulin resistance and type 2 diabetes. Since obesity is
highly associated with T2DM development, many of the previously mention
diabetes-related metabolic changes such as dyslipidemias and abnormal lev-
els of BAACs in plasma have been also found in obesity. In addition, a
large number of obesity-related metabolic disturbances have been identified
by metabolomics, both in animal models and humans (35).
Serkova et al. (36) performed a NMR-based metabolomic analysis of both
blood and liver tissue from obese and lean rats. Based on this study, metabolic
abnormalities in mitochondrial function and methionine metabolism were
related to obesity. In particular, liver extracts from obese rats showed in-
creased levels of fatty acids and triglyceride in liver, increase of methionine
concentration as well as decrease of betaine. Based on these findings, authors
suggested that the specific metabolic abnormalities in obesity might result
from a decreased hepatic energy state (36).
NMR has also been employed to investigate the metabolic effect of high-
calorie diets. Example of this is the work performed by Duggan et al. (2011)
(37) where NMR metabolic profiling of serum was used to differentiate be-
tween obesity-related effects to those effects specific from diet. Based on this
study, differences in metabolite levels such as elevated pyruvate, alanine and
lactate were identified. Most of these changes were attributed to diet-specific
effects.
A recent metabolomic-proteomic approach was used to identify circulat-
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ing molecules that differentiate healthy lean individuals from healthy obese
(38). Targeted serum metabolomics identified 12 metabolites significantly
related to obesity. Of the reported metabolic changes, glutamine and glycine
were significantly higher in obese compared to lean individuals.
1.3 Genomics with metabolomic traits
The analysis of genome and metabolome data individually can provide valu-
able information about molecular changes related to clinical traits. However,
to fully understand the biological processes and mechanisms that underlie
disease development, it is essential that we jointly consider the different lev-
els of molecular information. Here, we present a number of studies that
illustrate the advantages of combining metabolomics and genomics.
The first human study using metabolomic data as a phenotype for GWAS
was performed by Gieger et al.(2008) (39). Gieger and colleagues investi-
gated the use of ratios of individual metabolites to explore genetic factors
contributing to the modulation of the human metabolism. Despite the mod-
est sample size (N=284), authors were able to identify genetic variants that
exhibit large effect sizes on the metabolic phenotypes. Interestingly, nearly
all identified SNPs were in genes encoding for proteins functionally involved
in the metabolism of the associated metabolites. Through this analysis, it
was shown that the use of metabolic measures increases the power of GWAS,
allowing the identification of gene-phenotype associations with a very high
degree of significance.
In a recent GWAS study on the genetic impact on the human metabolome
(40), 37 loci were associated with metabolic concentrations in blood at genome-
wide significance level. Of these, 25 loci showed very high effect size, ac-
counting for up to 60% of the differences in metabolic levels per allele copy.
Moreover, 30 loci were mapped to a protein biochemically related to the
associated metabolite and 15 loci were related to complex diseases or drug
response.
Lipidomics - the global study of lipid molecules produced by cells, tis-
sue or organism - in combination with SNP data is an increasingly common
CHAPTER 1. GENOMICS AND METABOLOMICS 35
approach. It is used to investigate genetic variants contributing to changes
in lipid concentrations and therefore affecting the risk of cardiovascular dis-
ease development. Over 90 genetic loci have been so far identified in GWAS
of classic lipid measures (41). While some of the identified genetic variants
have not been implicated in lipids metabolism, the majority of the genetic
determinants are in or near genes previously known to influence plasma lipid
levels. More recently Kettunen et al. (2012) (42) performed a GWAS on 8330
Finnish individuals for whom a range of 216 serum metabolic traits were mea-
sured by NMR metabolomic platform. They identified 31 loci significantly
associated with one or more metabolic measures at a genome-wide signifi-
cance level. Eleven of the identified loci were newly reported for metabolic
measures or cardiometabolic disorders.
Tukiainen et al. (2012) (43) used a detailed dataset on lipids and lipopro-
tein subclasses measures (216 metabolic concentrations) measured by NMR
metabolomic platform to investigate association between NMR-based lipopro-
teins and the set of loci previously identified for enzymatic total lipid mea-
sures (41). Based on this approach, 30 new SNP-metabolic trait associations
were uncovered. For the majority of the loci, the strongest association was
to a more specific metabolite measure than the originally identified through
enzymatic total lipid measures (41). In addition, particle-specific effects were
identified in four loci and the smallest high-density lipoprotein (HDL) mea-
sures showed effects opposite to the larger ones. The findings indicated that
much greater resolution in the analysis can be obtained by looking at more
specific phenotypic measures than those from routine clinical lipid measures
(43).
1.4 Summary
With technological advances as well as development of novel analytical ap-
proaches, genomic and metabolomic studies have become powerful tools to
gain a better understanding of biological processes involved in disease de-
velopment. The information generated by these studies provides us with in-
creased knowledge of how molecular mechanisms are affected by pathogenic
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conditions. While genomic and metabolomic studies are very useful individ-
ually, these two approaches collectively hold exceptional promise. The liter-
ature illustrates that the combination of GWAS with metabolic phenotyping
is an effective approach for improving the identification of molecular factors
contributing to disease development. Furthermore, these studies revealed
that the use of metabolomics in GWAS can increase the power to identify
variations, yielding strong statistical associations and more importantly, can
provide direct evidence of molecular basis of disease aetiology.
Chapter 2
The Data Sets
This chapter presents the data sets used in this thesis. We begin by present-
ing the study populations investigated (section 2.1). Next, we describe the
two metabolomic data sets (serum and urinary data) employed in this work
(section 2.2). The analytical platforms and experimental protocols used for
metabolomic data acquisition are briefly described. To better understand the
biological significance of the metabolic measures investigated in this work,
we provide an overview of the main biological roles played by these sets
of metabolites. The genomic data and quality control methods applied are
briefly described in section 2.3. We finish this chapter describing the general
notation used throughout the thesis.
2.1 Study populations
The primary study population investigated in this thesis is the Northern
Finland Birth Cohort 1966 (NFBC1966) (subsection 2.1.1). In addition to
the NFBC1966, two other data sets are investigated: The Northern Finland
Birth Cohort 1986 (NFBC1986) which is described in subsection 2.1.2 and
the Cadmium study population, presented in subsection 2.1.3. All studies
were approved by local ethics committees and participants provided informed
consent.
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2.1.1 Northern Finland Birth Cohort 1966
The Northern Finland Birth Cohort is an epidemiological and longitudinal
research program started in 1965. A detailed description of the data can
be found on the study web page (http://kelo.oulu.fi/NFBC). In brief, this
birth cohort is based on a general, unselected and genetically homogeneous
population. It consists of data on individuals who were due to be born
between January 1st and December 31st of 1966 in the two northernmost
provinces of Finland, Oulu and Lapland. The cohort initially included data
on 12,068 mothers and their 12,058 live infants. The majority of the cohort
members (99%) are Finns (white Caucasians). According to Finland’s central
Office of Statistics, the cohort members comprised 96.3% of all births in
1966 in the target area. Data on the cohort members have been collected
prospectively since pregnancy and supplemented at the ages of 1, 14 and 31
years, when a wide range of biological, socioeconomic and lifestyle factors
as well as health conditions and family background information have been
included (44, 45, 46, 47). The data collection and the follow-ups are described
below. In Figure A.1 we represent how the NFBC data was used in this thesis.
The follow-ups
All mothers with expected delivery date in 1966 who were living in the study
area (Oulu and Lapland), were invited to participate in the study: 12,068
attended. Prenatal data were collected by local midwives in the antenatal
clinic visit (24th − 28th gestational weeks)(44). Altogether 12,058 children
were born into the cohort. The first follow-up data was collected in 1967,
when cohort members were one year old (1-year follow-up). Developmental
data and health status of the children were collected during the children’s
visits to welfare centres (44). The second follow-up was performed in 1980
and in early 1981, when cohort members were 14 years old (14-year follow-
up). All cohort members with known addresses received postal questionnaires
containing questions on their growth, health habits and family situation. A
shortened version of the questionnaire was sent to the families in cases where
the adolescent did not respond or to the school health nurse if neither the
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child nor the families responded. The postal questionnaire was returned by
94% (N = 11,010) of the adolescents, 52% (N = 389) of the parents and
97% (N = 354) of the nurses (45). The last follow-up was conducted when
cohort members were 31 years old (31-year follow-up) during 1997-98. All
living cohort members with known addresses (N=11,541) received a postal
questionnaire including questions on their health, lifestyle and occupation.
The questionnaire was returned by 75% (N = 8,690). At the same time, those
subjects living in the original study area - northern Finland or in the capital
area (Helsinki) - were invited to participate to a clinical examination and
71% (N = 6,007) of those invited participated. At this point, blood samples
were drawn after overnight fasting and samples were stored at −80oC until
analysed (46).
2.1.2 Northern Finland Birth Cohort 1986
The Northern Finland Birth Cohort 1986 (NFBC1986) consists of data on
individuals with expected date of birth between 1st July 1985 and 30th June
1986, also in the two northernmost provinces of Finland, Oulu and Lapland
(http://kelo.oulu.fi/NFBC) (48, 49). The number of mothers and deliveries
was 9,362 (99% of all eligible) and there were 9,432 children born alive. Each
cohort member has been followed up from early pregnancy until adolescence.
Growth measurements were obtained from communal child health clinics. All
those alive with known address were invited to a clinical examination at the
age of 15 to 16 years. Blood samples were collected from those participants
who provided written informed consent (N= 6,266).
2.1.3 Cadmium study population
The study population consists of individuals living near the lead/zinc smelter
Avonmouth (Bristol, England), one of the largest source of atmospheric
cadmium in the world. Details on the samples collection can be found in
(50). Briefly, study subjects were recruited using the National Health Ser-
vice database of patients registered with general practitioners (the Exeter
System) in the area (50). Subjects were stratified by age, sex and esti-
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mated exposure prior to random sample selection. A total of 865 people
were initially invited to take part to the study. Data collection consisted
of a questionnaire on health history, residential area, occupation and living
habits such as smoking as well as the consumption of home-grown vegetables
and the use of a private well. At the same time participants were asked to
provide one spot morning urine sample. Samples were frozen on the day of
collection and stored frozen until analysis.
2.2 Metabolomic data sets
In this work we investigate metabolomic data from urinary and serum sam-
ples. Both sets of metabolic data have been analysed by 1H NMR spec-
troscopy but the experiment procedures and data acquisition for each type
of data are different. In subsection 2.2.1, we describe the serum metabolomic
data and the 1H NMR metabolomic protocol used for its acquisition. The uri-
nary metabolomic data and 1H NMR metabolomic experiment are presented
in subsection 2.2.2.
2.2.1 1H NMR serum metabolites
Serum metabolic profiles were available for two of the study populations:
NFBC1966 and NFBC1986. Both cohorts were analysed using the same
high-throughput serum NMR metabolomic platform in a single analysis lab-
oratory. All analytical processes - sample collection, sample preparation, data
acquisition, data pre-processing and quality assurance - were performed by
Professor Mika Ala-Korpela and colleagues at the University of Oulu. Details
on the NMR platform and experiment protocol can be found in (51), (52),
(53). In brief, serum molecular data were acquired using a high-throughput
NMR platform (Bruker AVANCE III spectrometer) operating at 500 MHz. A
recently introduced NMR spectroscopy protocol, which optimizes measure-
ment and characterization of serum metabolites, was employed to determine
the serum metabolic profiles. To facilitate the identification and quantifica-
tion of the large variety of compounds in blood serum, measurements were
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performed following a three-molecular-window approach (51). The first set
of data (LIPO window) provides detailed information about macromolecules
such as lipids in lipoprotein subclasses. The second window (LMWM win-
dow) provides data on a variety of low-molecular-weight metabolites, such as
amino acids, creatinine and ketone bodies. The last window (LIPID window)
contains information on a range of lipid molecules along with their degree of
(poly)(un)saturation. The methodology currently provides information on
117 directed measured serum metabolites and > 100 derived variables, all
of them with high biological significance. Below we describe in more detail
each of the molecular windows.
LIPO window: The data for the LIPO window contain information
about lipoproteins subclasses distribution, particle concentrations and indi-
vidual subclass lipids content (Figure 2.1.a). The data were acquired from
native serum samples at 37.0oC. A standard NOESY-presat pulse sequence
was used with mixing time of 10 ms and irradiation field of 25 Hz to suppress
the water peak. The spectra were recorded with 80k data points using 8 tran-
sients acquired with an automatically calibrated 90o pulse. The acquisition
time was 2.7s and the relaxation delay 3.0s. Prior to lipoprotein quantifi-
cation the albumin signal was mathematically removed from the spectrum
to improve accuracy (51). To isolate the different lipoprotein categories, the
NMR-visible lipid amount was converted into information on the lipopro-
tein subclasses by a regression model. In addition, lipoprotein categories
were converted into lipoprotein fractions - cholesterol and triglyceride - by
assuming an average lipid composition of the lipoprotein particles at a cer-
tain NMR chemical shift range and calibrated to units of mmol/l (e.g. total
VLDL triglyceride). Thus, the lipoprotein, lipid and particle concentrations
are all different approximations based on the NMR measure. Quantification
of particle concentrations and various lipid components in 14 lipoprotein
subclasses were obtained using a computationally more efficient modification
of the regression approach presented in Vehtari et al. (2007)(54). The 14
lipoprotein subclasses along with the average particle diameter are presented
in Table 2.1. In addition, concentrations of apolipoprotein B and apolipopro-
tein A-1 were calculated using an extended Friedewald algorithm based on
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Figure 2.1: Illustration of 1H NMR spectra of serum obtained following
a three-molecular-window approach. a) The lipoprotein and albumin spec-
trum (LIPO window); b) The low-molecular weight metabolites spectrum (LMWM
window); c) The serum lipid extracts (LIPID window). FA, fatty acid; EC, es-
terified cholesterol; PGLY, phosphoglycerides; FC, free cholesterol; PC, phos-
phatidylcholine; PUFA, polyunsaturated fatty acid; sat, saturated; SM, sph-
ingomyelin; TC, total serum cholesterol; TG, total serum triglycerides. Figure
reprinted from Biochemical and Biophysical Research Communications, 375/3,
Tukiainen T, Tynkkynen T et al. A multi-metabolite analysis of serum by 1H
NMR spectroscopy: Early systemic signs of Alzheimers disease, 356-361, Copy-
right (2008), with permission from Elsevier.
triglycerides, total cholesterol and HDL cholesterol measures quantified from
the spectral data (55).
LMWM window: The low molecular weight metabolites (Figure 2.1.b)
data set was acquired from native serum samples and contains information
on various amino acids, a number of metabolites involved in the glycolysis
pathway, citric acid cycle and excretion metabolites (51). The chemical shifts
from the low-molecular-weight metabolites were uncovered by the applica-
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Table 2.1: Lipoprotein subclasses and particle diameter.
Lipoprotein Subclasses Diameter(nm/m)
Chylomicrons extremely large VLDL 75
very large VLDL 64
large VLDL 53.6
VLDL medium VLDL 44.5
small VLDL 36.8
very small VLDL 31.3
IDL IDL 28.6
large LDL 25.5
LDL medium LDL 23
small LDL 18.7
very large HDL 14.3
HDL large HDL 12.1
medium HDL 10.9
small HDL 8.7
tion of a pulse sequence that suppresses the majority of the signals from
macromolecules such as lipoproteins (52). These molecular windows - LIPO
window and LMWM window - are likely to contain most of the molecules
information currently observable by 1H NMR in native serum (51).
LIPID window: Following a standard lipid extraction protocol (52),
the lipoprotein particle structure is broken down. In the LIPID window,
the signals in the NMR spectrum arise from various lipid molecules within
the lipoprotein particles (Figure 2.1.c). In addition, information on the de-
gree of (poly)(un)saturation is available. The following fifteen lipids-related
metabolites are currently quantified from the LIPID spectra: total amount of
triglycerides; total amount of phosphoglycerides, total amount of cholesterol
esterified; total amount of omega-3; omega-6 and omega-9 fatty acids; total
amount of linoleic acid and total amount of docosahexaenoic acid (DHA);
total amount of fatty acids that contain more than one double bond in
their backbone (Polyunsaturated fatty acids); total amount of cholines; total
amount of phosphatidylcholines; total amount of sphingomyelin.
For NFBC1966, data on the three molecular windows were available and
used in this thesis. For NFBC1986, data on two molecular windows, LIPO
window and LMWM, were available. In appendix (Table A.1) we summarise
the data used.
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2.2.2 1H NMR urinary metabolites
Urinary metabolic profiles were available for only one of the study popula-
tions: the Cadmium study population. Urinary metabolic data were acquired
using 1H NMR spectroscopy. Details on the NMR platform and experiment
protocol can be found in Ellis et at. (2012)(56). In brief, the data were ac-
quired from native serum samples at 37.0oC using a high-throughput NMR
platform (Bruker AVANCE 600 spectrometer) operating at 600 MHz fitted
with a flow-injection mode probehead at a field strength of 14.1 T (600.13
MHz 1H frequency). The probe temperature was set to 300 K. Samples were
delivered to the probehead in 96-well plates using an automated flow injec-
tion system (Bruker). Following introduction to the probe, samples were left
to equilibrate (three minutes) prior to gradient shimming using the 1H chan-
nel to ensure good magnetic field homogeneity. All liquid sample handling,
automation and acquisition were controlled using XWIN-NMR 3.1 software
(Bruker) running on a UNIX workstation (Silicon Graphics, USA). One-
dimensional NMR spectra were acquired using a standard pulse sequence.
Excitation sculpting with gradients was used to suppress the water peak.
Following eight dummy scans, each spectrum was acquired into 64 k dat-
apoints over a spectral width of 20 ppm as the sum of 64 transients. The
acquisition time was 2.73 seconds and the relaxation delay two seconds. Peak
assignment was performed based on the addition of known standards to the
biological samples, together with published literature. Quantification of uri-
nary metabolites were obtained integrating manually placed bins.
This methodology provided information on a total of 22 urinary metabolic
measures, including amino acids, 3-hydroxybutyrate, creatinine and urea
and information on metabolites involved in gluconeogenesis pathway such
as pyruvate, lactate, glycerol. The complete list of metabolites included in
this analysis can be found in the appendix (Table A.2).
2.2.3 Biological context of 1H NMR metabolites
The metabolites quantified by the NMR platforms previously described play
important roles in a variety of biological functions. Here we provide an
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overview of the main roles and metabolic pathways in which they are in-
volved. Since lipoprotein are the most explored molecular data in this thesis,
a major emphasis will be given to these metabolites and their metabolism.
Lipids and lipoproteins
The term lipid defines a diverse group of naturally-occurring molecules which
includes fats, waxes, sterols, sphingolipids, glycolipids, fat-soluble vitamins
and phospholipids. The main biological functions of lipids include energy
storage, building-block of cell membranes and molecule signalling. There are
two main types of lipids in blood, triglycerides and cholesterol. Due to their
low solubility in water, blood lipids are carried in lipoproteins. It is well
established that elevated levels of blood lipids are risk factors for the devel-
opment of cardiovascular diseases and related disorders. Because lipoproteins
are the main lipids transporter in blood, abnormalities in lipoprotein profiles
are often used as strong indicator of lipid disorders and consequently of the
risk of cardiovascular disease development.
The overall structure of a serum lipoprotein is presented in Figure 2.2.
Lipoproteins are spherical macromolecular complexes consisting of a water-
soluble envelope and lipid-rich core and transport lipids to various body
tissues. Phospholipids (PL) are the main compound forming the envelope.
PLs have amphipathic character with a polar part oriented to the aqueous
surface and an apolar part that interacts with the hydrophobic core of the
lipoprotein. Free Cholesterol (FC) also appears forming part of the lipopro-
tein envelope. The core of the lipoprotein is formed mainly by cholesterol
ester (CE) and triacylglycerols (TG). The protein components of the lipopro-
tein are known as apoproteins (apo) and serve as cofactors for enzymes and
ligands for receptors.
Lipoproteins represent a heterogeneous group of particles that differ
in density, size, composition, functions and binding affinity. These physical
and chemical properties are influenced by the apolipoproteins type and the
amount of lipids that forms the lipoprotein structure. Lipoproteins can be
identified and classified based on their physical and chemical properties. Den-
CHAPTER 2. THE DATA SETS 46
Figure 2.2: Overall structure of a serum lipoprotein. Shown is a schematic
representation of a lipoprotein particle comprised of a hydrophilic layer of phos-
pholipids, apoproteins and free cholesterol and a hydrophobic core that contains
triglycerides and cholesterol esters. Figure reprinted from Wikimedia Commons,
the free media repository with permission from Free Software Foundation.
sity is one of the criteria used for lipoproteins classification. Based on this
property, there are five major lipoprotein classes which are chylomicron, very
low density lipoproteins (VLDL), intermediate density lipoproteins (IDL),
low density lipoproteins (LDL) and high density lipoproteins (HDL), each
of which has a different function in lipid metabolism. Properties of the five
major lipoprotein classes are listed in Table 2.2. Density and particle size
are related by lipid to protein ratio. For instance, when lipoproteins are
formed by more lipids than proteins, lipoprotein particles are larger and less
dense. In addition to the main classification, specific subfractions of three
lipoprotein classes (VLDL, LDL and IDL) can be determined. These differ-
ent subcategories are defined also by differences in particle size, density and
apolipoprotein content.
Table 2.2: Molecular properties of the five major lipoprotein classes.
Class Density Diameter Apo %Prot %TL %Cho %PL %TG
Chylomicrons < 1.006 100-1000 ApoB 2 98 8 7 83
VLDL 0.95-1.006 30-80 ApoA 10 90 22 18 50
IDL 1.006-1.019 25-50 ApoB 18 82 29 22 31
LDL 1.019-1.063 18-28 ApoA 23 77 50 20 7
HDL 1.063-1.210 5-15 ApoA 35 65 30 30 5
Class, main lipoprotein classes; Density, density of the particle measured in (g/mL); Di-
ameter, diameter of the particle measured in (nmm); Apo, main apolipoprotein; %Prot,
percentage of protein; %TL, percentage of total lipids; %Cho percentage of cholesterol;
%PL percentage of phospholipid; %TG percentages of triglycerides. Table partially taken
from Biochemistry 2nd Ed. 1995 Garrett & Grisham.
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Lipoprotein metabolism
The lipoprotein metabolism is divided into two pathways, exogenous and
endogenous. In the exogenous pathway (Figure 2.3.a), dietary fats (mainly
triglycerides) enter the intestinal mucosa (enterocytes) via the fatty acid
transporter (FA). Once inside the intestinal lacteals, triglycerides (TG) are
packaged with cholesterol ester and apolipoprotein B-48 (APOB48) into
nascent chylomicrons (nCMs). The nCMs are segregated via the intestinal
lymphatic system and enter the blood stream. While circulating in blood, the
nascent chylomicrons are converted into mature chylomicron (mCM) by ex-
changing apolipoprotein C-II (APOC2) and apolipoprotein E (APOE) with
high-density lipoproteins (HDL). Then TGs in the core of mCM are hy-
drolyzed into free fatty acids and glycerol by the endothelial-bound lipopro-
tein lipase with APOC2 as cofactor. This process produces smaller CM, so-
called remnants CM which enter the liver by hepatic LDL receptor (LDLR)
and breakdown (57).
In the endogenous pathway (Figure 2.3.b), very low density lipopro-
teins (VLDL) are synthesized by packaging TG with cholesterol and the
apolipoprotein B100, in liver cells. VLDLs are segregated into the blood
stream (nascent VLDL). As in chylomicron metabolism, nascent VLDLs are
converted into mature VLDL by exchanging apolipoprotein C-II (APOC2)
and apolipoprotein E (APOE) with HDL. In plasma, mature VLDL particles
are hydrolysed into free fatty acids and glyceride by lipoprotein lipase (LPL)
with APOC2 as cofactor. Most of the VLDLs are converted to an intermedi-
ary lipoprotein, IDL particles. Some of the IDL are removed through inter-
action of apolipoprotein E with the LDL on the liver surface and the others
are hydrolized by hepatic lipase to produce low density lipoproteins (LDL).
LDLs are cholesterol-enriched lipoproteins. Circulating LDL are taken up
by the liver and other tissues by endocytosis, process that involves the LDL
receptor (LDLR). If LDL are oxidized, LDLs enters the peripheral cell such
as macrophages via the scavenger receptor CD36 and SR-A(3). LDLs serve
to deliver cholesterol to the tissues for energy utilization. Nascent HDLs are
synthesized in the liver and intestine by the transfer of cholesterol and phos-
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pholipids onto apolipoproteinA-1 (ApoA-1). Nascent HDLs interact with the
peripheral cell and remove unesterified cholesterol through the ATP-binding
cassette (ABC1). Cholesterol in nascent HDL then is esterified to fatty acid
producing spherical mature HDL. Mature HDLs can transfer cholesterol es-
ter (CE) to the liver by interaction with the scavenger receptor B-1(SRB1)
and also transfer their CE-rich core to VLDL remnants creating LDL. HDL
of small size can be degraded by the kidney.
Figure 2.3: a) Exogenous Pathway; b) Endogenous Pathway. FA, fatty acids;
CM, Chylomicrons; MTTP, microsomal TG-transfer protein; B48, apolipopro-
tein B isoform B48 C3, apoliprotein C3; A5, apoliprotein A5; C2, apoliprotein
C2; B28, apolipoprotein B isoform B28; LPL, ipoprotein lipase; CMR, CM
remnants; TG, triglyceride; ATGL, adipose TG lipase; LRP1; LDLR-related
protein-1; VLDL, very low-density lipoprotein; B100, apolipoprotein B isoform
B100; C, free and esterified cholesterol; LDLR, hepatic LDL receptor; HL, hep-
atic lipase; IDL, intermediate density lipoprotein; LDL, low-density lipoprotein;
LIPG, endothelial lipase; CETP, cholesterol ester transfer protein; HDL, high-
density lipoprotein; LCAT, Lecithin-cholesterol acyltransferase; A1, apolipopro-
tein A1. Figure adapted by permission from Nature Publishing Group (2009):
Nature Reviews Genetics, Hegele, R. A. Plasma lipoproteins: genetic influences
and clinical implications, copyright (2009)(58).
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Glycolysis pathway
The metabolomic platform described allow the quantification of a number of
metabolites related to the glycolysis pathway (glycerol, glucose, pyruvate and
lactate). Glucose is the most important sugar in metabolism and the primary
source of energy for the cell. It also acts as intermediate metabolite in many
biochemical reactions. In glycolisis one molecule of glucose is converted into
two molecules of pyruvate, releasing energy in the form of ATP (Figure 2.4).
Pyruvate can be oxidized into acetyl-coenzyme A(acetyl-CoA), which is the
main input for a series of reactions such as Krebs cycle. Apart from being
the end product of glycolisis, pyruvate plays important roles in a range of
metabolic processes. For instance, pyruvate is one of the precursors for the
synthesis of glucose via gluconeogenesis pathway. It can be converted into
fatty acids through acetyl-CoA or being used as building block of amino
acids such as alanine. In absence or short supply of oxygen, pyruvate is
broken down anaerobically, process that produces lactate. Glycerol, which
is produced from triglycerides oxidation, can enter the glycolysis pathway in
the form of D-glyceraldehyde-3-phosphate.
Figure 2.4: Diagram of the glycolysis pathway. Figure repre-
senting the conversion of one molecule of glucose into two molecules
of pyruvate together with NADH and ATP. Picture taken from
http://www.bbc.co.uk/bitesize/higher/biology/cell biology/respiration/revision/2/
CHAPTER 2. THE DATA SETS 50
Citric acid cycle
Data on a number of metabolites involved in or related to the citric acid
pathway such as 3-hydroxybutyrate, acetate, acetoacetate and citrate are
identified and quantified by the NMR platform described in section 2.2.1.
The citric acid cycle (also known as Krebs cycle) is the final step of the
oxidation of fats, proteins and carbohydrates into C02, water and NADH.
An overview of the citric acid cycle is shown in Figure 2.5. Citric acid cycle
starts with the conversion of acetyl-CoA into citrate which goes through a
series of chemical transformations. Citrate is converted into a number of
citric acid cycle intermediates (e.g. succinate, malate) that can either be
used as precursors for the biosynthesis of other molecules or used for the
regeneration of a molecule of citrate. Citrate can also be re-transformed to
acetyl-CoA in cytosol and be used for fatty acid synthesis. In situations
where there is an excess of acetyl-CoA, this component can be converted
into ketone bodies such as acetoacetate, 3-hydroxybutyrate and acetone in
the liver. Two of these ketone bodies - acetoacetate and 3-hydroxybutyrate
- are transported by the blood to extrahepatic tissues such as skeletal and
heart muscle. In absence of other sources of energy such as glucose, tissues
can obtain energy from the oxidation of acetoacetate and 3-hydroxybutyrate
via the citric acid cycle. When the levels of glucose are low, the brain can
use 3-hydroxybutyrate to obtain energy.
Amino acids
Amino acids play central roles both as structural units of proteins and as
intermediate molecules in metabolism. Amino acids are classified into two
categories, essential and non-essential amino acid, depending on whether they
can be produced by the body or need to be supplied in the food. Data on four
essential (histidine, leucine phenylalanine and valine) and three non-essential
amino acids (alanine, glutamine and tyrosine) are available. Apart from their
key function as protein building blocks, all essential and non-essential amino
acid can be catabolized and used as energy source. In the catabolism of amino
acids, the carbon skeletons of amino acids are broken down into metabolites
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Figure 2.5: Diagram of the citric acid cycle. Picture taken
from http://www.bbc.co.uk/bitesize/higher/biology/cell biology/respiration/ re-
vision/2/
that can either be oxidized into CO2 and H2O to generate ATP, or can be
used in gluconeogenesis. Most of this process takes place in the liver, but
three branched-chain amino acids (BCAA) - isoleucine, leucine and valine -
are degraded in muscle or adipose tissues.
Urea cycle
The end products of amino acids’ metabolism are ammonia, CO2, water and
energy. Ammonia is a very toxic compound to cells. To be excreted from the
body, ammonia is converted into urea in the liver. Urea is transported in the
blood to the kidneys, where it is excreted from the body in urine. Another
product of metabolic degradation is creatinine, which is formed when creatine
breaks down in muscle tissue. As urea, creatinine is excreted by the kidneys.
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2.3 Genetic data
Genetic data from only NFBC1966 were used for the genetic analysis since
genome-wide data for the other two populations were not available. The de-
tails for the genotyping procedure and quality control are presented in (47).
In brief, all DNA samples were prepared and genotyped by the Broad Insti-
tute Biological Sample Repository (BSP). Genotyping was performed using
the HumanCNV370-Duo DNA Analysis BeadChip. This array contains an
informative set of tag’ SNPs which was derived from the HapMap European-
derived (CEU) sample (over 318,000 SNPs). In addition, 52,000 variants
were included to target approximately 14,000 copy number variant (CNV)
regions. This gives a total of over 370,000 genotyped markers. Genotyping
was initially completed for a total of 339,629 SNPs and 4,936 samples.
2.3.1 Data quality controls
Extensive quality controls of the data were performed by Dr. Chiara Sabatti,
Dr. Susan Service and colleagues at the University of California, Los Angeles
(UCLA) and by Ms. Marika Kaakinen (University of Oulu) and Dr. Inga
Prokopenko at the University of Oxford. The per-sample quality control
process included analysis of duplicate samples, gender discrepancy, sample
contamination and relatedness. Of the related pairs that shared over 20%
of the genome identical by descent (IBD), the individuals with less complete
genotype data were excluded. In total 173 subjects were excluded after the
quality control analysis. Call rate in the final data set was ∼ 99.7% on aver-
age (range 95.3-99.9%) and only 1.7% of individuals had call rate ≤ 97.5%.
Of the 339,629 genotyped genetic markers, 3,345 SNPs were excluded be-
cause the assumption of Hardy-Weinberg Equilibrium (HWE) did not hold
(P < 10−4). In addition, 55 SNP with call rate < 95% and 7,681 with minor
allele frequency (MAF) < 1% were removed. The average SNP call rate was
99.7% and only for 1.6% of SNPs it was 95.0− 97.5%. After quality control
the data comprised 329,091 genotyped SNPs in 4,763 individuals.
The whole quality control procedure was not repeated in this study. How-
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ever, we performed a minor allele frequency test at a 1% threshold, call rate
test with threshold 95% and Hardy-Weinberg Equilibrium (HWE) test at
threshold p < 1 × 10−4 which left N=318,443 SNPs for analysis. The soft-
ware SNPtest v.2 was used to perform this analysis.
2.4 General Notation
Throughout this thesis, we will use the following general notation. Random
variables are indicated with capital letters and values of the random variable
(observations) are denoted in lower letters. In a univariate context, random
variables are denoted in italic, non-bold. For instance, Y is a random vari-
able and y1, ..., yn are observations of Y . In a multivariate context, vectors
and matrices are indicated by bold font and each components of vectors or
matrices will be distinguished with subscripts. In this way, Y represents a
vector of random variables, y a vector of observations and Y a matrix whose
(i, j) entry is denoted yi,j. Greek characters are used to denote unknown
parameters (e.g β). The parameter estimates are represented by placing the
symbolˆover the corresponding Greek character (e.g βˆ ). We use prime to
indicate a transpose. Thus, the transpose of a matrix Y is Y′.
Chapter 3
Statistical methods for
Genome-Wide analysis
In this chapter, we perform an initial exploratory analysis of genomic data
in combination with metabolomic data. For that purpose, three statistical
methods namely, single-SNP, multi-SNP and multiple responses are applied
to investigate genetic variants associated with variations in metabolic phe-
notypes. The chapter is organised in the following way: In section 3.1 we
present a GWAS analysis of NMR serum metabolites which is performed
following the standard single-SNP tests of association. In section 3.2 we ex-
plore the use of multi-SNP methods in genome-wide association studies. In
particular, a variable selection approach, the HyperLasso regression, is used
to perform a multi-SNP analysis of metabolic traits. The last section of this
chapter (section 3.3) is dedicated to multiple responses methods. Rather than
treating each phenotype as a separate variable, in this section we perform
the combined analysis of different sets of related metabolic phenotypes. We
conclude this chapter by discussing the results (section 3.4) and performance
of each of the investigated methods.
3.1 Single-SNP analysis
Due to their fast implementation and easy interpretation, univariate meth-
ods play a very important role in the analysis of genetic data. Based on
this approach, association between genetic variants and a trait of interest is
tested considering only one SNP at a time. The methods applied to test for
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association are statistically straightforward - the testing is performed using
well established techniques such as univariate regression and the χ2 test.
Depending on whether the trait is continuous or binary (case-control),
different tests can be used for assessing association between a SNP and a
phenotype. The most commonly used statistical techniques for testing for
association in GWAS are regression models. Linear regression is the method
of choice for testing for association with continuous phenotypes. The linear
model assumes a linear relationship between genetic factors and the mean
value of the trait of interest.
yi = β0j + β1jxij + ij ij ∈ N(0, σ2j ), i = 1, ...N, (3.1)
where yi is the phenotype value for the ith observation, β0j is the inter-
cept, xij is the genotype for the jth SNP for the ith observation, β1j is the
regression coefficient and ij is the prediction error. The underlying assump-
tion in linear regression is that the trait distribution is approximately normal,
with a common variance and the error terms are normally distributed. If the
assumption of data normality does not hold, data distribution can be ap-
proximate to normality by transforming the original phenotype values (e.g.
log transformation).
The linear model outlined above for continuous phenotypes can not be
used for case-control phenotypes because the assumption of data normality
does not hold. This problem is overcome with the application of logistic re-
gression in which the transformation logit (pi) = log( pi
1−pi ) is applied to pi, the
probability of being a case. The logistic regression assumes that the log-odds
of the phenotype is a linear function of the jth genotypes.
log
Pr(yi = 1|xij)
Pr(yi = 0|xij) = β0j + β1jxij, i = 1, ...N. (3.2)
Regression models both in continuous and case-control traits have several
advantages compared to other statistical tools for GWAS. One of these ad-
vantages is the possibility of easy incorporation of confounders such age, sex
into the model. Regression models are also flexible tools that can be used to
accommodate multiple predictors simultaneously.
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3.1.1 Single-SNP association analysis
Here we present a GWAS analysis of NMR-based metabolic measures where
the conventional approach of single-SNP test of association is applied. The
aim is to investigate the performance of the per-SNP approach at identifying
genetic variants significantly associated with metabolic traits.
• Materials and Methods
The analysis was performed using fifty one measures of serum metabolites,
including 16 lipoprotein subclasses, 18 lipid-related traits, 13 low-molecular-
weight metabolites and 4 variables derived directly from the previous mea-
sures (Table A.1). Genotype and serum metabolic data were available on
3,683 individuals (5,747 individuals with serum metabolic data and 4,772
with genotype data) from the NFBC1966.
Test of association was performed by univariate linear regression models
assuming an additive contribution to the trait value. To correct for sex-
differences in metabolic profiles (59), each of the fifty one metabolic traits
was analysed including gender as covariate. In order to reduce skewness of
the data, each phenotype was log-transformed prior to the analysis. The
threshold for genome-wide statistical significance was set to P < 9.8× 10−9
which corresponds to a standard genome-wide statistical significance level of
P < 5× 10−8 corrected for the total number of tested metabolic phenotypes
(m = 51).
• Results
On the basis of genome-wide association significance (P < 9.8 × 10−9), we
identify thirty eight genetic variants that show significant association with
a total of twenty metabolic measures. The results for this analysis are pre-
sented in Table 3.1 where we provide a brief description of the identified
genetic variants, including their accession numbers, chromosomal positions,
the p-values obtained by the most associated metabolic trait (leading trait),
other traits associated with the identified genetic makers and the candidate
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genes associated with the genetic markers. The Manhattan plots for the
leading traits are presented in appendix (Figure B.1).
The identified SNPs are localized in ten different genetic regions across
eight chromosomes. Of these loci, three show association with low-molecular
weight metabolites and seven loci are associated with measures of lipopro-
tein subclasses and lipids measures. The most significant association is
found between total amount of polyunsaturated fatty acids (TotPUPA) and
SNP rs174537 localized at chromosome 11q21.3. Three of the identified loci
have not been previously observed to associate with metabolic measures at
genome-wide significance. The loci that reached genome-wide significance
are presented and discussed in more detail below.
Loci associated with lipids or lipoprotein subclasses
For lipoprotein or lipid measures, we identify a total of thirty one genetic
variants localized in seven genetic regions. All loci found through our anal-
ysis have been previously reported to be associated with metabolic traits
(41, 42). We observe association between SNPs localized at chromosome
2p24.1 and total lipids in very small, small, medium and large VLDL, total
lipids in IDL and measure of apolipoprotein B (ApoB). These SNPs are local-
ized within or near a gene encoding for apolipoprotein B (APOB), which is
the main apolipoprotein constituent of chylomicrons, VLDL (isoform B-48)
and LDL (isoform B-100) (58). Variations in this gene are known to relate
to metabolic disorders such as hyperbetalipidemia (60, 61) or hypercholes-
terolemia (62, 63). SNP rs1260326 localized at chromosome 2p23.3 shows
significant association with total lipids in medium, large VLDL as well as
measures of monounsaturated fatty acids (MUFA). This variant is localized
within a gene encoding for glucokinase regulatory protein (GCKR), a hepatic
regulatory protein essential in the metabolism of glucose (64). This protein
plays a critical role in controlling the activity of glucokinase (GK) by bind-
ing and inhibiting the GK complex (64). This polymorphism (rs1260326) has
been related to increased levels of fasting triglycerides (65, 66, 67), which is
known to be associated with increased risk of cardiovascular disease devel-
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opment. Interestingly, this genetic variant has also been associated with de-
creased levels of fasting glucose (68), which is related to the reduction in the
risk of diabetes and cardiovascular diseases. A variant (rs10096633) localized
at 8p21.3 shows significant association with total lipids in medium VLDL.
This variant is localized in a gene encoding for lipoprotein lipase (LPL). This
enzyme catalyses the hydrolysis of triglycerides in TG-rich lipoproteins such
as chylomicrons and very low density lipoproteins (69, 70). It is also known
that LPL aids the cellular uptake of chylomicron remnant, cholesterol-rich
lipoproteins, and free fatty acids (71, 72). Variants at chromosome 11q21.3
show significant association with several lipid-related traits, namely, total
amount of polyunsaturated fatty acids (ToTPUFA), linoleic acid (LA) and
ratio of triglycerides to phosphoglycerides (TGtoPG). The identified SNPs
are localized in or near genes encoding fatty acid desaturase cluster (FADS), a
well-known lipoprotein-related genetic region. This cluster of proteins is com-
ponent of lipid metabolic pathway and catalyzes the biosynthesis of highly
unsaturated fatty acids (73). Association between variants at chromosome
15q21.3 and total lipids in very large and large HDL as well as with mea-
sures of phosphatidylcholine and other cholines (PC) are observed. These
genetic variants are localized in a gene encoding for hepatic triglyceride li-
pase (LIPC), which is an important enzyme in HDL metabolism determining
the size and density of particles (74). Two genetic variants localized in chro-
mosome 16q13 show significant association with total lipids in medium, large,
high density liprotein (HDL) and apoprotein A-I (ApoA-1). These SNPs are
localized in a gene encoding for cholesteryl ester transfer protein (CETL),
also known as plasma lipid transfer protein. The encoded protein is essential
for the transport of lipids, mainly cholesterol ester and triglycerides, between
lipoproteins (75). Decreased production and/or activity of CETP has asso-
ciated with risk of atherosclerosis (76) and CVD (77). A genetic variant
localized at chromosome 20q13.12, in or near a gene encoding for phospho-
lipid transfer protein (PLTP) is found to be associated with both large and
small HDL. The product of this gene is known to be involved in the transfer
of phospholipids from triglycerides-rich lipoproteins (VLDL) to high density
lipoproteins (HDL) and plays a role in regulating the size of HDL particles
CHAPTER 3. STATISTICAL METHODS FOR GWAS 59
(78).
Loci associated with amino acids and other small molecules
We have identified three loci associated with at least one of the measures
of metabolites involved in amino acid metabolism and other low molecular
weight metabolites. None of these loci have been previously reported for
serum metabolic traits. A variant localized at chromosome 8q12.1 is associ-
ated with serum levels of creatinine. This genetic variant is localized near
a gene encoding for a member of the inositol monophosphatase family (IM-
PAD1). This enzyme catalyses the hydrolysis of phosphoadenosine phosphate
(PAP) to adenosine monophosphate (AMP) (79). Another variant found to
be significantly associated with variations in serum levels of creatinine is SNP
rs7217872 at chromosome 17q13.3. This genetic variant is localized in gene
encoding for rabphilin 3A-like (RPH3AL), which plays an important role in
regulating calcium-ion-dependent exocytosis in both endocrine and exocrine
cells (80). A number of loci at chromosome 22 show association with serum
levels citrate. These genetic variants are localized in a gene encoding for
clathrin, heavy chain-like 1 (CLTCL1), a important enzyme in the formation
of coated vesicles.
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Table 3.1: Summary of the results from the single-SNP association
analysis of serum metabolic traits adjusted for sex.
Gene Marker Ch Pos A1/A2 Leading P Other
APOB rs3923037 2 21069902 A/C S-VLDL-L 5.8E-10 XS-VLDL-L
APOB rs6728178 2 21105581 A/G XS-VLDL-L 1.4E-12 ApoB, M-VLDL-
L, S-VLDL-L
APOB rs6754295 2 21117835 G/T XS-VLDL-L 1.3E-12 ApoB, M-VLDL-
L, S-VLDL-L
APOB rs676210 2 21143176 A/G S-VLDL-L 9.3E-12 ApoB, M-VLDL-
L, XS-VLDL-L
APOB rs693 2 21143847 A/G ApoB 2.4E-9 IDL-L, XS-VLDL-
L
APOB rs673548 2 21149196 A/G S-VLDL-L 7.4E-12 ApoB, M-VLDL-
L, XS-VLDL-L
GCKR rs1260326 2 27642591 C/T M-VLDL-L 4.9E-10 MUFA, L-VLDL-
L
LPL rs10096633 8 19875201 C/T M-VLDL-L 7.7E-11
IMPAD1 rs16921974 8 58362727 C/T Crea 1.6E-19
FADS1-3 rs509360 11 61305135 A/G TotPUFA 7.5E-19 FAw3-FA, TG-PG
FADS1-3 rs174537 11 61309256 G/T TotPUFA 9.9E-53 FAw3-FA, LA,
TG-PG
FADS1-3 rs102275 11 61314379 C/T TotPUFA 1.3E-52 FAw3-FA, LA,
TG-PG
FADS1-3 rs174546 11 61326406 C/T TotPUFA 1.5E-52 FAw3-FA, LA,
TG-PG
FADS1-3 rs174556 11 61337211 C/T TotPUFA 1.0E-51 FAw3-FA, LA,
TG-PG
FADS1-3 rs174570 11 61353788 C/T TotPUFA 6.4E-34 FAw3-FA, TG-PG
FADS1-3 rs1535 11 61354548 A/G TotPUFA 2.6E-52 FAw3-FA, LA,
TG-PG
FADS1 rs2072114 11 61361791 A/G TotPUFA 5.9E-45 FAw3-FA, LA,
TG-PG
FADS2 rs2851682 11 61372588 A/G TotPUFA 2.7E-33 FAw3-FA, TG-PG
FADS2 rs174611 11 61384457 C/T TotPUFA 2.3E-9
FADS3 rs174449 11 61396955 A/G TotPUFA 1.5E-27 FAw3-FA, TG-PG
FADS3 rs174450 11 61398118 G/T TotPUFA 8.3E-29 FAw3-FA, TG-PG
FADS3 rs1000778 11 61411881 A/G TotPUFA 3.3E-17 TG-PG
RAB3IL1 rs174478 11 61435152 G/T TotPUFA 1.1E-22
LIPC rs166358 15 56468097 A/G L-HDL-L 1.6E-13 XL-HDL-L
LIPC rs1532085 15 56470658 A/G L-HDL-L 7.0E-25 PC, XL-HDL-L,
XS-VLDL-L
LIPC rs415799 15 56478046 A/G L-HDL-L 2.3E-14 L-HDL-L, XL-
HDL-L
LIPC rs16940213 15 56482629 C/T L-HDL-L 1.6E-11
LIPC rs473224 15 56524633 G/T L-HDL-L 1.7E-11
LIPC rs261336 15 56529710 A/G XL-HDL-L 2.0E-12
CETP rs3764261 16 55550825 A/C L-HDL-L 9.3E-18 ApoA1, M-HDL-L
CETP rs1532624 16 55562980 A/C ApoA1 3.8E-12 L-HDL-L
RPH3AL rs7217872 17 88988 C/T Crea 3.5E-10
PLTP rs6065906 20 43987422 C/T XL-HDL-L 3.2E-11 S-HDL-L
CLTCL1 rs712964 22 17530671 C/T Cit 1.8E-11
CLTCL1 rs1061325 22 17558649 C/T Cit 9.7E-10
CLTCL1 rs2073740 22 17570666 A/C Cit 2.6E-9
CLTCL1 rs885978 22 17572780 A/G Cit 1.8E-9
CLTCL1 rs1340958 22 17627886 A/G Cit 1.2E-9
Gene, the plausible candidate gene in the locus or the nearest annotated gene to the lead
SNP; Marker, SNPs with P < 9.8× 10−9 (standard genome-wide statistical significance
level of P < 5 × 10−8 corrected for the total number of tested metabolic phenotypes;
m = 51); Ch, Chromosome; Pos, SNPs position at the corresponding chromosome; A,
listed are 1st major allele, 2nd minor allele; Leading, The serum metabolites with best
p-value among the traits; P, p-value for the leading traits; Other Additional traits with
P < 9.8× 10−9.
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3.2 Multi-SNP analysis
Analysing one SNP at a time can be a valid approach if a single genetic vari-
ant or a number of unrelated variants are responsible for variations in a phe-
notype. However, for most complex traits - which are known to be controlled
by a combination of multiple genes potentially interacting between them -
the per-SNP approach is seldom able to provide accurate estimates of genetic
effects to complex traits. An alternative class of methods for analysing SNP
data are multivariate models. This class of methods takes into account all
factors potentially related to the outcome simultaneously. However, when
the number of predictors is greater than the number of observations p >> n
- which is the typical situation in GWAS studies - the joint analysis of all
genetic data becomes infeasible using Ordinary Least Squares methods. Pe-
nalized regression methods are an attractive class of techniques for variable
selection and has been effectively applied to deal with the high-dimensional
data.
In this section HyperLasso (Hlasso) regression (81) - a generalization of
the Lasso approach - is applied as a variable selection method in a multi-SNP
association analysis. With this method the parameters’ estimation is per-
formed while applying a penalty function, the Normal-Exponential Gamma
probability density (NEG), that causes shrinkage of the regression coefficients
towards zero. This is equivalent to find the posterior mode in a Bayesian re-
gression framework with the NEG prior. The mode at zero for some of the
coefficients in the prior reflects the belief that the variable’s effect has a high
probability of being near zero. Posterior mode with non-zero values are in-
dicative of markers-trait association. Because only the posterior mode is
found, the algorithm is Bayesian-inspired rather than fully Bayesian. With
this method, we attempt to find the subset of SNPs that best explain the
phenotype variation for a specified type I error.
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3.2.1 Lasso
The Least absolute shrinkage and selection operator (Lasso), originally pro-
posed by Tibshirani (82) is a widely used shrinkage method in regression
analysis for large models. The Lasso procedure performs regularized pa-
rameter estimation and variable selection at the same time. It minimizes
the residual sum of squares by the addition of a L1 norm penalty, namely∑p
j=1 | βj |≤ λ, corresponding to the sum of absolute values of the regression
coefficients. This selective shrinkage favours sparse solutions and allows the
handling of extremely large datasets.
Suppose we have data (xi, yi) , where i = 1, 2, ..., N is the total number
of observations, yi is the dependent variable and xi = (xi1, ..., xip) is a 1 ×
p vector of explanatory variables. Assume that the observations yis are
conditionally independent given the xij and that the data xij are standardized
so that the mean is 0 and the standard deviation is 1. The Lasso estimate
of the coefficients βˆ
Lasso
= (βˆ1, ..., βˆp) can be achieved by:
βLasso = argmin

n∑
i=1
(
yi −
∑
j
βjxij
)2 subject to ∑
j
| βj |≤ λ ,
where βLasso is the set of shrunk coefficient estimates that minimizes
the residual sum of squares subject to constraint. The parameter λ ≥ 0
is the penalty factor and plays an important role controlling the degree of
shrinkage. Tibshirani (82) observed that estimating the parameters using
the Lasso approach is equivalent to a Bayesian maximun a posteriori (MAP)
estimate using the double exponential prior (DE) for all the βj with mode at
zero.
p(βj | λj) = (λ
2
) exp(−λ | βj |)
Assuming that λj = λ∀j , the prior for β can be expressed as the product
of p independent DE densities
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p(β | λj) =
p∏
j=1
(
λ
2
) exp(−λ | βj |)
Figure 3.1 shows the density of the DE distribution for penalty factor λ
equal to 0.5 and 1. As the value of λ increases more mass is placed around
zero and less in the tails. With large values of λ the probability of the co-
efficients to be retained by the model decreases. In a Bayesian framework,
large values of the penalty factor λ reflect the prior belief that the effects of
variables will be near zero. Small values of λ encode no prior assumption
about the effect size.
Figure 3.1: The DE density distribution for penalty factors λ equal to
0.5 and 1.
Although the Lasso method has been successfully applied to a range of
studies, the Laplace implemented in the Lasso has the limitation of over-
shrinking informative variables. The light tails away from zero correspond
to a prior belief that non-zero effects are small(81). In this way non-zero
parameters tend to be severely shrunk towards zero, producing estimates
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that are either small or zero. Ideally the model should retain parameters
that are informative and thus, important for the model.
3.2.2 HyperLasso
To overcome the limitation of over-shrinking, Hoggart et al. (2008) (81)
proposed the use of a generalization of the double exponential distribution,
the normal exponential gamma (NEG) which is sharper at zero and heavier
at the tails. Parameters with non-zero effect size will be less shrunk once
included in the model.
The normal exponential gamma can be represented as:
NEG(β | λ, γ) =
∫ ∞
0
∫ ∞
0
N(β | 0, σ2) Ga(σ2|1, ψ) Ga(ψ2|λ, γ2) dσ2 dψ
= k exp
β2
4γ2
D−2λ−1
| β |
γ
.
where λ and γ are the shape and the scale parameters, respectively, D is
the parabolic cylinder function and k is the normalizing constant. Algorithms
for computing the parabolic function and its derivatives are described in
Zhang and Jin (83). Figure 3.2 shows three NEG density functions with
λ values equal to 0.05, 1 and 10. The shape and scale are the parameters
that control the intensity of the peak and the gradient of the tails. When
the shape is small the NEG density function presents a sharp spike at zero
and very high gradients near zero, but flat tails away from zero. The peak
around zero - as with the DE - corresponds to the prior belief that there are
few true causal variables and severe penalty on any non-zero coefficient. The
NEG has flatter tails than the DE which results in less severe shrinkage of
non-zero parameter towards zero. For large values of λ the NEG is peaked
at around zero and converges to the DE distribution.
Hoggart et al. (81) implemented a CLG algorithm (84) (85) to obtain
MAP estimates. The algorithm is run several times with the order of the
SNPs permuted at each run. If a set of SNPs carries the same information, the
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Figure 3.2: Logarithms of NEG and DE densities.
Figure taken with permission from PLoS genetics, 4(7), Hoggart, C. J., Whittaker,
J. C., De Iorio, M., and Balding, D. J. (2008) Simultaneous analysis of all SNPs
in genome-wide and re-sequencing association studies (81).
algorithm chooses only one of the markers, reducing in this way redundancy.
3.2.3 The HyperLasso regression analysis
Here we present a GWAS analysis of NMR-based metabolites where the
HyperLasso regression is applied. With this method, we attempt to find the
subset of SNPs that best explains the phenotype variation for a specified
type I error.
• Materials and Methods
For this analysis we use the same set of metabolic traits and genetic mark-
ers that were investigated with the single-SNP approach. Prior to analysis
metabolic data were log-transformed to reduce the skewness of the data and
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the model was adjusted for sex differences in serum metabolites. As for the
per-SNP analysis, we assumed an additive genetic contribution to the phe-
notype value.
The software runHLasso (86) was used to perform the HyperLasso regres-
sion analysis. Although, the case-control phenotype is the default design,
runHLasso can also accommodate continuous phenotypes using the linear
regression assumption of Gaussian residuals. We considered the NEG dis-
tributions as prior distributions for the effect-size parameter. The genotype
data were standardized prior to analysis to have mean zero and standard de-
viation equal to one. As previously described, the NEG probability density
function has two parameters, a scale parameter and a shape parameter. In
a simulation study, Hoggart et al. (81) showed that shape parameter λ of
0.05 was the most suitable value to select the causal variants given an appro-
priate Type I error. Large values of λ result in several tightly-linked SNPs
being brought to into the model whereas smaller values of λ gave rise to com-
putational problems. Stephens and Balding (2009) (87) suggested that the
NEG distributions with lambda values between 1 and 2 were most suitable
to identify non-zero effect variants, since small values of λ tend to give more
weight to SNPs with large effect sizes. Therefore, the input parameters used
to run Hlasso were defined as follows: 1) The NEG shape parameter (λ) was
set to 0.05, 1 and 2; 2) the per-SNP type-I error rate (α) was set at 10−5; 3)
the number of mode searches was set to 10.
• Results
The results for the HyperLasso regression are based on the higher posterior
mode found from 10 permutations of the search order using the optimization
algorithm described in Hoggart et al. (81). In Table B.1 we present the
best-fitting model found for each of the NMR serum metabolites for type I
error α = 10−5 and shape parameter λ of 1. These results are very similar
to those using λ of 0.05 and 2. From a total of 318,443 SNPs, 381 were
identified by the HyperLasso regression as associated with at least one of 51
serum metabolites. The number of SNPs included in the best-fitting models
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largely vary between metabolites. For instance, 38 genetic variants were re-
turned by the HyperLasso regression as the subset of SNPs that best explain
variations in serum levels of glycerol for the specified type I error whereas
only two SNPs were returned for serum levels of leucine.
Of the set of SNPs retained by HyperLasso regression, 19 were also iden-
tified by the single-SNP test and all of them have been previously associated
with metabolic traits (41, 42). These loci correspond to genetic variants lo-
calized in or near genes encoding for proteins involved in the metabolism of
serum metabolites such as apolipoprotein B-100 (APOB), glucokinase regu-
latory protein (GCKR), lipoprotein lipase (LPL), fatty acid desaturase clus-
ter (FADS1,FADS2,FADS3), hepatic lipase (LIPC), cholesteryl ester trans-
fer protein (CETP), phospholipid transfer protein (PLTP), clathrin, heavy
chain-like 1 (CLTCL1). Interestingly, we observe that SNP rs1260326, which
was previously identified only for total lipids in VLDL subclasses, has been
retained by HyperLasso regression for a larger number of metabolites includ-
ing amino acids such as alanine and isoleucine, pyruvate and total triglyc-
erides (TGtoPG). As already mention, GCKR plays an important role in the
metabolism of triglycerides and glucose(65, 66, 67, 68). Recently, significant
association has been found between SNP rs1260326 and alanine as well as
VLDL and total triglycerides (42). Levels of isoleucine have been shown to
be associated with the risk for developing type 2 diabetes (34). However,
to the best of our knowledge association between this genetic variant and
isoleucine, pyruvate has not been previously reported.
Among the set of genetic variants returned by HyperLasso regression but
not identified by single-SNP tests, the following SNPs are in or near genes
encoding proteins known to be associated with cardiometabolic traits. For
total lipids in IDL as well as in small, medium and large LDL, we iden-
tify a genetic marker (rs646776) at 1p31. This genetic variant is localized
in a gene encoding for cadherin EGF LAG seven-pass G-type receptor 2
(CELSR2). Previous studies have reported a strong association between
variants at CELSR2 and levels of total cholesterol, suggesting a potential
implication of this gene in cholesterol metabolism and coronary risk (88, 89).
Another SNP (rs2056387) also localized at 1q12 was identified for concen-
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tration levels of FAw3toFA. This SNP is localized in a gene encoding for
ryanodine receptor 2 (RYR2), a protein found in cardiac muscle sarcoplas-
mic reticulum. The encoded protein is one of the components of a calcium
channel and has been found that variations in RYR2 gene are among the
causes of familial arrhythmogenic right ventricular dysplasia type 2 (90). A
SNP (rs2943641) at 2q36.3 was identified for isoleucine. This marker is local-
ized near a gene encoding for insulin receptor substrate 1 (IRS1). Variations
in the gene encoding insulin receptor substrate (IRS)-1 have been reported
to be associated with the risk of type 2 diabetes and susceptibility to insulin
resistance (91, 92). Additionally, it has been reported that increased con-
centration of isoleucine along with another four amino acids (valine, pheny-
lalanine, tyrosine and leucine) are associated with the risk type 2 diabetes
development (34). However, to our knowledge, association between genetic
variants at this gene and isoleucine has not been previously reported.
At 4q32.1, a genetic variant (rs1328925) localized in a gene encoding for
transmembrane protein 144 (TMEM144) was identified for total lipids in
small VLDL. Association between this genetic marker and blood pressure
and arterial stiffness has been reported in a previous genome-wide associa-
tion study (93). A SNP (rs2000571) at 11q23.3 was identified for total lipids
in small VLDL which encodes for apolipoprotein A-I (APOA1); apolipopro-
tein C-III (APOC3); apolipoprotein C-IV (APOC4) and apolipoprotein A-V
(APOA5). This set of apolipoproteins is the main class of apolipoprotein
in HDL and to a lesser extent with VLDL. They are known to be impor-
tant determinant of plasma triglyceride levels. Furthermore, genetic vari-
ants of apolipoprotein A-V have been associated with abnormal VLDL-TG
metabolism (94). At chromosome 19, the marker rs157580 was associated
with total lipids in very small VLDL, IDL and large LDL as well as ApoB.
Candidate genes for this variant are: mitochondrial import receptor sub-
unit TOM40 homolog (TOMM40) and apolipoprotein E cluster (APOE).
Apolipoprotein E is a key protein constituents for cholymicrons, VLDL, IDL
and HDL and plays a critical role in lipoprotein metabolism and cardio-
vascular disorders (95). A SNP (rs1800961) at chromosome 20q13.12 was
associated with total lipids in large HDL. This SNP is localized in a gene
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encoding for hepatocyte nuclear factor 4, alpha (HNF4A). Genetic variant
in HNF4A gene have been associated with total levels of cholesterol in HDL
(96).
HyperLasso regression analysis and LD
A typical situation is GWAS studies is that multiple tightly-linked SNPs are
identified for the same trait. Such a situation can happen because there
are several highly-correlated true causal variants or because there is only
one causal variants and all the others identified SNPs show association only
through their tight-linkage to the causal SNP. While the selection of highly
correlated SNPs can be biologically informative, most of tightly-linked SNPs
will provide redundant information about the genetic regions associated with
the phenotype of interest. A key feature of the HyperLasso regression is that
in presence of high LD between genetic variants, typically only one variant
will be chosen to be included in the model, reducing information redundancy.
In order to explore this property of HyperLasso regression, we calculated
the correlation structure (LD) among the selected genetic variants included in
the best-fitting model and compared them to the results from the single-SNP
approach. We simplify this analysis by only looking the ten leading traits
(see Table 3.1). The correlation structure for the set of SNPs identified in the
single-SNP analysis are presented in Figure B.2 and for HyperLasso regres-
sion in Figure B.3. We observe that SNPs selected by HyperLasso regression
are in general in low LD (|r| < 0.5) (see Figure B.3). Among the SNPs iden-
tified for serum levels of apolipoprotein B (APOB), only two SNPs (rs639
and rs6728178 at chromosome 2) were in hig LD (|r| > 0.8). In a similar way,
we observe that of the thirty four genetic variants included in the best model
for total levels of PUPA, only one pair of SNPs (rs10808546 and rs6982636)
is in high LD (|r| > 0.9). On the contrary, the majority of genetic markers
identified by the single-SNP are in high LD among them (Figure B.2).
Based on these results, we can conclude that LD is more effectively han-
dled by HyperLasso. This analysis shows that when a genetic region which
is tagged by multiple SNPs in high LD - is found to be associated with a
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given phenotype, the Hlasso generally selects just one SNP from this region.
Unless the set of SNPs are in perfect LD, the selected genetic variant will typ-
ically be the one showing the strongest signal. This feature of the Hlasso has
two main benefits: 1) while HLasso might identify the same genetic regions
related to the phenotype as the single-SNP analysis, it will return a less re-
dundant set of variants; 2) by selecting a subset of low-LD and strong-signals
SNPs, the HyperLasso approach might offer better results in localizing the
true causal SNPs.
3.3 Multiple response analysis
Tests of association in GWAS studies are generally conducted one-phenotype
at a time, without taking into consideration the correlation structure between
phenotypes. However, many complex disorders like diabetes, hypertension or
obesity are typically studied based on a cluster of risk factors which are them-
selves intercorrelated. Therefore, in situations where multiple phenotypes are
related by their risks to a given disorder, the joint analysis of all phenotypes
can provide a more powerful approach to detect genetic associations (97, 98).
Several approaches have been proposed for performing multivariate associ-
ation tests on GWAS studies (99, 100, 101, 102). Yet, despite methods for
multivariate association analyses are available, this approach is still rarely
used in GWAS of correlated complex phenotypes.
In this section, we investigate the application of multiple responses meth-
ods to jointly analysis different sets of correlated phenotypes. To this aim,
we consider the most general case of multiple response models, the Seem-
ingly Unrelated Regression (SUR). The SUR-based analysis is performed for
the genetic variants identified for at least one of the fifty one NMR serum
metabolites in the single-SNP analysis. The results of the SUR analysis are
compared and discussed with those obtained using single-SNP association
analysis.
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3.3.1 SUR model
Multivariate association analysis for correlated qualitative phenotypes is per-
formed using the Seemingly Unrelated Regression (SUR)(103). SUR is an
extension of Ordinary Least Squares estimation which takes into account the
residual correlation structure across the univariate linear regressions of each
phenotype. The generic expression for a system of SUR applied to genotype
data can be illustrated as follows.
Lets N be the total number of unrelated subjects. For each individual ob-
servation i, there are P dependent variables yi1, .., yij, ..., yiP . From the same
individuals, L SNPs are genotyped. We indicate with Xj the N × (Kj + 1)
design matrix, with Kj represents the number of terms in the model for
phenotype Yj excluding the intercept, so that Yj = Xjβj + j with βj =
(β0j, ..., βkj)
′ a (Kj + 1)× 1 vector of coefficients and j = (1j, 2j, ..., jN)′ a
N × 1 vector of zero-mean random error terms. Under the SUR model, the
system of P equations can be written as (103):
y1
y2
...
yP
 =

X1 0 · · · 0
0 X2 · · · 0
...
...
...
0 0 · · · XP


β1
β2
...
βP
+

1
2
...
P
 (3.3)
The SUR model can be also presented in a more compact way as:
Y = Xβ +  (3.4)
with Y = (Y ′1 , Y
′
2 , ..., Y
′
P )
′, β = (β′1,β
′
2, ...,β
′
P )
′, = (′1, ′2, ..., ′P )′, and
X a J × K block-diagonal matrix, J = N × P , K = ∑jKj. The resid-
ual errors  are assumed to be normally distributed with mean 0 and with
covariance matrix given by:
Σ = Σ ⊗ I
where I is the identity matrix with size N ×N and Σ a P ×P matrix with
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generic entry σjj′ = E(ijij′) for j = 1, ..., P, i = 1, ..., N . The SUR model
allows different genetic effects for different correlated traits as well as the
possibility that some loci might be associated with some of the phenotypes
but not all of them.
3.3.2 The SUR analysis
The list of SNPs identified by the single-SNP analysis are re-analysed follow-
ing a multiple response approach. The SUR analysis results are compared
and discussed with those obtained using the single-SNP association approach.
• Materials and Methods
From our previous analyses, we observed that some of the metabolic mea-
sures belonging to the same metabolic class or involved in the same molecular
pathway showed association with a similar set of genetic variants. For in-
stance, we identified a set of genetic variants localized at chromosome 2 which
were mainly associated with total lipids in VLDL subclasses. In a similar
way, genetic markers at chromosomes 15, 16, 20 showed stronger association
with total lipids in HDL subclasses than with any other class of lipopro-
teins. Therefore, in the SUR-based analysis, the previously identified genetic
markers are re-analysed according to the metabolic group to which they were
significantly associated.
We initially constructed four systems of linear equations namely ’VLDL
subclasses’, ’HDL subclasses’, ’metabolites involved in the citric acid cycle’
and ’metabolites involved in the urea cycle’. They represent the four classes
of serum metabolites that showed significant association with genetic vari-
ants in the single-SNP analysis. In the SUR-based analysis, all metabolic
traits included in the same systems of equation are tested for association
with the same set of SNPs. For instance, from the single-SNP association
tests we identified eight SNPs significantly associated with at least one of the
six VLDL-related measures. Therefore, in the SUR analysis, we investigate
the association between these eight genetic markers and all VLDL-related
variables.
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The package systemfit in R environment was used to test for association
between the systems of linear equations and genetic variants. For the SUR
analysis, association between genetic variants and the metabolic traits are
determined using the significance threshold of P < 0.05/K where K is equal
to the number genetic variants tested in each system of equations.
• Results
The results for the SUR analysis are showed in Table B.2-B.5. For the
VLDL system (Table B.2), eight loci were tested for association. Five of
these SNPs, (rs3923037, rs6728178, rs6754295, rs676210, rs673548) do not
show significant association with any metabolic traits under the combined
SUR-analysis. Two SNPs (rs1260326 and rs10096633) are found to be sig-
nificantly associated with all the VLDL subclasses included in the analysis,
with the exception of total lipids in very small VLDL. As indicated before,
the SNP rs1260326 is located in a gene encoding glucokinase regulatory pro-
tein (GCKR) and rs10096633 is located in a gene encoding lipoprotein lipase
(LPL). Interestingly, a strong association is observed between SNP rs1532085
and total lipids in very small VLDL but not with all the other VLDL sub-
classes. These findings may indicate a differential genetic effect between very
small VLDL subclass and all the other VLDL subclasses, which can relate to
a differential role of very small VLDL subclass within the VLDL metabolism.
For the total lipids in HDL system (Table B.3), eight loci were tested for
association. SNP rs261336, which is localized in a gene encoding for hepatic
lipase (LIPC), shows strong association with very large HDL subclasses but
is not associated with large, medium and small HDL subclasses. On the other
hand SNP rs1532085 also localized within hepatic lipase gene shows associ-
ation with large HDL subclasses but does not show any association with all
the other HDL-related traits. In a similar way, the SNP rs3764261, which is
in a gene encoding cholesteryl ester transfer protein (CETP), shows signif-
icant association with large and medium HDL but not with very large and
small HDL. Only one genetic marker (rs6065906) is significantly associated
with all the HDL subclasses included in the analysis. The combined analysis
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of all HDL subclasses indicates a heterogeneous effect of the genetic variants
to the different HDL subclasses. These results may reflect the differential
function that each HLD subclass has in the lipoproteins metabolism.
For the remaining two systems of equations (’metabolites involved in the
citric acid cycle’ and ’metabolites involved in the urea cycle’), we observe
that under the multiple response approach the tested SNPs failed to reach
significant levels (Tables B.4,B.5).
3.4 Summary
In this chapter, we have performed an initial exploratory analysis of genomic
data in combination with metabolomic data. Three different statistical ap-
proaches have been employed to investigate the genetic basis of metabolic
traits. Firstly, we have performed a GWAS analysis based on the standard
single-SNP approach. Following this approach, we have identified a number
of genetic variants significantly associated with metabolic traits. The ma-
jority of these loci have been previously associated with metabolic measures
at genome-wide significance and most of them matched physiological roles
of the associated metabolic traits. Secondly, we have explored the use of
multi-SNP methods such as penalized regression in genome-wide association
studies. Specifically, we have applied the HyperLasso regression as a variable
selection method which allows the identification of the subset of SNPs that
best explain variation in metabolic traits at the specified type I error. Based
on the HyperLasso regression, we have identified genetic variants known to
be related to metabolic traits, some of these finding were not reported by
the single-SNP approach. The HyperLasso regression selected SNPs that
were less correlated with the other SNPs included in the model. In this
manner, HyperLasso identified the same genetic regions associated with the
phenotype as the single-SNP analysis but returning less redundant genetic
information. The last part of this chapter has been dedicated to the use of
multiple response methods to investigate SNP-phenotype associations. The
top SNPs identified in the univariate analysis have been further investigated
following a multiple response approach, which was based on the Seemingly
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Unrelated Regression (SUR) model. Based on this analysis, we have been
able to discriminate between genetic variants that have a significant effect
on all the traits as well as the genetic variants that have significant effect on
several phenotypes but not on all of them.
Chapter 4
Differential Networks
The aim of this chapter is to investigate the use of variations in patterns of
molecular associations as a tool to uncover key differences between different
physiological conditions. To this end, we have developed a formal statistical
approach for the differential analysis of molecular associations via network
representation. The chapter starts with an introduction to the topic un-
der investigation (section 4.1). A brief description of the basic concepts of
network analysis is provided in section 4.2. In section 4.3, first we review
a number of statistical methods commonly used in correlation analysis and
then we present the differential network methodology. We assess the per-
formance of the proposed differential network at identifying differences in
molecular associations between two different groups by performing a simu-
lation study (section 4.4). Subsequently, we illustrate the potential of the
method to reveal molecular differences related to physiological states on a
real data application (section 4.5). We conclude this chapter (section 4.6)
discussing the main results.
The research described in this chapter has been published in: Valca´rcel,
B., Wu¨rtz, P., Seich, a. B., Tukiainen, T., Kangas, A. J., Soininen, P.,
Ja¨rvelin, M., Ala-Korpela, M., Ebbels, T. M. and de Iorio, M. (2011) A
Differential Network Approach to Exploring Differences between
Biological States: An Application to Prediabetes. Plos One. 6 (9),
e24702.
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4.1 Introduction
Abnormal levels of certain molecules in blood or other biofluids are tradition-
ally used as indicators of changes in physiological conditions. While the study
of variations in mean levels of single molecules is of great importance, looking
at those changes is not enough to fully understand the biological basis of dis-
ease development. For instance, in the transition process from health towards
disease status, in addition to individual changes in molecules’ abundances,
variations in the pattern of molecular associations are also observed (104).
That is, under different physiological conditions, different patterns of molec-
ular associations can occur (105). The comprehensive analysis of molecular
association patterns and their changes in relation to different physiological
conditions can yield insight into the biological basis of phenotype variation
in the process of disease development, yet the analysis of these molecular
changes is often still underused.
Molecular profiles are complex and information-rich, requiring effective
tools to analyse, visualize and compare the underlying molecular features in
detail. Association measures of molecules concentrations such as correlation
and partial correlation are useful approaches to explore underlying features
of phenotypic variations. However, the biological interpretation of the corre-
lation matrix is very complex, especially in the analysis of highly correlated
molecular processes and data such as in the case of serum metabolites.
With advances in the theory of complex networks (106) and its application
to describe architectural features of molecular systems (107), network-based
approaches have been increasingly used to capture underlying properties of
biological systems. An appealing feature of this approach is the ability to
create a visual simplification of the observed pattern of molecular associa-
tions. Network theory is also of interest to identify variations between differ-
ent physiological stages as well as biological systems. Several studies based
on gene expression data have already explored the idea of using differen-
tial network-based methods for a variety of purposes. Examples include the
use of association networks to identify species-specific network connections
(108), gene expression associations to detect body weight-related genes (109)
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or the assessment of changes in association patterns in patients with chronic
fatigue syndrome (110). A more formal statistical methodology for differen-
tial analysis of gene associations was presented in Gill et al. (2010)(111). In
this study all the statistical tests were based on a set of scores that measure
the strength of the genetic associations in two different networks. An early
analysis of metabolic association networks employed metabolic correlation
networks to distinguish silent phenotypes in plants (112). More recently,
Szymanski et al. (2009)(113) demonstrated the potential of metabolic net-
work analysis to identify important molecules for stress adaptation. Yet,
despite being a promising approach, few studies have employed metabolic
association networks to investigate underlying features of phenotypic varia-
tions.
In this study, we describe a formal statistical approach for the differen-
tial analysis of metabolic associations and demonstrate the potential of the
methodology to reveal metabolic differences related to (patho) physiological
states in the context of lipoprotein metabolism.
4.2 Basic Concepts of Complex Networks
Many natural phenomena such as gene expression, protein-protein interac-
tion networks and metabolic networks are all examples of complex systems
and can be naturally modelled using network methods. A network is repre-
sented by a set of nodes, which in biology stand for each of the biological
entities under study such as genes, proteins or metabolites and a set of edges
between nodes which denote interaction between components (e.g. protein-
protein interaction, metabolic reactions). Connections between nodes in bi-
ological systems can exhibit very complicated structural patterns. With the
detailed analysis of the networks’ topological properties, key features of the
organizing principles of the complex systems can been uncovered. These net-
works measurements allow the quantifiable description as well as comparison
of different complex networks. The most basic and commonly used topolog-
ical properties for network analysis are listed and described below.
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Degree, ki, (or connectivity) indicates the number of connections that a
node i has in the network. The degree of a node is a very elementary network
measure, but it is a very important property because it helps to characterize
nodes within the network. The number of connections reflects the relative
importance of a node in a network. Highly connected nodes also known
as hubs generally serve fundamental functions within the system, indicating
therefore key points of the represented system (114) .
Networks density, D, measures how well connected a network is by
comparing the number of connections in a given network with the maximum
possible number of connections between all pairs of nodes. The density is
calculated as follows:
D =
2× E
N × (N − 1)
where N is the total number of nodes and E denodes the numbers of links
in a given graph.
The average node degree, A, is a connectivity property which mea-
sures how many connections and nodes are in a given graph. The average
degree is calculated as follows:
A =
2× E
N
Degree distribution, P (k), is the measure that gives the probability
that a chosen node i has k links. P (k) can be calculated by computing the
number of nodes with degree k = 1, 2, ... and dividing by the total number
of nodes N .
Slope of degree distribution is the value of the scaling exponent (−γ)
for a power-law degree distribution. Estimation of this value can be made
through the log-log plot of the connectivity distribution, in which a straight
line with slope −γ is expected if the networks is scale-free.
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Path length is the measure that gives the number of nodes that need to
be crossed while going from one node i to another node j. The path with the
less number of steps between two nodes is called the shortest path and has
a special role in the description of network structure (115). Another measure
related to path length is the average path length which gives the average
length over the shortest paths between all pairs of nodes.
Clustering coefficient, ci, is the network measure that indicates to
what extent the neighbours of a selected node i are connected to each other.
In other words, in many networks it is likely that if node i is linked to node
j, and node j is connected to node g, then i and g are also linked. Clustering
coefficient can be obtained for each node i by:
c(i) =
2Ki
ki(ki − 1)
where Ki denotes the links observed among the neighbours of node i and
ki represents its degree. For ki < 2, ci , is defined to be zero.
Betweenness centrality, bi, is the measure that indicates how central
a node i is in the graph and it can be calculated by:
b(i) =
σ(i)
σ
where σ denotes the total number of pairs of nodes and σ(i) denotes the
number of shortest paths between nodes that pass through i.
4.3 Statistical Methods
In this section we describe the statistical methods applied to investigate
differences in patterns of molecular association between different groups.
Firstly, a number of methods commonly used for correlation analysis will
be reviewed and then we will describe the differential network methodology.
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4.3.1 Individual network analysis
The pattern of metabolic associations for each group is investigated by con-
structing individual networks. To measure the underlying interdependencies
between variables, we consider three different correlation methods namely,
Pearson’s correlation, partial correlation and shrinkage partial correlation.
These correlation procedures compute the correlation coefficients which de-
scribe the degree and direction of linear relationship between two variables.
The correlation coefficient takes a value ranging between -1 to 1. The sign
of the correlation coefficient indicates the direction of the relationship, either
positive or negative. A positive association (> 0) indicates that two vari-
ables tend to increase or decrease simultaneously whereas a negative value of
(< 0) indicates that one variable tends to increase when the other decreases.
Perfect correlation between two variables is indicated by an absolute value
of 1.
Pearson product moment correlation coefficient (Pearson’s cor-
relation): Pearson’s correlation (r) is the most commonly used measure of
correlation. The Pearson’s correlation between two given variables, Yi and
Yj, can be obtaining as follows:
rYi,Yj =
cov(Yi, Yj)
σYiσYj
(4.1)
where cov(Yi, Yj) is the covariance between variables Yi and Yj and σYi , σYj
the standard deviation for such variables. Significant correlation between two
variables is defined by computing the p-value for the two-sided test with null
hypothesis:“Correlation between variables Yi and Yj is equal to zero”versus
the alternative hypothesis:“Correlation between variables Yi and Yj is not
equal to zero”. The p-value is computed using the Fisher’s z’ transformation
(116):
zYi,Yj =
1
2
ln(
1 + rYi,Yj
1− rYi,Yj
) (4.2)
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where ln is the natural logarithm. The Z-statistics is:
Z =
zYi,Yj√
N − 3 (4.3)
where N is the sample size. We reject the null hypothesis at significance
level α = 0.01
I
, where I = M(M−1)
2
represents the total number of possible
metabolite pairs.
Partial correlations: Partial correlation quantifies the correlation be-
tween two variables conditional on the remaining variables. In this way, we
can determine to what extend correlations between two variables, Yi and Yj,
are direct and therefore do not originate via intermediate variables. When
the number of observation is greater than the number of variables (n > p),
the covariance matrix (Σ) is invertible and the partial correlation matrix can
be calculated from the inverse of the covariance matrix Σ−1. If we define
C = Σ−1, the partial correlation rpartialYi,Yj between two variables Yi and Yj can
be defined as follows:
rpartialYi,Yj = −
cYi,Yj√
cYi,YicYj ,Yj
(4.4)
where cYi,Yj is the ij− th element of the inverse of the covariance matrix (C).
To interpret zero partial correlation as an indicator of conditional indepen-
dence between two variables, the assumption that all variables included in
the calculation have a joint multivariate normal distribution must hold. To
determine the significance of the partial correlations, the Fisher’s transfor-
mation in equation 4.2 and the Z-statistics in equation 4.3 become:
Z =
zpartialYi,Yj√
N − q − 3 (4.5)
where N is the sample size and q is the number of variables on which the
calculation is conditioned.
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Shrinkage partial correlations: The calculation of the partial correla-
tion matrix can be a straightforward process in situations where the number
of variables is lower than the number of observations n > p. However, the
calculation of the partial correlation is problematic when the number of vari-
ables is very large. If the number of variables is greater than the number
of observations n << p, the covariance matrix looses its full rank and its
inverse does not exist. Moreover, due to the sheer number of pairwise corre-
lations in biological systems, the interpretation of the correlation matrix is
very complex. To overcome these difficulties and avoid the potential problem
of over-fitting, we propose the use of a linear shrinkage estimator to calculate
the covariance matrix and hence the partial correlations between variables.
Details about the method employed for the calculation of the partial corre-
lation matrix can be found in (117). The method proposed by the authors is
based on the combination of the sample covariance matrix U and the shrink-
age target matrix T to obtain a regularized estimate of the covariance matrix
U∗, as follows:
U∗ = λT + (1− λ)U, (4.6)
where λ is the shrinkage intensity. Here, we use the identity matrix as the
shrinkage target T to shrink to zero the covariance elements. In this way, cor-
relations remaining significantly different from zero are indicators of strong
dependence between the variables.
The optimal shrinkage intensity was calculated from the data using the
R package GeneNet. Details about the shrinkage intensity selection and
shrinkage procedure can be found in (117).
Individual networks: Once we have calculated association between
variables, we build the individual networks. The networks are constructed
by drawing the edges between those pairs of metabolites whose association
(Pearson’s correlation, partial correlation and shrinkage partial correlation)
exceeds the chosen criteria for edge inclusion. For our analysis we use a
conservative Bonferroni corrected threshold, p < 0.01
I
, where I = M(M−1)
2
represents the total number of possible metabolite pairs.
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4.3.2 Differential network analysis
The main aim of this study is to test the applicability of association networks
to reveal key metabolic differences between two groups, A and B. To this
end, we propose a statistical framework to perform a differential analysis of
molecular associations. In this analysis, we test the null hypothesis:“The
partial correlations of two metabolites in the two groups are the same”versus
the alternative hypothesis:“The partial correlations of two metabolites in
the two groups are different”by performing a two-sample permutation test.
Given NA samples from the first group (A) and NB samples from the second
group (B) all the samples are pooled together in one set and their labels are
permuted. Permutation was performed for all metabolic variables simulta-
neously. At each iteration, i, of the permutation test two new datasets are
obtained, A∗i and B
∗
i of size NA and NB, respectively. For each of the new
datasets we compute the partial correlation matrix r∗A and r
∗
B. We follow the
same approach described in Equation 4.6 for the estimation of the covariance
matrix and hence the computation of the partial correlation matrix. Finally,
we calculate the absolute difference between the partial correlations among
the new groups, | r∗A − r∗B |. We repeat this procedure 100,000 times.
In order to find those metabolite associations that significantly change
across the two groups we compute the absolute difference between the par-
tial correlations among the two original groups, | robsA − robsB |. The p-values
that indicate which interactions differ significantly between states are ob-
tained by:
p = Pr( | r∗A − r∗B | > | robsA − robsB | )
To define which edges are included in the differential network we set a
cut-off on the two-tailed p-value. For the same sample size, the power to
estimate correlations is lower than that to estimate a change in a single vari-
able mean level. Therefore, we choose to set the cut-off for the inference of
the differential network based on the uncorrected threshold P < 0.01. An
edge in the differential network is included if the partial correlations between
two given metabolites are significantly different across the two groups. The
association network inferred under this set-up is referred to as the differential
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network.
Computation of Pearson’s correlation, partial correlation and shrinkage
partial correlation were performed using the R package GeneNet. The indi-
vidual and differential networks were built and visualized using the R package
igraph. All analysis was carried out using R version 2.10.0.
4.4 Simulation study
A simulation study was designed to assess the performance of the differential
network at identifying differences in pair-wise association between variables
across different groups. Firstly, the differential network method was tested
when the null hypothesis:“The partial correlation of two variables in the two
groups is the same” is known to be false. For this study, we simulated
two data sets (A,B) each of them consisting of five variables and N=1,000
observations per variables. For group A, each of the variables’ values were
simulated by sampling from a multivariate normal distribution with means
(µ) equal to 0 and Σ equal to the covariance matrix. The identity matrix
was initially used to define partial correlations between variables. Then,
for two randomly selected variables (Yi and Yj) the partial correlation co-
efficient rAYi,Yj was simulated by sampling from a uniform distribution. The
variables’ variances (σ2A) were generated from an inverse-gamma distribution
with shape α = 1 and scale β = 1. The diagonal entries of the covariance
matrix were increased sufficiently to ensure positive definiteness.
To simulate the variable’s values for group B, we followed similar pro-
cedure as previously described, that is, the values of each observation were
simulated by sampling from a multivariate normal distribution with means
(µ) equal to 0 and Σ equal to the covariance matrix of the variables. The
partial correlation between all variables in group B were initially set to be
equal to those in group A. Then for the two previously selected variables Yi
and Yj a change in their partial correlation coefficient was introduced so the
partial correlations of variables Yi and Yj between the two groups A and B
are different. The change in partial correlations was simulated by sampling
from a uniform distribution. As with group A, an inverse-gamma distribu-
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tion with shape α = 1 and scale β = 1 was used to generate the variable’s
variances (σ2B). We constructed the covariance matrix using each variables
standard deviation (σB) and ensured positive definiteness of the covariance
matrix by increasing sufficiently the diagonal entries.
In addition, the differential network performance was tested when the
null hypothesis:“The partial correlation of two variables in the two groups is
the same” is known to be true. The data sets for A and B for this study were
simulated following the same procedure as previously described. In this sim-
ulation, the change in partial correlation between Yi and Yj between groups
A and B was equal to zero.
Once data sets were simulated, we analysed them using the differential
network approach presented in subsection 4.3.2. For the inference of the
differential network, we used a significance threshold of α = 0.01. The sim-
ulation process was repeated 100 times. Each of the times the total number
of connections captured by the differential network were recorded.
Scenarios for data simulation
With this simulation study, we are interested in investigating: (1) whether
the strength of association between variables influences the performance of
the differential network, (2) whether a small and/or large differences in asso-
ciation between two variables and across the two groups are captured by the
differential network method. To evaluate these aspects of our methodology,
we simulate the data sets following six scenarios. For variables, Yi and Yj :
1. Scenario 1: The partial correlation between Yi and Yj in group A is
low (| rAYi,Yj |≤ 0.1). The difference in association between these two
variables across the two groups, A and B, is small (| rAYi,Yj − rBYi,Yj |≤
0.1).
2. Scenario 2: For group A, the partial correlation between variables Yi
and Yj is low (| rAYi,Yj |≤ 0.1). The difference in correlation between
these two variables across the two groups is large (| rAYi,Yj−rBYi,Yj |≥ 0.5).
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3. Scenario 3: The pairwise correlations between Yi and Yj is high for
group A (| rAYi,Yj |≥ 0.5). The difference in correlation between these
two variables across the two groups is small (| rAYi,Yj − rBYi,Yj |≤ 0.1).
4. Scenario 4: For group A, the pairwise correlations between two vari-
ables is high (| rAYi,Yj |≥ 0.5). The difference in correlation between
these two variables across the two groups is large (| rAYi,Yj−rBYi,Yj |≥ 0.5).
5. Scenario Null 1: The partial correlations between variables Yi and
Yj is low | rYi,Yj |≤ 0.1 and equal between the two for groups | rAYi,Yj −
rBYi,Yj |= 0.
6. Scenario Null 2: The partial correlations between variables Yi and
Yj is high | rYi,Yj |≥ 0.5 and equal between the two for groups | rAYi,Yj −
rBYi,Yj |= 0.
4.4.1 Simulation Study Results
Table 4.1 shows the results from the simulation study. We show the total
number of connections captured by the differential network at each simula-
tion and under each scenarios. A connection is considered to be true if the
difference in association between variables Yi and Yj is correctly identified
by the differential network. A false connection represents any connection
wrongly identified by the differential network.
From this study, we observe that all differences in association are cor-
rectly identified by the differential network when the difference in partial
correlation between two variables is large (scenario 2 and 4). However, if the
difference in association between the variables across the two groups is lower
(scenario 1 and 3), the differential network is not able to identify changes in
association. The results between simulation null 1 and null 2, scenario 1 and
3, scenario 2 and 4 are very similar which indicates that the performance of
the differential network is not affected by the strength of association between
variables for each group, A and B, and it is only affected by the difference
in association. In addition, for all simulated scenarios the number of false
connections identified by our method is very low. Based on this results of the
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simulations, we can conclude that the differential network is able to identify
differential associations between variables.
Table 4.1: Results for the simulation study.
Total Connections TC FC
Null 1 5 0 5
Null 2 7 0 7
Scenario 1 12 1 11
Scenario 2 105 100 5
Scenario 3 11 5 6
Scenario 4 101 100 1
TC, true positive ; FC,false positive. Results are based on 100 simulation pro-
cesses per scenario.
4.5 Case study: Prediabetes dyslipidemias
We illustrate the differential network methodology using a real data set.
Specifically, we explore differences in metabolic associations between indi-
viduals with normal fasting glucose (NFG) and individuals with impaired
fasting glucose (IFG). Impaired fasting glucose also known as prediabetes
refers to a physiological state at which individuals are enhanced risk for de-
veloping T2DM (31). To evaluate metabolic changes related to prediabetes
we use extensive data on lipoprotein subclasses, enabling the assessment of
changes in lipoprotein metabolism, which are known to be strongly connected
to the risk and development of T2DM (58).
4.5.1 Study population and metabolic dataset
For this study we use the NFBC1966 metabolic data. In particular we use
sixty measures of lipoprotein subclasses measured by NMR spectroscopy (see
Table A.1). The data is initially divided into two groups according to levels
of fasting glucose and following the categorical criteria of the American Dia-
betes Society (ADA) for prediabetes classification (118). The normal fasting
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glucose (NFG) group represents individuals with fasting glucose levels lower
than 5.6 mmol/L. The impaired fasting glucose (IFG) group includes indi-
viduals with fasting glucose levels from 5.6 mmol/L to 6.9 mmol/L. Subjects
with fasting glucose levels greater than 6.9 mmol/L, clinically considered as
having type 2 diabetes Mellitus, or missing data on lipoprotein subclass pro-
file and/or glucose measures were excluded which left 4,937 subjects for the
analysis. The sample size for each group is NNFG = 4,406 (2,021 males and
2,385 females) and NIFG = 531 (390 males and 141 females). Due to the
well-known sex-specific difference in lipoprotein profiles (59) we perform the
analysis separately for men and women. Due to a predominance of males
in the IFG group, we base our biological interpretation on the male data;
the differential network for the female data is shown in appendix Figure C.4.
The clinical characteristics of the study groups are presented in appendix
Table C.1.
4.5.2 Results and Discussion
To explore differences in metabolite concentrations between the two defined
groups (NFG and IFG) we perform a non-parametric two-sample Mann-
Whitney test. We determine significant differences in the metabolic con-
centrations by setting a conservative Bonferroni corrected threshold, P <
0.01/M , where M = 60 denotes the total number of measures. The results
for males are shown in Table C.2. This initial inspection of the data showed
no significant differences in concentration levels of the 60 lipoprotein subclass
components between individual with normal fasting glucose and impaired
fasting glucose at the Bonferroni corrected threshold P < 0.01/M . When
the significance threshold is not corrected for multiple testing, P < 0.01,
eleven measures, extremely large VLDL (phospholipids), very large VLDL
(phospholipids and particle concentration), large LDL (phospholipids and
particle concentration), medium LDL (cholesterol, phospholipids and par-
ticle concentration), small LDL (cholesterol and particle concentration) and
Apolipoprotein B show significant differences in concentration levels between
the two groups (NFG vs. IFG).
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The few significant differences in lipoprotein concentrations between the
two groups may reflect a generally healthy status of the young population
studied. Nevertheless, the prediabetic state represents increased risk for the
development of T2DM and it has been suggested that lipid abnormalities are
associated with the progression of T2DM (31). Despite there being only a
few significant variations in the concentration levels of lipoprotein subclass
components between the two groups, we hypothesize that the lipoprotein sub-
class dependencies could be affected and assess this by building association
networks.
• Individual Networks
The individual networks are built to examine the specific pattern of asso-
ciations exhibited under each condition (NFG and IFG). The aim of this
analysis is to explore variations in the observed pattern of metabolic associa-
tions between the groups as well as to define some topological features of the
metabolic networks. The construction of the individual networks is based
on a binary representation of underlying partial correlations (significant and
non-significant partial correlation) and therefore the correlation strength be-
tween the measures is not represented here.
We present the individual networks obtained using three measures of
correlation, Pearson’s correlation (Figure 4.1a), standard partial correlation
(Figure 4.1b) and shrinkage partial correlation(Figure 4.1c). To better il-
lustrate associations between metabolites, in the appendices we also show
correlation maps where the pair-wise associations have been quantified using
the three measures of correlation (Figure C.1, Figure C.2, Figure C.3). Using
partial correlation and shrinkage methods for the network construction, the
number of connections is largely decreased. This implies the reduction in the
network complexity and thus, the improvement on the biological interpreta-
tion of the association networks. These results show the advantage of using
partial correlations in combination to shrinkage methods instead of other
correlation measures, especially when the variables under study are highly
interrelated, such as lipoprotein subclasses.
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Table 4.2: Global properties of the individual networks obtained using
shrinkage partial correlation as measure of pair-wise association.
Topological Properties NFG IFG
Connected nodes 54 54
Isolated nodes 6 6
Total number of edges 134 126
Networks density 0.075 0.071
Average degree 4.41 4.2
Slope of degree distribution -0.12 -0.14
Clustering coefficient 0.26 0.29
The connectivity, k, for each of the nodes can be used to quantitatively
define differences between the two individual networks. The global prop-
erties of NFG and IFG networks are presented in Table 4.2. In terms of
total number of connections, both individual networks represent similar in-
formation (NFG = 134; IFG =126). Six VLDL-related measures are also
isolated in both individual networks. A large number of these links are in
common between the two individual networks. For the IFG network, 83% of
the connections overlap with connections in the NFG network. Despite the
large similarities between the two individual networks, some differences in
the pattern of association between measures can be identified in Figure 4.2).
Overall, LDL-related measures show a tendency to reduce their associations
(light-blue nodes in Figure 4.2) from NFG to IFG state whereas measures
in large to extra large HDL show a relative increase in their associations in
the IFG condition (cluster of extra large HDL, left in Figure 4.2). In rela-
tion to VLDL-related measures, a more heterogeneous pattern of changes in
their pair-wise association is observed. Several measures in medium VLDL
(top and central-right in Figure 4.2) increase their number of associations in
the IFG condition whereas very small VLDL (central in Figure 4.2) and free
cholesterol in medium VLDL present a large reduction in their pair-wise as-
sociations from NFG to IFG state. Overall, the differences between the two
networks represent a reduction in pair-wise association for the IFG network.
The reduced metabolic connectivity can indicate that the inverse relation
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Figure 4.1: The individual networks obtained using: (a) Pearsons correlation;
(b) partial correlation; (c) shrinkage partial correlation as measure of pair-wise
association between the lipoprotein components.
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Figure 4.2: The individual networks inferred from male data. Each of
the connections indicates significant pair-wise association between two lipopro-
tein measures using the Bonferroni corrected threshold p < 0.01/z , where
z = M(M1)/2 is the total number of possible interactions and M=60 is the total
number of metabolites. The NFG network indicates the pattern of pair-wise asso-
ciation for the normal fasting glucose group. The IFG network reflects the pattern
of association for the impaired fasting glucose group. The node size is proportional
to the degree of connectivity (number of connections).
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Topological properties of the individual networks
Figure 4.3: The degree distribution shows the probability that a node i has k
connections in the network. For both individual networks the degree distribution is
well approximated by a power-law. The betweenness indicates how central a node
is in the network. For both individual networks, the nodes with higher degree
connectivity are also the most central nodes.
between small VLDL and large HDL subclasses is less tightly regulated in
the prediabetic state.
Other measures that can be used to quantitatively define the network’s
features are the degree distributions, and the network centrality. The degree
distributions of the individual networks are shown in Figure 4.3. It appears
that both individual networks are scale-free networks, class of networks that
is characterised by a power-law distribution where the probability of a node
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having k links is P (k) ∼ kγ. An important property of scale-free networks is
the existence of a relatively small number of highly correlated nodes, so-called
hubs (106). Triglycerides in small HDL and particle concentration in small
HDL clearly represent the main hubs for both individual networks (central
in Figure 4.2). These highly connected nodes are expected to be the cen-
tral components of the networks, reflecting important points of the network
organization (107). This central property can be quantified by computing
betweenness centrality in relation to the degree connectivity (Figure 4.3).
Although this analysis shows that some low-connected lipoprotein measures
have high betweenness scores, the expected property ’high connectivity-high
betweeness’ holds for both individual networks. The high connectivity and
the central position that small HDL (triglycerides and particle concentra-
tion) have in the individual networks indicate an important role of small
HDL in the lipoprotein metabolism. It is widely accepted that large size
HDL have a protective role in the premature development of coronary heart
diseases (CHD) and related traits (119). However, the role that small HDL
have in the lipoprotein metabolism is still unclear. It has been suggested
that small HDL may contribute to the production of medium and large HDL
particles during maturation of HDL in plasma. In this manner, small HDL
may connect HDL metabolism to VLDL metabolism and also contribute to
atheroprotective the role of HDL in CHD (120).
The global clustering is another measure used to describe the organiza-
tion in complex networks. High values of this measure indicate modular
organization of the network. Both individual networks exhibit this modular
property where values of clustering coefficients are c ≥ 0.25. Furthermore,
metabolites involved in the same clusters are mainly components belonging
to the same lipoprotein subclass e.g. large HDL subclasses with clustering
coefficients c ≥ 0.5. The tendency to form clusters among metabolites par-
ticipating in the same metabolism has been reported previously (121).
Based on the theory of complex networks, the organization of metabolic
systems has been described as large sets of densely interconnected modules
that combine into larger and less interconnected units, with both degree of
clustering and degree distribution following a power law (122). Thus, explor-
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ing the network’s topological properties certain features of metabolic systems
can be determined. However, individual networks do not enable clear iden-
tification of key metabolic differences between the two groups. To approach
this aspect we construct the differential network.
• Differential Network: NFG-IFG
The differential network inferred from male data is presented in Figure 4.4.
Each of the connections in the differential network indicates a significant
change in partial correlation between two lipoprotein measures across the
(patho)physiological conditions. A set of 22 connected measures, organized
in 16 pair-wise interactions are observed. The remaining 38 metabolites show
no differential connections. The differential network indicates that the differ-
ential connections occur throughout a significant increase or decrease in the
pair-wise partial correlation between the lipoprotein measures across the two
groups, as well as significant alteration in the partial correlations sign (with
NFG as reference group). For instance, the largest cluster in the differential
network (right most in Figure 4.4) indicates that large and extra large HDL
(phospholipids and triglycerides, respectively) are differentially connected to
very small VLDL throughout an increase in their pair-wise associations (Fig-
ure 4.4; red edges). In the same way, this connected component (main cluster)
reflects the decrease in partial correlation between measures of small VLDL
(phospholipids and free cholesterol) and phospholipids in very small VLDL
(blue edges). Of biological relevance is the double variation in pair-wise asso-
ciation that is observed between medium VLDL (ester cholesterol) and two
measures of very small VLDL (in the largest cluster, central connections).
This cluster reflects the shift from positive (NFG) to negative (IFG) partial
correlation between medium VLDL and phospholipids in very small VLDL
and the change from negative (NFG) to positive (IFG) pair-wise association
between medium VLDL and particle concentration in VLDL. The interpre-
tation of these variations points to a change in the underlying regulation of
the system.
As with the individual networks, the network’s topological properties
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Differential Network:
NFG-IFG
Figure 4.4: The differential network inferred from males with nor-
mal fasting glucose (NFG) and impaired fasting glucose (IFG). Each
of the connections indicates a significant change in partial correlation between
two lipoprotein measures across the physiological conditions. Edge colours repre-
sent how the partial correlation between two measures has changed across the two
groups.
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Topological properties of the differential network
Figure 4.5: The degree distribution shows the probability that a node i has k
connections in the network. For the differential network the degree distribution
is well approximated by a power-law. The betweenness indicates how central a
node is in the network. For the differential network, the nodes with higher degree
connectivity are also the most central nodes.
can be used to quantitatively define the differential network. Three VLDL-
related measures present the highest connectivity scores. These highly con-
nected lipoprotein measures are the central components of the main cluster
in the differential network (Figure 4.5). The first of these measures, very
small VLDL (phospholipids) is differentially connected to large HDL (phos-
pholipids), small VLDL (free cholesterol), small VLDL (phospholipids) and
very small VLDL (particle concentration). The second measure, medium
VLDL (ester cholesterol) is connected to medium VLDL (particle concen-
tration) and very small VLDL (particle concentration). The last measure,
very small VLDL (particle concentration) is connected to very large HDL
(triglycerides) and very small VLDL (triglycerides).
The differential network indicates that change in metabolic associa-
tion occur throughout the size-range of lipoprotein subclasses, except the
smallest HDL. For instance, both extremely large and small VLDL particles
decrease their partial correlation with medium LDL cholesterol (cholesterol
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ester), possibly reflecting decreased regulation of the lipoprotein cascade, as
observed for the individual networks. The most prominent cluster in the
differential network reflects differential changes (in the correlation pattern)
between very small to medium VLDL subclasses with large and very large
HDL subclasses. For instance, there is an increase in partial correlation of
phospholipids in very small VLDL with phospholipids in large HDL. Phos-
pholipids are key metabolites in shaping HDL (123). In addition, we find
that large VLDL and very large HDL change in partial correlation (upper
most cluster), and that cluster also involves LDL subclasses. While high
levels of large VLDL particles are known to cause increased risk for diabetes
(31, 124), the pathogenic role of small VLDL is less recognized. The finding
of decreased metabolic regulation between small VLDL and large HDL em-
phasises the continuous nature of VLDL to LDL cascade. In addition, the
lack of differential associations for composite measures such as apolipopro-
tein B and A-1 illustrates the benefit of analysing the metabolic data on the
lipoprotein subclass levels. Overall, our results show that lipoprotein associ-
ation patterns are significantly different from normal fasting glucose already
at prediabetic state. Although even more pronounced differences would be
expected for diagnosed diabetics, the changes observed at the early stage of
disease progression, with less metabolic regulation observed, reflect the grad-
ual disease progression towards diabetes, which is associated with decreased
insulin resistance for prediabetics and changes in lipoprotein metabolism.
The differential network results are consistent with existing knowledge on
the development of T2DM. Studies based on lipoprotein profiles have resulted
in the recognition of a complex pattern of atherogenic-associated changes in
size and particle concentration within the major lipoprotein classes in pa-
tients with diabetes (124, 125). These disorders are reported as increased
levels of medium and large VLDL and small LDL and reduction in size of
HDL. It has been suggested that elevated glucose can lead to an increase in
the levels of triglycerides in liver, resulting in the shift from small VLDL par-
ticle to enlarged VLDL (124, 126). These variations in size range in lipopro-
tein subclasses, which relate to diabetic dyslipidemias, have been captured
by the differential network. The large presence of VLDL-related measures
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in the differential connections reflects the early variations in the lipoprotein
metabolism during the continuous process towards diabetes condition.
4.6 Summary
In this chapter, our main aim was to investigate the potential use of molecu-
lar associations to identify key molecular differences across different groups.
We have developed a formal statistical approach for the differential analysis
of metabolic associations via network representation. Firstly, we have as-
sessed the performance of the differential network at identifying differences
in pair-wise association between groups in a simulation study. Secondly, we
have demonstrated the application of our method in the context of lipopro-
tein metabolism by identifying differences between individuals with normal
fasting glucose and individuals with impaired fasting glucose (prediabetes).
The results illustrate the advantage of using the network-based approaches to
explore topological features of biological systems and to identify differences
between physiological groups. Initial inspection based on standard statistical
methods showed relatively few significant differences in concentration levels
of lipoprotein subclasses between subjects with normal fasting glucose and
those with impaired fasting glucose (prediabetes). With the construction
of the individual networks, we were able to examine the specific pattern of
associations exhibited under each condition (NFG and IFG). Although no
major differences were found between the two individual networks, several
notable topological properties of lipoproteins system were identified through-
out this analysis such as free-scale organization, hubs metabolites and cluster
of nodes. By performing the differential analysis of networks, we were able to
identify various changes in lipoprotein metabolism between the two groups.
Many of the lipoprotein variations highlighted by the differential network
analysis are known to be related to diabetic dyslipidemias. The results indi-
cate the suitability of network-method to investigate subtle molecular varia-
tion indicative of (patho)physiological status.
Chapter 5
GEMINi: GEnome Metabolome
Integrated Network analysis
In this chapter, we investigate the application of differences in molecular
dependencies to uncover genetic variants associated with phenotype varia-
tion. To this end, we propose a novel analytical approach, which we refer to
as GEMINi, (GEnome Metabolome Integrated Network analysis) and illus-
trate its use in the context of obesity. The chapter starts with section 5.1,
where we give a short introduction to the topic. In section 5.2, we describe
the datasets used and define the statistical framework proposed in this work
(section 5.3). The results of the analysis are presented in section 5.4. We
conclude the chapter summarizing the main results, strengths and limitations
of the GEMINi approach (section 5.5).
5.1 Introduction
Despite the success of GWAS studies at identifying loci associated with com-
plex traits, a large proportion of the genetic variation contributing to the
observed variability in phenotypes still remains unmapped (127, 128). In
trying to discover the “missing variants”, a number of strategies have been
proposed (18). It has been suggested that considering alternative models
of genetic effect and their influence on complex traits can help discovering
some of the missing variants (18). For instance, some studies have already
shown that testing for equality and heterogeneity of variances of the pheno-
types among different genotypes can be used as an alternative approach to
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uncover unknown information about the system state beyond that reported
by changes in mean levels alone (129, 130, 131).
In this study, we hypothesise that some of the undetected variants might
be associated not with changes in mean levels of a phenotype, as studied
by conventional GWAS, but with alterations that occur at a higher system-
level. In previous chapter, we have shown that in addition to mean level
alterations of single phenotypes, differences in association between different
traits are observed across different physiological states. Such differences in
molecular correlations between states can reveal information about the sys-
tem state beyond that reported by changes in mean levels alone.
With this in mind, our aim is to investigate the use of differences in molec-
ular dependencies to uncover genetic variants associated with phenotype vari-
ation. We present a novel analytical approach to integrate metabolic and
genetic information, which we refer to as GEMINi, (GEnome Metabolome
Integrated Network analysis). It consists of a combination of correlation
network analysis, genome-wide correlation study and pathway analysis. To
demonstrate the use of this approach, we investigate metabolic changes in
relation to obesity.
5.2 Materials
• Study Populations
We used data from two large population-based cohorts, the Northern Finland
Birth Cohort 1966 (NFBC1966) and the Northern Finland Birth Cohort 1986
(NFBC1986). The methods and aims of these studies have been described
previously on section 2.1). In brief, the NFBC1966 includes 12,068 children
who were due to be born in the provinces of Oulu and Lapland in 1966.
Data were collected since pregnancy and supplemented at the age of 1,14
and 31 years. Blood samples were taken when individuals were 31 years old.
The NFBC1986 includes 9,432 live born children with expected dates of birth
between 1st July 1985 and 30th June 1986 also in the above area. The cohort
has been monitored since early pregnancy until adolescence. All those alive
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with known address were invited to a clinical examination at the age of 15
to 16 years when blood samples were taken.
• Phenotype measures
For obese and non-obese group classification, we use a newly introduced
method for estimating body fat, the body adipose index (BAI) (132). In com-
parison to BMI as a measure of obesity, BAI allows us to take into considera-
tion sex-specific differences in total body fat and is also considered to offer an
improved classification in subjects with elevated lean body mass. Addition-
ally, the multiple cardiometabolic risk factors related to obesity are known
to be mainly associated with adipose accumulation - particularly around the
waist (133, 134) - thus making BAI a particularly relevant physiological end
point to consider. The BAI is calculated as follows:
BAI =
hip
height1.5
− 18
where hip refers to circumference in cm and height is measured in me-
ters. For the differential network analysis, individuals are classified into two
groups, obese and non-obese. To classify individuals into obese and non-obese
groups, we use the cut-off values for body fat as proposed in by Gallagher
et al. (2000) (135). In this way, the non-obese group includes women with
measures of BAI equal or lower than 33 and equal or greater than 21 and men
with BAI equal or lower than 19 and equal greater than 8. The obese group
includes women with BAI greater than 39 and men with BAI greater than
25. Individuals were excluded from analysis based on the following criteria:
non-fasting, diagnosed type I or II diabetes, pregnancy, lipid lowering medi-
cation, missing data on glucose and/or hip measures and/or height. For the
differential network analysis, the sample size for NFBC1966 is 2,794 subjects
(Nnormal = 2,208 and Nobese = 586) and for NFBC1986 it is 2,645 subjects
(Nnormal = 2,356 and Nobese = 289).
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• Metabolomic data
For GEMINi analysis, we included 38 metabolic measures representing a wide
variety of metabolic processes, such as amino acid, energy and lipoprotein
metabolism. Metabolites were selected to allow a consistent analysis across
the two cohorts.
• Genetic data
Only genetic data from NFBC1966 were used for the genetic analysis since
genome-wide data for the NFBC1986 was not available. The final genetic
data set included 4,028 individuals.
5.3 Statistical Methods
In this study we compare two statistical procedures. First, we perform a
standard analysis of association between metabolic levels and BAI using uni-
variate linear regression and between genetic variants and BAI following a
conventional genome-wide association study (GWAS) approach. The second
approach, which we refer to as GEMINi, is a combination of (i) differential
network analysis of metabolic associations (ii) genome-wide correlation study
and (iii) pathway-level analysis. All analyses were adjusted for the effect sex
differences on serum metabolites.
5.3.1 Conventional analysis
We use linear regression to test the effect of serum metabolites on body
adipose index (BAI). The analyses are performed following a univariate ap-
proach where metabolites are tested one at a time. We included gender
as covariate to correct for sex-differences in serum metabolic profiles. To
identify significant association between serum metabolites and BAI, we use
a conservative Bonferroni corrected significance level, P < 0.01/M , where
M = 38 denotes the total number of serum metabolite measures.
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A standard GWAS approach is used to test the association between ge-
netic variants and BAI. The analysis is performed following the standard
single-SNP approach where SNPs are tested one at a time. Associations
were investigated using linear regression assuming an additive effect on the
trait and including sex as a covariate. Significant associations between ge-
netic variants and BAI measures were assessed by setting genome-wide sig-
nificance to P < 5× 10−8(19).
The above analyses were conducted including all the individuals for which
genetic and metabolic data were available (N=4,028).
5.3.2 GEMINi
An outline of the GEMINi analysis is presented in Figure 5.1. Initially we
perform a differential network analysis that allows us to test whether the
pattern of pair-wise associations between metabolites is the same in two
physiological groups (non-obese and obese) or whether it significantly dif-
fers across groups. To eliminate the confounding effect of sex on the serum
metabolites, the data used for the analysis are the residuals from a linear re-
gression model of each metabolite on sex. To build the differential networks,
we use the same methodology presented in subsection 4.3.2. To validate the
differential network analysis results, we compare the network structure be-
tween the two cohorts. The replicated results between cohorts are further
investigated in the next step of the analysis.
In the second step, we perform a genome-wide correlation analysis to iden-
tify genetic variants associated with variations in metabolic associations. As
for the standard GWAS study, all individuals for which genetic data are avail-
able were included in the analysis. To find the desired associations, we first
classify individuals according to the number of copies of the less frequent al-
lele carried, giving genotype groups A (0 copies) and B (1 or 2 copies). SNPs
are tested one at a time. Subsequently, the correlation between metabolites
m1 and m2 is calculated for each group, rA and rB, and variation in cor-
relation between groups A and B is tested. As in the differential network
analysis, we eliminate the confounding effect of sex on the serum metabolites
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by using the residuals of a linear regression of the metabolite level on sex.
To test if the two correlation coefficients, rA and rB are the same, we use the
z transform method as described in (136). To correct for multiple testing,
significant associations between genetic variants and variations in metabolic
association are determined using the genome-wide significance threshold (
p < 5−8/D ), where D refers to the number of differential connections iden-
tified in step one.
To assess the biological significance of our findings, identified SNPs
are assigned to the nearest gene (maximum distance 1 Mb). We use stan-
dard over representation analysis, implemented within the web tool IMPaLA
(137), to highlight pathways which are significantly enriched in these genes.
IMPaLA tests 3,000 pre-annotated pathways from 11 databases and employs
the classical hypergeometric distribution to test for enrichment. Over repre-
sentation analysis was performed independently for each pathway using the
list of genes associated with each metabolite pair (e.g. Tyr-Glu) as well as
using the combined list of genes identified by the genome-wide correlation
study.
All analyses were conducted in R version 2.14.1, apart from the conven-
tional GWAS that was carried out in SNPtest v2.0 and the pathway analysis
which used IMPaLA version 4. Computation of the partial correlation ma-
trix was performed using the R package GeneNet. The differential networks
were built and visualized using the R package igraph. The package psych
in R was used to test for differences between correlation coefficients.
5.4 Results and Discussion
5.4.1 Conventional analysis of metabolic and genetic
data
We performed an initial inspection of the data using linear regression to
explore the association between serum metabolites and BAI (Table 5.1, Ta-
ble 5.2). The analysis showed that all very low density lipoprotein subclasses
(VLDL), intermediate density lipoprotein (IDL), all low density lipopro-
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Figure 5.1: GEMINi analysis outline. Stage 1: We perform the differential
analyses of metabolic associations with the aim of identifying a set of metabolic
associations most affected by BAI/obesity condition. Replicated results between
populations are investigated in stage 2 to highlight genetic mechanisms. Stage 2:
Genome-wide correlation study aims to determine the existence of genetic vari-
ants associated with variations in metabolic associations. Stage 3: Pathway-level
analysis is performed to identify the subsets of genes acting in the same functional
pathways.
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tein subclasses (LDL), small high density lipoprotein subclass (HDL), and
apolipoprotein B were positively associated with the BAI and very large,
large HDL were inversely associated with BAI in both cohorts. In the
NFBC1966, medium HDL was inversely associated with BAI but shows
no association in the NFBC1986, which may due to the age difference be-
tween cohorts (138). No association was found between BAI and apolipopro-
tein A in either of the cohorts. Tests of association between BAI and
low-molecular-weight metabolites showed that alanine, glycerol, isoleucine,
leucine, phenyalanine, pyruvate, tyrosine and valine were positively asso-
ciated with BAI in both cohorts whereas citrate and glutamine were in-
versely associated with BAI. No association was found between BAI and
3-hydroxybutyrate or urea. We observed that glucose and lactate were posi-
tively associated with BAI and creatinine was negatively associated with BAI
in the NFBC1966 but these three metabolites showed no association in the
NFBC1986. On the other hand, acetate was negatively associated with BAI
and histidine positively associated in NFBC1986 but showed no association
in NFBC1966. The same analyses were performed using the body mass in-
dex (BMI) (Table D.1,Table D.2) instead of BAI. The results from BAI and
BMI analyses were similar, apart from three metabolites (apolipoprotein A,
3-hydroxybutyrate and creatinine) which showed different associations with
BAI and BMI in the NFBC1986.
Furthermore, we performed a standard GWAS analysis where associ-
ations between genetic variants and BAI (as a continuous variable) were
tested. Using this approach, however, we did not find any association that
was significant at the genome-wide significance level. The fact that we found
no association at a genome-wide significance level might be due to the lack of
power in this cohort to identify loci with key roles in determining variations
in BAI.
The large number of significant associations between BAI and the metabo-
lite concentrations reflects close relationship between obesity and systemic
metabolism. Body fat especially around the waist - is known to represent
an increased risk for the development of many chronic disorders associated
to obesity (133, 139, 140). It is not only the concentration levels of serum
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Table 5.1: Linear regression analysis in the NFBC1966 between body
adipose index (BAI) and the serum metabolite measures
Metabolic measure Abbreviation Estimate (β) P
Total lipids in chylomicrons XXL-VLDL-L 26.8 9.05E-50
Total lipids in very largeVLDL XL-VLDL-L 10.86 5.47E-50
Total lipids in large VLDL L-VLDL-L 3.29 2.69E-54
Total lipids in medium VLDL M-VLDL-L 2.54 3.18E-62
Total lipids in small VLDL S-VLDL-L 3.81 1.69E-77
Total lipids in very small VLDL XS-VLDL-L 5.22 1.64E-59
Total lipids in IDL IDL-L 2.05 1.59E-42
Total lipids in large LDL L-LDL-L 1.59 4.72E-44
Total lipids in medium LDL M-LDL-L 2.77 5.42E-52
Total lipids in small LDL S-LDL-L 4.88 1.69E-67
Total lipids in very large HDL XL-HDL-L -1.98 5.22E-16
Total lipids in large HDL L-HDL-L -2.17 1.20E-59
Total lipids in medium HDL M-HDL-L -1.01 3.23E-8
Total lipids in small HDL S-HDL-L 0.99 1.82E-4
Apolipoprotein A-I ApoA1 -0.66 2.51E-3
Apolipoprotein B ApoB 3.99 4.43E-70
Mean diameter for VLDL particles VLDL-D 0.55 9.06E-46
Mean diameter for LDL particles LDL-D -2.2 3.81E-13
Mean diameter for HDL particles HDL-D -3.75 2.92E-62
3-hydroxybutyrate bOHBut -0.22 0.6
Acetate Ace -7.05 2.46E-3
Acetoacetate AcAce -0.49 0.66
Alanine Ala 5.99 1.42E-20
Citrate Cit -5.92 0.02
Creatinine Crea -14.67 1.18E-5
Glucose Glc 0.22 1.25E-4
Glutamine Gln -3.59 7.19E-12
Glycerol Glol 18.85 1.65E-39
Glycoprotein acetyls Gp 3.21 2.40E-62
Histidine His 3.4 0.38
Isoleucine Ile 54.41 9.72E-62
Lactate Lac 0.83 5.70E-15
Leucine Leu 41 6.62E-54
Phenylalanine Phe 66.87 1.34E-89
Pyruvate Pyr 12.91 5.44E-12
Tyrosine Tyr 57.1 2.32E-43
Urea Urea 0.3 0.87
Valine Val 15.89 4.73E-45
A P-value given in bold indicates a statistically significant association between BAI and
a metabolite measure with a Bonferroni corrected threshold, P < 0.01/M , where M = 38
is the total number of metabolites included in the analyses. Estimate(β), estimate BAI
effect size.
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Table 5.2: Linear regression analysis in the NFBC1986 between body
adipose index (BAI) and the serum metabolite measures
Metabolic measure Abbreviation Estimate (β) P
Total lipids in chylomicrons XXL-VLDL-L 37.09 1.51E-45
Total lipids in very large VLDL XL-VLDL-L 14.88 6.25E-52
Total lipids in large VLDL L-VLDL-L 4.43 6.05E-55
Total lipids in medium VLDL M-VLDL-L 3.3 2.59E-60
Total lipids in small VLDL S-VLDL-L 4.9 8.89E-72
Total lipids in very small VLDL XS-VLDL-L 6.59 1.31E-51
Total lipids in IDL IDL-L 2.9 1.02E-44
Total lipids in large LDL L-LDL-L 2.41 6.28E-50
Total lipids in medium LDL M-LDL-L 4.11 4.62E-56
Total lipids in small LDL S-LDL-L 6.69 4.93E-64
Total lipids in very large HDL XL-HDL-L -3 8.86E-29
Total lipids in large HDL L-HDL-L -2.15 5.87E-36
Total lipids in medium HDL M-HDL-L 0.89 7.45E-4
Total lipids in small HDL S-HDL-L 4.16 4.46E-29
Apolipoprotein A-I ApoA1 0.03 0.91
Apolipoprotein B ApoB 5.19 2.02E-74
Mean diameter for VLDL particles VLDL-D 0.36 5.16E-22
Mean diameter for LDL particles LDL-D -1.4 2.91E-7
Mean diameter for HDL particles HDL-D -3.5 1.07E-53
3-hydroxybutyrate bOHBut -4.24E-6 3.06E-3
Acetate Ace -6.32E-5 2.62E-5
Acetoacetate AcAce -7.55E-6 0.03
Alanine Ala 1.19E-5 1.28E-6
Citrate Cit -5.92E-5 9.21E-24
Creatinine Crea -9.76E-6 0.55
Glucose Glc 1.30E-6 0.07
Glutamine Gln -1.77E-5 4.82E-15
Glycerol Glol 4.03E-5 1.69E-13
Glycoprotein acetyls Gp 1.24E-5 1.17E-64
Histidine His 9.24E-5 1.39E-8
Isoleucine Ile 1.46E-4 1.20E-32
Leucine Leu 1.17E-4 6.91E-33
Phenylalanine Phe 2.17E-4 1.66E-52
Pyruvate Pyr 3.38E-5 3.25E-5
Tyrosine Tyr 1.37E-4 2.99E-21
Urea Urea -9.62E-6 0.15
Valine Val 3.36E-5 1.71E-15
A P-value given in bold indicates a statistically significant association between BAI and
a metabolite measure with a Bonferroni corrected threshold, P < 0.01/M , where M = 38
is the total number of metabolites included in the analyses. Estimate (β), estimate BAI
effect size.
CHAPTER 5. GEMINI 111
metabolites that can change due to variations in total body fat percentage but
also the dependencies between metabolites can be affected. To investigate
how metabolic associations differ between non-obese and obese individuals
and to what extent these differences can serve as an indicator of impor-
tant molecular alteration between these physiological states, we employ the
GEMINi approach.
5.4.2 GEMINi
Differential Networks: Normal and Obese individuals
Differential network analysis is performed with the aim of determining the
subset of metabolic associations that significantly differ between non-obese
and obese individuals. We examine the same metabolic variables from the
two independent cohorts (NFBC1966 and NFBC1986), and use estimates of
partial correlation as measures of metabolic dependency. Metabolic associa-
tions that are consistently different across physiological conditions in the two
study cohorts are interpreted as obesity-related molecular characteristics and
are further investigated in the genome-wide correlation study and pathway
analysis.
The differential analysis for BAI is presented in Figure 5.2. Each connec-
tion in the differential network indicates that a significant difference is found
between the two physiological conditions in the pair-wise correlation between
two variables. To assess the robustness of differences in the serum metabo-
lite associations, we compare the two differential networks (Figure 5.2c).
The differential network for NFBC1966 (Figure 5.2a) consists of a set of 30
connected variables, which are organized in 46 pair-wise differential inter-
actions. The differential network for NFBC1986 (Figure 5.2b) comprises a
group of 28 differentially connected variables, which are organized in 27 pair-
wise differential interactions. We observe similar patterns of differences in the
metabolic associations in these two differential networks. For both networks
(Figure 5.2), the majority of the connected variables represent measures of
very-low-density lipoproteins (dark green nodes), low-density lipoproteins
(light blue nodes), high-density lipoproteins (light-blue nodes) and amino
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acids (pink nodes). In addition, three metabolites - 3-hydroxybutyrate , ace-
toacetate and valine - show no connections in either of the two networks. Ten
overlapping connections are observed between the two networks (Figure 5.2c).
This overlap is significantly higher than expected at random. The overlap-
ping connections highlight differences in the pair-wise associations between
metabolites which occur throughout all size ranges of VLDL and HDL (apart
from very-large HDL), two measures of low-density lipoproteins (S-LDL-L
and LDL-D) and two amino acids (tyrosine and glutamine). Moreover, not
only are a significant number of connected components overlapping between
the two networks but also the signs of the difference in partial correlations
are identical (represented as connection colours). We observe that the corre-
lation is significantly lowered (blue edges) in the obese group for the pairs:
very-large and large VLDL, extremely-large VLDL and small HDL, mean di-
ameter for VLDL and large HDL and tyrosine and glutamine. On the other
hand, the correlation is higher in the obese group for small LDL and mean
diameter for LDL, ApoB and mean diameter for VLDL, large VLDL and
small VLDL and very large and medium VLDL (red edges). VLDL-related
measures present the highest number of connections in overlapping connected
component. The equivalent analysis for BMI is presented in Figure D.1 and
shows broadly similar features.
Differences in metabolic associations and obesity
A number of obesity-related differences in metabolic associations identified
here are in line with prior studies on obesity-related traits. For instance,
the central position and abundance of VLDL-related measures in the dif-
ferential networks may reflect disregulation in VLDL metabolism. These
alterations may result from the shift from small VLDL particles to enlarged
VLDL (126). There is also evidence to suggest that in obesity-related dys-
lipidemia an overproduction of large VLDL particles is the initiator of all
sequences of lipoprotein changes, resulting in a decrease in levels and parti-
cle size of HDL and smaller-denser LDL particles (34). Previous studies on
obesity-related dyslipidaemias have recognised a complex pattern of change
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Figure 5.2: Differential network analysis for serum metabolites inferred
from normal and obese individuals. (a) Differential Network inferred from
NFBC1966; (b) differential network inferred from NFBC1986; (c) Replicated dif-
ferential connection between NFBC1966 and NFBC1986 differential networks. In-
dividuals are classified using body adipose index (BAI) definitions.
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in size and particle concentration within the major lipoprotein classes in pa-
tients with obesity, especially abdominal obesity (141, 142). These disorders
are related to elevated VLDL triglycerides that trigger the shift from small
VLDL to medium and large VLDL, increased levels of small LDL and re-
duction in concentration and size of HDL. These variations in lipoprotein
particle size subclasses, which relate to dyslipidaemias associated with obe-
sity, are captured by the differential network of lipoprotein associations.
Of the low-molecular-weight metabolites, six amino acids were repeat-
edly involved in the differential connections. Of these, two are branched
chain amino acids (BCAAs) leucine and isoleucine, two are aromatic amino
acids - phenylalanine and tyrosine, and two represent non- essential amino
acids - alanine and glutamine. Although only one of these connections is
overlapping between the two cohort (tyrosine and glutamine), the repeated
presence of this set of amino acids in the networks may indicate the ro-
bust association between obesity and alterations in amino acid metabolism.
In fact, the implication of the BCAAs in obesity-related metabolic disor-
ders has been previously reported. For instance, several studies in animal
models have suggested that BCAAs play a role in a variety of important bio-
chemical functions such as regulation of satiety, leptin, glucose and cell sign-
ing (143, 144). Moreover, studies on humans have highlighted the increased
levels of BCAAs in obese individuals (diabetic and non-diabetic) (33, 145).
It has been suggested that the specific BCAAs perturbed in obese individ-
uals may be due to a loss of catabolism capacity, which may lead to the
increased levels of BCAAs (146). Another interesting connection, although
not replicated between cohorts, is the differential associations between ala-
nine and glutamine observed in NFBC1986 network (Figure 5.2b). Among
other functions, glutamine has been reported to play a role in glucose and
glycogen metabolism (147). It has been suggested that transamination of
pyruvate to alanine may be increased by a high rate of flux through BCAA
catabolic pathways and accumulation of glutamate (33). Given that alanine
is a gluconeogenic amino acid, its disregulation could be a contributor to the
development of glucose intolerance in obesity.
The large number of independently replicated results and the known rel-
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evance of the identified metabolites to obesity provide strong support for
differential association analysis in improving our understanding of the bio-
logical mechanisms of disease. Assuming that these metabolic differences are
related to obesity, we hypothesized that these measures could be used as an
additional phenotype to identify genetic variants associated to obesity-related
traits. To test this hypothesis, we performed a genome-wide correlation anal-
ysis.
Genome-wide correlation analysis
The associations of 318,443 SNPs with the metabolite-metabolite partial cor-
relations were individually tested. Our analysis revealed 37 loci significantly
associated (P < 5×10
−8
D
), where D = 10, with differences in partial corre-
lation between two pairs of metabolites, namely total lipids in large VLDL
and very-large VLDL, as well as total lipids in medium VLDL and very-large
VLDL. A brief description of these genetic variants, including their accession
numbers, chromosomal positions, p-values obtained, along with candidate
genes associated with the genetic marker is presented in Table 5.3.
Of the 37 loci identified, 16 are related to differences in the associa-
tion between large and very large VLDL total lipids and 30 are associated
with the association between total lipids in medium and very-large VLDL.
Nine loci are shared between these two metabolic associations. Several of
the genes associated with these loci have been reported to be involved in
obesity-related processes. For instance, among the genetic variants associ-
ated with differences in the association between large and very-large VLDL,
we identify a SNP (rs1078248) at chromosome position 3p21.33, which is lo-
calized within 1 Mb from a gene encoding the abhydrolase domain containing
5 protein (ABHD5/CG1-58). The protein coded by this gene is known to be
linked to triglyceride (TAG) metabolism, the primarily energy source in ver-
tebrates (148). TAGs are stored in adipose tissue and hydrolyzed into fatty
acids and glycerol and can be used by body tissues during times of fast or
energy deprivation (149). Mutations in the gene encoding for ABHD5 have
been associated with a triglyceride storage disease with impaired long-chain
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Table 5.3: Genetic loci associated with differences in metabolite-
metabolite correlations between obese and non-obese individuals.
1P 2P SNP Gene Chr Pos
1.19E-9 2.56E-7 rs1334806 USP1 1 62875313
9.37E-14 < 2.00E − 16 rs3817222 PPP1R12B 1 202464760
1.01E-13 < 2.00E − 16 rs12743401 PPP1R12B 1 202476648
7.33E-14 < 2.00E − 16 rs3881953 PPP1R12B 1 202528021
1.93E-5 8.50E-10 rs4669444 YWHAQ 2 9869267
1.23E-9 7.44E-9 rs7592040 OTOF 2 26741551
2.11E-7 3.02E-9 rs966859 DPP10 2 115828493
2.02E-9 3.05E-6 rs1078248 ABHD5 3 43794357
9.96E-9 1.19E-10 rs2175730 TRH 3 129677772
1.38E-8 1.64E-10 rs9856606 TRH 3 129680366
1.72E-6 5.15E-10 rs10517060 CCDC149 4 24929280
1.85E-6 1.71E-10 rs7719640 IRX1 5 3752812
1.30E-12 8.88E-16 rs34868670 PTGER4 5 40237843
1.64E-9 1.33E-10 rs573496 GRIA1 5 152893433
2.11E-6 9.07E-11 rs11957360 SCGB3A1 5 180010639
2.72E-8 8.04E-11 rs681283 CRISP2 6 49673195
6.85E-8 1.64E-11 rs1319087 EYA4 6 133897107
7.77E-10 2.97E-10 rs2500542 UST 6 149331204
1.69E-5 3.98E-10 rs1403185 DLX6 7 96540655
5.36E-10 4.17E-7 rs1454953 DLC1 8 13315983
2.00E-10 2.14E-7 rs7814428 DLC1 8 13324439
4.29E-9 4.44E-10 rs7357357 FAM84B 8 127189138
6.21E-9 4.54E-10 rs10094775 FAM84B 8 127197554
1.92E-9 4.89E-9 rs4557669 FAM84B 8 127306602
4.95E-6 6.07E-12 rs10811316 MLLT3 9 20095103
1.20E-6 6.41E-10 rs1014807 PIP5K1B 9 71302196
5.08E-6 9.78E-10 rs2386636 ASB13 10 5712087
2.58E-7 4.79E-11 rs7923418 ZNF365 10 64230159
7.77E-7 1.47E-9 rs1727 LIPA 10 91066769
3.81E-10 1.38E-5 rs17315588 RP11-494M8.4 11 7913911
1.57E-9 1.43E-9 rs9971532 EED 11 85929490
9.48E-8 2.68E-9 rs7110414 GRIA4 11 105861507
3.38E-8 1.20E-11 rs484580 CLMP 11 123109469
3.36E-8 1.23E-11 rs558362 CLMP 11 123114359
2.86E-9 3.89E-8 rs1650307 LDH8 12 21803770
2.82E-7 5.85E-10 rs11175596 TBC1D30 12 65340828
4.49E-13 2.22E-16 rs2451078 TPTE2 13 20098289
8.60E-6 1.57E-9 rs2224442 VRK1 14 97272382
2.67E-9 5.33E-10 rs2302553 NAGPA 16 5056295
8.15E-10 1.70E-10 rs3815490 NAGPA 16 5060568
1.15E-7 1.99E-9 rs2072620 ZP2 16 21216033
4.26E-5 2.89E-10 rs9303619 RP11.173M1.1 17 25446389
9.26E-10 1.47E-8 rs8106239 ATP4A 19 36085358
1.90E-6 2.87E-9 rs844879 CD93 20 23102665
7.22E-10 2.57E-7 rs2093066 BPIFB3 20 31652596
6.84E-10 1.47E-7 rs378098 BPIFB3 20 31660543
1P , p-value for association between locus and variation in correlation between XL-
VLDL/L-VLDL; 2P , p-value for association between locus and variation in correlation
between XL-VLDL/M-VLDL; Chr, chromosome; Pos, SNP position in NCBI human
genome build 36; Gene, potential candidate gene in the region. Bold indicates signif-
icant association between genetic variant and variation in association between pairs of
metabolites using genome-wide significance level threshold.
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fatty acid oxidation called Chanarin-Dorfman syndrome (150, 151). Despite
the fact that ABHD5 is involved in TGAs metabolism and highly expressed
in adipose tissue, patients with Chanarin-Dorfman syndrome are not obese
(152). No previous association between ABHD5 and obesity-related traits
has been reported.
Among the genetic variants associated with differences in association
between medium and very-large VLDL, we found a marker (rs966859) at
2q14.1, which is located in a gene encoding for inactive dipeptidyl peptidase
10 (DPP10). Genetic variants in DPP10 are associated with susceptibility
to asthma (153). Asthma is a complex disorder with a heterogeneous phe-
notype, largely attributed to the combined effect of multiple genes (154) and
environment. A number of studies have shown a consistent association be-
tween asthma and obesity (155, 156). This strong relationship has led to
the hypothesis that both disorders may be related due to shared genetic fac-
tors (157, 158). This hypothesis was tested in a candidate gene study where
known genes for BMI and asthma were jointly analysed (158). Several of
these genes, including DPP10, showed shared associations between these two
conditions, which supports the hypothesis of shared genetics between asthma
and obesity. However, after correction for multiple testing none of the identi-
fied associations remained significant (158). Two other markers (rs2175730,
rs9856606) at 3q22.1 are also associated with the difference in the association
between medium and very-large VLDL. These SNPs are localized near a gene
encoding thyrotropin-releasing hormone (TRH). A number of studies have
indicated the important role that TRH plays in central regulation of the car-
diovascular system and hypertension induced by body weight gain (159, 160).
This function appears to be mediated by leptin (161), an adipocyte-released
hormone, and it has been suggested that the interaction between TRH and
leptin is an important contributor to the strong association existing between
hypertension and obesity (161). Another variant associated with the differ-
ence in the association between medium and very-large VLDL is SNP rs1727
at chromosome 10q23.3. This marker is localized within a gene encoding for
lipase A, lysosomal acid, cholesterol esterase (LIPA). This enzyme is found in
the lysosomes and plays a role in the hydrolysis of lipids such as cholesteryl
CHAPTER 5. GEMINI 118
esters and triglycerides. Cholesteryl ester storage disease (CESD) is a rare
recessive disorder associated with lysosomal acid lipase deficient activity. Pa-
tients with CESD are characterized by a massive accumulation of cholesteryl
esters and triglycerides in most tissues of the body (162). This disorder is
known to be due to mutations in LIPA, which is gene encoding the lysosomal
acidic lipase (163). Moreover, a recent study on subjects with severe obesity
has reported significant associations between a number of LIPA genetic vari-
ants and obesity-related metabolic complications such as cholesterol in HDL
(164). Two more genetic variants were associated with the difference in the
association between medium and very-large VLDL (rs1192198 and rs558362)
at chromosome 11q24.1. These genetic variants are localized near a gene en-
coding for a CXADR-like membrane protein (CLMP). It has been suggested
that CLMP may play a role in adipose tissue differentiation (165) and be in-
volved in cell-cell adhesion (166). Of the genes associated with the difference
in the association between both pairs of lipoprotein fractions, we identified
SNP rs573496 at chromosome 5q33.2. This SNP is localized within a gene
encoding for glutamate receptor 1 (GRIA1). In addition to this SNP, we also
identified SNP rs7110414 at chromosome 11 which is within 1Mb distance
from a gene encoding for glutamate receptor 4 GRIA4. Glutamate receptors
are protein complexes formed by the combination of four different subunits
(GRIA1-GRIA4) and are known to be the main excitatory neurotransmit-
ter receptors in the mammalian brain. Regulation of glutamate receptors is
influenced by leptin levels (167), as discussed below.
Pathway-level analysis
To further the interpretation of the genetic findings, the set of identified ge-
netic markers was tested in aggregate using pathway-level approaches. The
aim is to assess the combined contribution of the identified genetic variants
and to determine to what extent the products of the associated genes act
within obesity-related pathways. For this purpose we apply an over- rep-
resentation analysis using the web tool IMPALA. The top three pathways
for the general analysis are presented in Table 5.4. Of these, the top-ranked
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pathway is the activation of AMPA receptors pathway, with 4 genes in the
pathway (P = 2.34× 10−5).
Examination of the activation of AMPA receptors pathway shows that a
subset of two genes from our selected list of genes GRIA1, GRIA4 - belong
to this pathway. AMPA receptors are members of the ionotropic class of
glutamate receptors. It is well established that AMPA receptors are the pre-
dominant regulators of the fast synaptic transmission in the central nervous
system (CNS) (168). Evidence is growing that glutamate receptor traffick-
ing processes can be regulated by the hormone leptin (167, 168, 169). This
hormone is predominantly synthesized in adipose tissue and it is known that
leptin plays an important role in the regulation of appetite and control of
body weight (170). It is also well established that there is an inverse relation-
ship between plasma levels of leptin and food intake (171). In addition, leptin
secretion is proportional to body fat content (172). Alterations in the leptin
system are also linked to a number of CNS-driven diseases and neurodegen-
erative disorders (173). It has been hypothesized that regulation of AMPA
receptor trafficking by leptin is likely to have important implications not only
in health but also in diseases associated with leptin dysfunction (172). In ad-
dition, it has been hypothesized that AMPA receptors may play a pivotal role
in the comorbidity between depression and cardiovascular disorders (174).
Table 5.4: Pathway analysis of the whole set of genetic variants identi-
fied by the GWC analysis of variation in metabolic associations.
Pathway Pathway
source
N.o Overlapping
genes
N.p P Q
Activation of AMPA
receptors
Reactome 2 GRIA1;
GRIA4
4 2.34e-5 0.0752
Trafficking of GluR2-
containing AMPA re-
ceptors
Reactome 2 GRIA1;
GRIA4
16 0.000461 0.559
Unblocking of NMDA
receptor
Reactome 2 GRIA1;
GRIA4
17 0.000522 0.559
N.o, Number of overlapping genes; N.p, Number of all pathway genes;P, p-value; Q,
q-value
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5.5 Summary
Our aim in this chapter was to investigate the use of additional phenotypic
variations such as differences in associations between metabolic measures to
aid the discovery of genetic factors involved in complex traits. We have de-
veloped a novel analytical approach for the combined analysis of metabolic
and genetic information.
Initially, we have examined the relationship between obesity and serum
metabolites by performing a differential analysis of metabolic associations.
Using this approach a number of obesity-related characteristics were identi-
fied comprising several metabolites linked by previous studies to the devel-
opment of obesity-related disorders. Metabolites involved in such differential
connections included all sizes of very low density lipoprotein (VLDL) and
high density lipoprotein (HDL) as well as several amino acids such as ty-
rosine and glutamine. A significant proportion of these findings overlapped
between two independent cohorts. In the light of these results, we postu-
lated that differences in metabolite associations could potentially be used as
an additional phenotype to investigate genetic factors in obesity. We further
investigated this metabolic differences by performing a genome-wide corre-
lation analysis where genetic variants were tested for association with the
metabolic correlations. These analysis revealed a large set of associations
between genetic variants and these differential metabolic dependencies. Sev-
eral of the associated genes have been previously implicated in obesity-related
traits.
A clear limitation of our study is lack of a replication cohort for our
genetic findings. However, the fact that we found no associations follow-
ing standard GWAS, but did find a large number of associations using our
genome-wide correlation approach, many of which are implicated in obesity,
is very promising. This study therefore highlights the importance of inves-
tigating differences in correlation between metabolites or other phenotypic
indicators as an additional phenotype to identify novel loci with key roles in
the pathogenesis of complex traits.
Chapter 6
Variance and Covariance Regres-
sion Models
In chapter 4, we have highlighted the importance of exploring differences
in molecular association patterns in relation to different physiological condi-
tions to identify key features of phenotype variations. In chapter 5, we have
showed the applicability of using changes in correlation between metabolites
as an additional phenotype to identify novel loci with key roles in the patho-
genesis of complex traits. Yet, despite their potential, these two approaches
have the limitation of being based on a two-groups comparison - healthy and
non-healthy - where individuals are classified based on cut points for disease
state such as impaired fasting glucose (IFG) for prediabetes or body adipose
index (BAI) for obesity. Considering the data as binary phenotype might
ignore some important details on the underlying biological mechanisms of
phenotype variation, providing a limited view into the continuous process of
disease development.
With this in mind, the focus in this chapter is on investigating contin-
uous changes in molecular traits as response to a pathogenic stimulus. In
particular, we propose to employ Bayesian hierarchical models to investi-
gate changes in mean level, variance and correlation of metabolic traits in
relation to covariates. To illustrate our approach we investigate changes
in urinary metabolic traits in response to cadmium exposure, a toxic envi-
ronmental pollutant. The chapter starts with section 6.1, where we give a
short introduction to the problem under consideration. Next, we describe
the dataset used for statistical inference (section 6.2) and then define the
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statistical framework proposed in this work (section 6.3). The results of the
analysis are summarized in section 6.4.
6.1 Introduction
Over the last decade, our understanding of the pathogenesis of many com-
plex disorders has expanded considerably. It has become clear that condi-
tions such as obesity, diabetes or chronic kidney disorders stem from a web
of complex interactions between genetic and environmental factors, result-
ing in increased predisposition to a clinical phenotype. In the presence of
pathogenic factors, a progressive cascade of subtle abnormalities at molec-
ular level can be observed. Many of these abnormalities begin early during
the course of the disease development and progressively continue until they
manifest as clinical disease. Since the pathogenesis of complex conditions
are continuous in nature (175), considering data as continuous phenotype,
rather than the conventional two-groups comparison, might provide a much
detailed view into biological processes and potentially reveal key features of
disease development.
From the statistical point of view, it can be expected that if a particu-
lar factor (physiological or environmental) has an effect on a specific trait,
the marginal mean of such a trait would be modified at increasing exposure
to such a stimulus. In addition to effects on mean values of a quantitative
trait, effects on other statistical properties such as the variance or covariance
could also be expected. Hence investigating changes of additional molecular
properties can be used as an approach to detect potentially novel effects on
a trait of interest. Several genetic studies have already explored the idea of
testing for equality and heterogeneity of variances of quantitative traits to
further characterize the consequence and risk of genetic variations (129, 130).
The problem of characterising and modelling the conditional mean is a well-
studied topic, both in the univariate and multivariate cases. While there
is also a relatively rich literature in methods allowing the variance to vary
across different values of an explanatory variable (176), (177), little has been
done in the case of multivariate covariance regression. Recently Hoff and
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Niu (178) introduced a covariance regression method which parametrises the
covariance of a multivariate response vector as a function of explanatory vari-
ables. Unlike methods which characterize the heteroscedasticity in the form
of the mean-variance relationship, the covariance regression model proposed
by Hoff and Niu (178) allows for the mean function µx and the covariance
function Σx to be separately parameterized.
In this study, we propose a novel statitical framework for detecting pro-
gressive changes in molecular traits as response to a pathogenic stimulus. To
illustrate our approach, we use urinary metabolic data on individuals living
near an industrial source of cadmium. Cadmium (Cd) is a highly toxic metal
commonly found in industrial workplaces and it is known to have important
health effects. We employ Bayesian hierarchical models to investigate varia-
tions in mean levels and variances of a set of urinary metabolic traits across
a range of values of urinary cadmium. In addition, we investigate variations
in correlations between pairs of metabolic traits in relation to covariates. To
assess the potential of this approach to reveal key molecular changes related
to pathogenic stimuli, we compare our results with existing knowledge of
cadmium-induced physiological and biochemical effects.
6.2 Material
• Study Populations
We used data from the Cadmium study population. Urinary metabolic data
were available on 127 individuals from the Cadmium study population.
• 1H NMR urinary metabolites
The analysis was performed using a total of 22 urinary metabolic measures
including amino acids, 3-hydroxybutyrate, creatinine and urea and informa-
tion on metabolites involved in gluconeogenesis pathway such as pyruvate,
lactate, glycerol. The complete list of metabolites included in this analysis
can be found in Table A.2.
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• Cadmium exposure
Data on urinary cadmium (U-Cd) was used to assess lifetime kidney accu-
mulation from chronic cadmium exposure. Details on data acquisition can
be found in Thomas et al. 2009 (50). Since urinary cadmium excretion levels
increase with age, as consequence of increased body burden and also urinary
cadmium excretion levels are higher in smokers than non-smokers and in
women than men (50), data on biological and lifestyle factors including age,
gender, smoking status (current, past, never) were used in the analysis.
6.3 Statistical Methods
Firstly, we perform a multiple linear regression to explore associations be-
tween levels of urinary metabolites and urinary levels of cadmium. Sec-
ondly, we perform a variance regression analysis for estimating changes in
the variance of urinary metabolites across different values of urinary cad-
mium. Thirdly, we employ the covariance regression model proposed by Hoff
and Niu (178) to estimate changes in pair-wise correlation between metabo-
lites at different levels of U-Cd. To ensure normality of the metabolic data,
each metabolic phenotype was log-transformed prior to analysis.
• Association between levels of urinary metabolites
and urinary cadmium
Multiple linear regression was applied to investigate the association between
levels of urinary metabolites and urinary cadmium. A set of lifestyle and bio-
logical factors - sex, age, and smoking status - expected to have a confounding
effect on the concentration of levels of urinary cadmium was included into
the model. We determine significant association between levels of urinary
metabolites and urinary cadmium by setting the significance threshold to
P < 0.05.
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• Variance Regression Model
To investigate the potential effect of cadmium exposure on the mean and the
variance of traits of interest across different values of an explanatory variable,
we propose to use Bayesian hierarchical models. The variance regression
model employed to estimate changes in the mean and variance of a set of
urinary metabolic traits over a range of cadmium exposure can be defined as
follows.
Let Y denote the N × K set of normally distributed random variables
(metabolites) where N is the number of observations and K is the number of
variables. For the purpose of this analysis, Yk = (y1k, ..., yNk) represents each
of the urinary metabolic traits and yik is the ith observation for the variable
Yk. We assume
yik ∼ N(µik, σ2ik) for i = 1, ..., N ; k = 1, ..., K. (6.1)
where N(µ, σ2) denotes the normal distribution with parameters µ and σ2.
The conditional mean µik = E[yik|xi] can be expressed as follows:
E[yik|xi] = βkxi for i = 1, ..., N ; k = 1, ..., K. (6.2)
where xi represents a q-dimensional vector of covariates for individual i whose
first entry is the intercept and βk is a q-dimensional vector of parameters.
Similarly to the conditional mean, the variance σ2ik = V ar[yik|zi], can be
expressed in terms of a linear regression model as:
log[V ar[yik|zi]] = λkzi for i = 1, ..., N ; k = 1, ..., K. (6.3)
where zi is a p-dimensional vector of covariates for individual ith whose first
entry is the intercept and λk is a p-dimensional vector of parameters. The
zi of equation 6.3 and xi of equation 6.2 can be the same. Each regression
is fitted individually per metabolite. To estimate the model parameters β =
(β1, ...,βk) and λ = (λ1, ...,λk), we perform a Bayesian analysis. In Bayesian
statistical inference, a prior distribution for all unknowns parameters p(β,λ)
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has to be specified. In this analysis we follow a non-informative prior for all
unknowns parameters (β,λ). The prior density for the parameters β is:
βk ∼ Nq(µβ,Σβ)
with µβ = 0 and Σβ = τβI. The prior density of λ is:
λk ∼ Np(µλ,Σλ)
with µλ = 0 and Σλ = τλI. The prior for τβ and τλ for the Inverse-Gamma
variance were set to 0.1 and 1. To check posterior sensitivity to these pre-
specified values, we analysed the data with several other values (0.01, 0.01
and 0.001, 0.001). From the prior distribution and the likelihood function
together, the posterior distribution of the parameters can then be obtained
as:
p(βk,λk|Yk,Xk,Zk) ∝ p(Yk|Xk,Zk,βk,λk)p(βk)p(λk)
where Xk is the N × q matrix of predictors for the mean and Zk is the N ×p
matrix of predictors for the variance. Because the posterior distribution is
not available in closed-form, a MCMC approximation of the joint posterior
distribution can obtained via Gibbs sampling. We used JAGS linked to
R.2.14.1 via the R2jags package to perform this analysis. We run 50,000
iterations of the Gibss sampler with the first 1,000 discarded as burn-in. To
determine if the variance of a urinary metabolite Yk changes with cadmium
exposure we calculate the posterior 95% credible intervals of the parameters
λk.
• Covariance Regression Model
The effect of urinary levels of cadmium on the pair-wise association between
metabolic variables is investigated by using the covariance regression model
developed by Hoff and Niu (178). This methodology provides a parsimonious
model and estimation method for the conditional covariance matrix of a
multiple response vector Y over a range of values of an explanatory variable
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x, here levels of urinary cadmium.
Let now consider two continuous random variables Yk1 = (y1,k1 , ..., yN,k1) and
Yk2 = (y1,k2 , ..., yN,k2) where 1, ..., N is the number of observations. The
covariance regression model proposed by Hoff and Niu (178) is based on an
analogy with linear regression and starts by expressing the conditional mean
in terms of linear regression:
E[YkJ |x] = xTβJ for J = 1, 2 (6.4)
where x is a q-dimensional vector of explanatory variables whose first en-
try is the intercept and β is q-dimensional vector of parameters. The simplest
version of the proposed covariance model can be expressed as Cov[y|x] = Σx
with:
Var[Yk1|x] = ψk1,k1 + bTk1xxTbk1 (6.5)
Cov[Yk1 , Yk2|x] = ψk1,k2 + bTk1xxTbk2 (6.6)
where ψk1,k1 and ψk1,k2 are elements of Ψ, a 2×2 positive-definite baseline co-
variance matrix and bk1 ,bk2 are the rows of B, a 2× q matrix of parameters.
As described in Hoff and Niu (178), the parametrization of the variance sug-
gests that the models requires the variance of each element of Y to increase
in the elements of x, as the minimum variance is obtained when x = 0. As
proposed in Hoff and Niu (178), this constraint can be relaxed by including
an intercept term.
To estimate the model parameters represented in Equation 6.6, we use a
MCMC approximation via a Gibbs sampling. We follow Hoff and Niu (178)
and specified the prior distribution for the unknown parameters p(β,B,Ψ)
in terms of the following semi-conjugate priors:
Ψ ∼ Inverse−Wishart(Ψ−10 , v0),
β ∼ N(0, 100 · I2),
B ∼ M(B0,Ψ ·V0),
where v0 = p + 2 degrees of freedom, Ψ0 is the sample covariance matrix,
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B0 = 0 and V0 = N × (XTX)−1. We run 50,000 iterations of the Gibbs
sampler with the first 1,000 discarded. From the the estimated covariance, we
calculate the correlation between metabolic traits. To determine variations in
correlation between metabolic traits, we calculate the 95% credible intervals
of the estimated correlation.
• Covariance regression model networks
To improve the interpretation of the covariance regression results, we con-
struct seven correlation networks. Each network indicates the pair-wise cor-
relation between metabolites under seven different levels of exposure to cad-
mium (U-Cd(nmol/mmol creatinine)=0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8). We
define the edges in the networks by computing the 95% credible interval of
the posterior probability distributions for the correlation conditioned on the
urinary cadmium concentration. The networks are built by drawing the edges
between those pairs of measures if the credible interval does not contain zero.
The networks were built and visualized using the R package igraph. All
analysis were carried out using R version R.2.14.1.
6.4 Results and Discussion
Our first aim is to determine whether measures of cadmium exposure are as-
sociated with variations in urinary metabolic levels (U-Cd). Initial inspection
of the data using a multiple linear regression shows that three of the urinary
metabolites are associated with cadmium urinary levels after adjusting for
sex, age and smoking status (P < 0.05) (Table 6.1). Two metabolites - suc-
cinate and dimethylglycine - are negatively associated with levels of U-Cd
whereas citrate shows positive association with U-Cd. Two of these metabo-
lites are involved in the citric acid cycle (succinate and citrate) whereas
dimethylglycine is related to choline metabolism.
Our next objective is to evaluate if the variance of urinary metabolites
changes across a range of values of urinary cadmium. The trace plot from
the MCMC for the parameter λ is presented in Figure 6.1. It show that the
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Table 6.1: Multiple linear regression analysis between exposure to cad-
mium (U-Cd) and the urinary metabolite measures.
Metabolites Abbreviation B P
4-deoxyerythronic acid 4-DEA 144.8 0.49
3-hydroxyisovalerate 3-HV -411.8 0.12
Lactate Lac -32.46 0.41
Alanine Ala 152.5 0.22
Acetate AcO 32.85 0.09
Pyruvate Pyr -96.1 0.34
Succinate Suc -316.6 0.04
Citrate Cit 18.76 0.04
Dimethylamine DMA 141.2 0.28
Trimethylamine TMA 20.16 0.94
Dimethylglycine DMG -558.4 0.03
Creatine Crea 43.12 0.26
Creatinine Creat -13.85 0.22
Proline betaine PB -6.34 0.81
P-cresol sulphate PCS 73.56 0.69
Phenylacetylglutamine PAG 37.02 0.53
Hippurate Hip 9.35 0.49
N-methyl-nicotinic acid NMNA 154.3 0.42
Trimethylamine oxide TMAO 0.38 0.93
Glycine Gly 10.99 0.78
Urea Urea -1.1 0.21
Formate For -386.4 0.35
B, Effect size; P, P-values for the multiple linear regression; Bold font indi-
cates association between concentration levels of urinary metabolites and urinary
metabolic levels (P < 0.05) adjusted for sex, age and smoking status.
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parameter converges rapidly to the stationary distribution.
Figure 6.1: The trace plot from the MCMC for the parameter λ from
50,000 iterations after 1,000 burn-in period
The variances regression fits are plotted as a function of urinary cadmium
(Figure 6.2). Results for the 22 urinary metabolites are presented in appendix
Table E.2. From this analysis, we observe that the variance of one of the
urinary metabolites, dimethylglycine (DMG), changes across the range of
values of urinary cadmium. Specifically, we observe a decrease in the variance
of dimethylglycine as the levels of urinary cadmium increase (Figure 6.2).
In addition to changes in mean level and variance, we are interested in
investigating whether correlation between metabolic traits changes in relation
to urinary cadmium. To this end, we have employed the covariance regression
model(178). Results for the 22 urinary metabolites are presented in the
appendix Table E.3. The empirical correlation between metabolites as a
function of urinary cadmium are showed in Figure 6.3 (blue lines). The
pair-wise correlations calculated from the covariance regression fits are also
presented in Figure 6.3 (black lines) with the 95% credible interval (green
and red lines). Using the covariance regression model, we find that the
associations between four pairs of urinary metabolites change across the range
of values of urinary cadmium (Figure 6.3).
Interestingly, we observe that dimethylglycine is consistently involved in
the four pairs of metabolites identified. This analysis indicates that corre-
lation between dimethylglycine and phenylacetylglutamine and acetate de-
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Figure 6.2: Variance regression for dimethylglycine
crease as levels of urinary cadmium increase. On the other hand, the pair-
wise association between dimethylglycine and trimethylamine oxide (TMAO)
and dimethylglycine and Proline betaine (PB) increase as a function of uri-
nary cadmium. As previously indicated, dimethylglycine is related to choline
metabolism. In addition, two of the metabolites identified by the covari-
ance regression analysis - acetate and trimethylamine oxide - are also re-
lated to choline metabolism (Figure 6.4). Specifically, in this metabolic
process choline is metabolised to betaine (Figure 6.4.a). Betaine donates
a methyl group to homocysteine to form methionine (Figure 6.4). This
methylation reaction also generates dimethylglycine (Figure 6.4.b), which
is further metabolized to glycine (Figure 6.4.c). Moreover, dietary choline
forms trimethylamine (TMA) in a reaction catalyzed by enzymes within
gut bacteria (179)(Figure 6.4.d). TMA together with acetate biosynthesizes
trimethylamine-N-oxide (TMAO)(Figure 6.4.e). Dimethylglycine that is not
metabolised in the liver is transported by the circulatory system to body
tissue or it is excreted by urine. While association between mean levels of
urinary dimethylglycine and urinary cadmium have been reported previously
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Figure 6.3: Changes in pair-wise associations between urinary metabo-
lites across the range of values of urinary cadmium
in a human population (56), these additional variations in the metabolism of
dimethylglycine and related metabolites are novel.
To further explore the covariance regression results, we have constructed
seven correlation networks (Figure 6.5) which indicate the pair-wise correla-
tion between pairs of metabolites under different levels of urinary cadmium
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Figure 6.4: Graphic representation of choline metabolism as described
in (180) and (181). Metabolites identified by the covariance regression analysis
are highlighted in the graph with red continuous line. TMAO, trimethylamine
oxide; TMA, trimethylamine; MMA, Methylamine.
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(U-Cd (nmol/mmol creatinine)= 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8). To quan-
titatively describe the topological features of the correlation networks, we
calculate the connectivity, centrality and betweenness for each node of the
seven correlation networks. The connectivity for each of the nodes for dif-
ferent levels of urinary cadmium are presented in Table E.1. We can see
that while a large number of these links are in common between the seven
networks (Figure 6.5), there is an overall tendency to decrease the number
of links as the level of urinary cadmium increases (Total Connectivity, Ta-
ble E.1). Of the 22 urinary metabolites, dimethylglycine is the metabolic
measure that shows the largest reduction in associations, from seven con-
nections at urinary cadmium levels 0.2 nmol/mmol creatinine to only two
at U-Cd of 0.8 nmol/mmol creatinine. Interestingly, the largest decrease in
connectivity occurs at U-Cd of 0.5 nmol/mmol creatinine, which is the lower
limit of potential risk of renal damage suggested by the Scientific Committee
on Toxicity, Ecotoxicity and the Environment (50). Despite the overall ten-
dency to decrease their connectivity, several metabolites exhibit a tendency
to increase their connectivity as levels of U-Cd increase. Of these metabo-
lites alanine shows the large increase in connectivity, from four connections at
cadmium levels of 0.2 nmol/mmol creatinine to nine at U-Cd 0.8 nmol/mmol
creatinine.
In addition to connectivity, there are other networks’ topological fea-
ture that can reflect important points of the networks’ organization. The
betweenness-centrality of a node is very important property because it indi-
cates how central a node is in the graph. It is known that nodes with central
position in the network have great influence in the overall structure of net-
work (114). We observe that for the lower level of urinary cadmium (U-Cd
(0.2 nmol/mmol creatinine), dimethylglycine shows the highest betweenness-
centrality however as levels of urinary cadmium increase, dimethylglycine
loses its central position in the network and other urinary metabolites be-
come more central in the structure of the correlation networks Figure 6.6.
We observe that under high levels of urinary cadmium, alanine becomes the
most central metabolite in the structure of the correlation networks
It is well-established that prolonged exposure to cadmium (Cd) is asso-
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ciated with number of adverse health effects(182, 183). Due to its long bio-
logical half-life, cadmium accumulates with age in human tissues, especially
the liver and kidney, causing their damage. Increased excretion of alanine
aminopeptidase (AAP) and other enzymes of renal tubular origin, such as
N-acetyl-β-D-glucosaminidase (NAG) are often used as biomarkers of early
symptom of cadimum-induced renal lesions (184). In particular, positive as-
sociation between urinary concentration of AAP and urinary cadmium has
been previously reported (184). The main role of alanine aminopeptidase
is to cleave the amino end of an amino acid from various peptides, amide
or arylamide. Although most amino acids can be used by the enzyme, ala-
nine is the preferable amino acid released in reaction catalysed by alanine
aminopeptidase. Our analysis indicates that as levels of urinary cadmium,
alanine becomes the most central component in the correlation networks.
While the interpretation of these large changes in topological properties of
the network - large changes in nodes’ connectivity and betweenness-centrality
- is not obvious, these variations may point to a marked change in the un-
derlying regulation of the system as levels of urinary cadmium increase.
6.5 Summary
Our aim in this study was to investigate continuous changes in metabolic
traits in response to pathogenic stimuli. This study describes a methodolog-
ical approach to investigate changes in mean levels, variance and correlation
of metabolic traits in relation to urinary cadmium, a common environmental
and occupational pollutant. The results illustrate the advantage of using
the proposed methodology to investigate the continuous effect of pathogenic
stimulus in molecular traits. Following our approach we have been able
to identify previously unreported variations in the metabolism of urinary
metabolites in relation to urinary cadmium. For instance, exploring the po-
tential effect of urinary cadmium on the variance and correlation of urinary
metabolites we have identified changes in a number of metabolites involved
in the metabolism of choline. Moreover, by conducting a detailed examina-
tion of the changes in the topological properties of association networks, we
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were able to identify pattern of molecular changes across different levels of
cadmium exposure.
Throughout these comprehensive analyses of network changes, we have
been able to evaluate not only the structural principles of the system but
also to identify what are the key structural points of the system and how
their role change under increasing pathogenic influence. From this analy-
sis, inferences can be drawn about the importance of individual molecules in
disease processes. This study demonstrates the benefit of applying network-
based methods and hierarchical modelling for a more in depth analysis of
the changes induced on molecular traits by potential pathogenic stimulus.
In this context, we can conclude that analysis of molecular changes across
the whole spectrum can provide a much more detailed view into biological
processes and potentially reveal key features of disease development.
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Figure 6.5: Correlation Networks inferred from the covariance regres-
sion analysis. Each of the connections indicated pair-wise correlations between
pairs of metabolites which was calculated from the covariance regression fits un-
der seven different levels of urinary cadmium different levels of urinary cadmium
(U-Cd (nmol/mmol creatinine)= 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8). The node size is
proportional to the degree of connectivity (number of connections).
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Figure 6.6: Betweenness-centrality of the correlation networks. The
betweenness indicates how central a node is in the network under seven different
levels of urinary cadmium (U-Cd (nmol/mmol creatinine)= a) 0.2, b) 0.3, c) 0.4,
d) 0.5, e)0.6, f) 0.7, g) 0.8).
Chapter 7
Discussion
The two main aims of this thesis were 1) to investigate and develop new sta-
tistical methodologies for the integrative analysis of omics data; 2) to explore
the potential of use of association networks as an additional phenotype to
uncover underlying features of phenotype variation. Throughout this work
we presented three novel network-based methodologies - differential network,
GEMINi and Variance and Covariance regression - and illustrated their ap-
plicability in the context of genomic (SNP data) and metabolomic data anal-
ysis. The methods showed promising results, highlighting novel variations in
molecular systems in relation to (patho)physiological conditions, which were
undetectable by more conventional analytical approaches.
In this final chapter, we first summarise the main objectives of this re-
search project thesis. Then we briefly discuss what we believe are the main
achievements of this research project. Some of the challenges and limitations
encountered throughout this work will also be presented. We conclude the
chapter with suggestions regarding future works and how the investigation
presented in this thesis can be further developed.
7.1 Summary
We initiate our work by performing an exploratory analysis of SNP data in
combination with metabolomic phenotypes. Our objective in this chapter
was to show the value of accounting for correlation in ’omics data analysis,
where multiple levels of molecular data, such as genetic variants or metabolic
phenotypes, are generally highly correlated. Consequently, two multivariate
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statistical methods, in addition to the traditional one-SNP-one-phenotype
at-a-time approach, were employed. Each of the three applied approaches
providing access to different levels of biological information. For instance,
the well-established univariate approach provided us with information about
genetic variants that individually have a large effect on each of the serum
metabolic traits. With the HyperLasso regression, we were able to explore
the potential joint effect of genetic variants on each of the metabolic pheno-
types and selected sets of SNPs that in combination best explain the trait’s
value. Finally, with the SUR-based analysis we were able to identify genetic
variants that have a significant effect on a set of related traits as well as the
genetic variants that have a significant effect on several phenotypes but not
on all of them.
For the following three chapters our research was focused on the use of
association networks. In particular, we were interested in investigating the
use of variations in molecular associations as a tool to yield new insight into
the biological basis of disease-specific phenotype changes. First, we presented
a novel statistical methodology, the differential network. The performance
of the differential network method at identifying differences in pair-wise as-
sociation in relation to a binary outcome was tested in a simulation study.
Additionally the use of the differential network method was investigated in
a real data set in the context of diabetic dyslipidemias. Based on a stan-
dard statistical analysis, a few significant differences in concentration levels
of lipoprotein subclasses between subjects with normal fasting glucose and
those with impaired fasting glucose (prediabetes) were found. Interestingly,
with the application of the differential network approach we were able to
identify significant differences in lipoprotein metabolism between the two
groups, many of which were known to be related to the development of di-
abetic dyslipidemias. The results of this analysis are potentially of clinical
relevance, showing that alterations in the lipoproteins metabolism can occur
early in the progression towards disease onset, preceding the clinical diagno-
sis.
In chapter 5, our objetive was to extend the differential network method-
ology to jointly investigate metabolomic and genetic variations in relation to
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phato-physiological conditions. We started this work postulating that differ-
ences in metabolite associations could potentially be used as an additional
phenotype to investigate genetic factors that influence complex traits. To in-
vestigate this hypothesis, we developed a new analytical approach (GEMINi)
which combines correlation network analysis with genome-wide correlation
study and pathway analysis. We illustrated the GEMINi approach by ex-
ploring molecular changes related to obesity. Application of our approach
revealed a set of serum metabolite associations which differ between nor-
mal and obese individuals. Most importantly further investigation of these
metabolic differences identified a number of loci, several of which have been
previously implicated in obesity-related traits such as LIPA, a recently re-
ported gene for obesity-related metabolic complications.
In our last chapter, we proposed to apply network analysis in combination
with Bayesian hierarchical models to explore changes in mean level, variance
and correlation of variables in relation to covariates. This methodology was
illustrated in the context of urinary metabolic traits in response to cadmium
exposure. The results show the potential of the proposed approach to in-
vestigating the continuous effect of pathogenic stimuli in molecular traits.
With the application of this statistical procedure we were able to identify
previously unreported variations in the metabolism of urinary metabolites in
relation to urinary cadmium.
7.2 Main achievements
From the results obtained, we can conclude that the major contributions of
this thesis to the field of omics data analysis are:
• It highlights the need for a more in depth analysis of molecu-
lar features, beyond those detectable using mean level changes.
Throughout this thesis we have shown that to fully understand how
molecular systems change in relation to phatho-physiological stimuli,
it is essential to consider multiple and more complex features of the
available data. Unlocking the full potential of ’omics data requires new
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approaches that move beyond the convectional analysis of mean level
changes. Systematic identification of meaningful relationships between
different entities of the system can yield new insights into underlying
biological basis of disease-specific phenotype variation.
• It demonstrates the use of differential association networks
as a tool to uncover new features of disease development. This
work showed that the comprehensive assessment of changes in molec-
ular associations via network analysis represents a promising tool to
better understand the biological basis of phenotype variation in the
process of disease development. Moreover, the combination of methods
proposed in this work - shrinkage estimates of partial correlations and
network methods - provides a simple approach to investigate the com-
plex web of molecular interactions and consequently helps to improve
the biological interpretation of the results. Our findings demonstrated
the potential of the differential network approach to identify subtle
molecular variations that occur at early stages of disease development.
• It shows the potential use of variations in molecular associa-
tions as an alternative phenotype. In this work, we have presented
and investigated the idea of using molecular associations as a pheno-
type when studying the genetic basis of complex traits and diseases.
This novel approach shows promising power gains over the conventional
genetic and metabolomic analyses.
• It reinforces the need to combine multiple levels of ’omics
data to characterize the mechanisms implicated in the de-
velopment of complex disorders. This work illustrates how the
various types of ’omic data capture different features of the biological
system, being complementary to each other. To enhance our knowledge
of mechanisms involved in disease aetiology, an integrative approach to
omics data analysis is becoming essential.
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7.3 Challenges and limitations
Several challenges and limitations of the proposed methods need to be ac-
knowledged. A first clear limitation of this study is the lack of an indepen-
dent cohort that can be used to replicate our genetic findings. Although the
application of the proposed methodologies showed promising results, we are
unable to draw more final conclusions without the adequate validation study.
A second limitation is related to the relatively small sample size of the
NFBC1966 and the young age of the cohort members which makes difficult
to investigate cardiometabolic disorders. This issue has a clear impact on
the performance of the convectional GWAS in chapter 5, where we found no
association at a genome-wide significance level. Although this limitation was
overcome by the application of the GEMINI approach, we could expect that
with larger sample sizes, undetected associations could have been uncovered.
A main limitation for the inference of the differential networks was the
unbalanced design of the study groups when clinical criteria were used for
the classification of phenotypic groups (e.g.fasting glucose levels). With un-
balanced data, the power of the test is lower than when sample sizes are
equal and therefore higher significance level was required. Thus, to define
which edges were to be included in the differential network we had to set the
cut-off for significance to an uncorrected threshold.
Another limitation encountered throughout this project was the often lim-
ited biological knowledge available to interpret results from omics data sets.
For instance, to assess the potential of the differential networks to reveal key
differences related to different physiological conditions, we compare our re-
sults with existing knowledge of differences in lipoprotein composition related
to the development of T2DM. However, we found that in some cases there
was very limited biological information regarding the metabolic measures in-
vestigated in this thesis (e.g. components of lipoprotein subclasses). This
problem arises from the fact that while the development of high throughput
technologies has provided a large amount of valuable molecular data, ad-
vances in theoretical biology have not kept pace.
A similar limiting issue is the current lack of functional knowledge of
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genetic variants localized away from protein-coding gene or well-known reg-
ulatory region. The common practice in GWAS to interpret genetic finding
is to associate SNPs to the closest protein-coding gene. While it is certainly
true that some disease causing variants alter protein function, there are other
modes of action such as modification of gene expression through alteration of
regulatory regions. In our study, there was a number of identified SNPs that
fell into genetic regions where the closest protein-coding gene was several Mb
away. Although this is the standard approach in GWAS study, evaluation
of the results based on proximity to protein-coding gene do certainly lead to
less sound conclusions.
Future Work
There is a number of ways in which the work in this thesis can be extended.
One potential area of future research is the use of pathway information to
improve the construction of molecular networks. In particular, it would be
interesting to extend our methodologies to incorporate prior knowledge of
molecular pathways. The prior information about network structure could
be extracted from a publicly available database or literature. An example
of use of pathway information is the boosting approach proposed by Shazia
et al. (2008) for learning the structure of networks. This study showed the
value of using pathways information to increase the statistical power and
improve the inference.
Another extension could be the use of different measures of associations
for the inference of the networks, such as rank correlations - which does not
depend on linearity and normality of the data - and nonlinear measures of
association.
The methods proposed in this thesis have been presented based on two
types of omic data: SNP and metabolomic data. However, these analytical
approaches can easily be applied to the analysis of other molecular profiling
techniques such as transcriptomics and proteomics. Thus, a natural exten-
sion of this research is to use the proposed methods to analyse additional
types of molecular information to obtain a complete picture of how biological
CHAPTER 7. DISCUSSION 145
systems change in relation to disease development. One interesting analysis
would be the systematic application of the differential network methodology
to investigate molecular changes at different levels of biological systems. The
subsequent superimposition of the inferred differential networks can help to
identify the subset of molecular mechanisms involved in particular biologi-
cal process. Moreover, this integrative approach can allow the identification
of specific points along the chain of biological processes that become dys-
regulated under disease condition. This superimposing analysis might also
present the benefit of allowing the validation of the results without the need
of incorporating data on new study populations. For instance, the identifi-
cation of an altered pathway at one level of the system (e.g. gene expres-
sion) can be validated by the observation of altered molecules (e.g enzymes
and metabolites) related to such pathway. In addition, it may be useful to
construct combined gene-protein-metabolic-phenotype interaction networks.
Complex outcomes are known to be defined by multiple molecular factors,
which are interconnected between them. Therefore, with the construction of
networks that simultaneously use data on phenotypic characteristic (BMI,
fasting glucose levels), gene expression, enzymatic activity and metabolic
profiles, we can get an understanding of how the patterns of molecular associ-
ation change across different levels of biological systems in disease, which can
potentially allow the identification of dysfunctional regions in the systems.
These multiple- system analyses can provide an in-depth understanding of
the cascade of biochemical changes associated with disease development aid-
ing the generation of biologically meaningful hypotheses which can be the
basis for further detailed analysis (e.g. to design lab experiments that can
help to establish the causal influences of the system dysregulation).
Another avenue for future work is to further develop our methodologies to
facilitate the analysis of longitudinal data. Association networks applied to
longitudinal data can be used to characterize dysregulated part of molecular
systems over time. An example of this approach could be the application of
the differential network approach to analyse data from a study whose aim is
the evaluation of the effects of medication/treatment used on patients with
a given disorder. The differential networks can be constructed at different
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time points of the trial to evaluate molecular differences between e.g. respon-
ders and non-responders to treatment. The examination of network changes
with time can provide information which may be useful in determining the
molecular mechanism underlying a given phenotype. This information can
help the design of further investigations of properties of biochemical reactions
and give us information about pathways that can be modified through more
targeted therapies.
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Appendix A
Data Sets
Table A.1: List of all serum metabolic measures included in this thesis
Full name Abbreviation Ch3 Ch4 Ch5 Ch6
Total lipids in extremely large VLDL XXL-VLDL-L X X
Phospholipids extremely large VLDL XXL-VLDL-PL X
Concentration extremely large VLDL particles XXL-VLDL-P X
Total lipids in very large VLDL XL-VLDL-L X X
Phospholipids in very large VLDL XL-VLDL-PL X
Triglycerides in very large VLDL XL-VLDL-TG X
Concentration of very large VLDL particles XL-VLDL-P X
Total lipids in large VLDL L-VLDL-L X X
Cholesterol in large VLDL L-VLDL-C X
Free cholesterol in large L-VLDL-FC X
Phospholipids in large VLDL L-VLDL-PL X
Triglycerides in large VLDL L-VLDL-TG X
Cholesterol esters in large VLDL L-VLDL-CE X
Concentration of large VLDL particles L-VLDL-P X
Total lipids in medium VLDL M-VLDL-L X X
Cholesterol in medium VLDL M-VLDL-C X
Free cholesterol in medium VLDL M-VLDL-FC X
Phospholipids in medium VLDL M-VLDL-PL X
Triglycerides in medium VLDL M-VLDL-TG X
Cholesterol esters in medium VLDL M-VLDL-CE X
Concentration of medium VLDL particles M-VLDL-P X
Total lipids in small VLDL S-VLDL-L X X
Cholesterol in small VLDL S-VLDL-C X
Free cholesterol in small VLDL S-VLDL-FC X
Phospholipids in small VLDL S-VLDL-PL X
Triglycerides in small VLDL S-VLDL-TG X
Continued on next page
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Full name Abbreviation Ch3 Ch4 Ch5 Ch6
Concentration of small VLDL particles S-VLDL-P X
Total lipids in very small VLDL XS-VLDL-L X X
Phospholipids in very small VLDL XS-VLDL-PL X
Triglycerides in very small VLDL XS-VLDL-TG X
Concentration of very small VLDL particles XS-VLDL-P X
Total lipids in IDL IDL-L X X
Free cholesterol in IDL IDL-FC X
Phospholipids in IDL IDL-PL X
Concentration of IDL particles IDL-P X
Total lipids in large LDL L-LDL-L X X
Cholesterol in large LDL L-LDL-C X
Free cholesterol in large LDL L-LDL-FC X
Phospholipids in large LDL L-LDL-PL X
Cholesterol esters in large LDL L-LDL-CE X
Concentration of large LDL particles L-LDL-P X
Total lipids in medium LDL M-LDL-L X X
Cholesterol in medium LDL M-LDL-C X
Phospholipids in medium LDL M-LDL-PL X
Cholesterol esters in medium LDL M-LDL-CE X
Concentration of medium LDL particles M-LDL-P X
Total lipids in small LDL S-LDL-L X X
Cholesterol in small LDL S-LDL-C X
Concentration of small LDL particles S-LDL-P X
Total lipids in in very large HDL XL-HDL-L X X
Cholesterol in very large HDL XL-HDL-C X
Free cholesterol in very large HDL XL-HDL-FC X
Phospholipids in very large HDL XL-HDL-PL X
Triglycerides in very large HDL XL-HDL-TG X
Cholesterol esters in very large HDL XL-HDL-CE X
Concentration of very large HDL particles XL-HDL-P X
Total lipids in large HDL L-HDL-L X X
Cholesterol in large HDL L-HDL-C X
Free cholesterol in large HDL L-HDL-FC X
Phospholipids in large HDL L-HDL-PL X
Cholesterol esters in large HDL L-HDL-CE X
Concentration of large HDL particles L-HDL-P X
Total lipids in medium HDL M-HDL-L X X
Cholesterol in medium HDL M-HDL-C X
Free cholesterol in medium HDL M-HDL-FC X
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Full name Abbreviation Ch3 Ch4 Ch5 Ch6
Phospholipids in medium HDL M-HDL-PL X
Cholesterol esters in medium HDL M-HDL-CE X
Concentration of medium HDL particles M-HDL-P X
Total lipids in small HDL S-HDL-L X X
Triglycerides in small HDL S-HDL-TG X
Concentration of small HDL particle S-HDL-P X X
Apolipoprotein A-I ApoA.I. X X X
Apolipoprotein B ApoB. X X X
Apolipoprotein B by Apolipoprotein A-I ApoB/ApoA.I X
3-hydroxybutyrate bOHBut X X
Acetate Ace X X
Acetoacetate AcAce X X
Alanine Ala X X
Citrate Cit X X
Creatinine Crea X X
Glucose Glc X X
Glutamine Gln X X
Glycerol Glol X X
Histine His X X
Isoleucine Ile X X
Lactate Lac X X
Leucine Leu X X
Phenylalanine Phe X X
Pyruvate Pyr X X
Tyrosine Tyr X X
Urea Urea X X
Valine Val X X
esterified cholesterol EstC X
Free cholesterol FreeC X
Omega-3 fatty acids FAw3 X
Omega-6 fatty acids FAw6 X
omega-9 and saturated fatty acids FAw79S X
Total fatty acids TotFA X
18:2, linoleic acid (LA) LA X
Polyunsaturated fatty acids 18:2 TotPUFA X
22:6, docosahexaenoic acid (DHA) DHA X
Monounsaturated fatty acids MUFA X
Total phosphoglycerides TotPG X
Phosphatidylcholine and other cholines PC X
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Full name Abbreviation Ch3 Ch4 Ch5 Ch6
Sphingomyelins SM X
Ratio of omega-3 fatty acids to total fatty acids FAw3toFA X
Ratio of omega-6 fatty acids to total fatty acids FAw6toFA X
Ratio of omega-9 and saturated fatty acids to
total fatty acids
FAw79StoFA X
Total phosphoglycerides to Total triglycerides TGtoPG X
Table A.2: List of all urinary metabolic measures included in this thesis
Full name Abbreviation Ch3 Ch4 Ch5 Ch6
4-deoxyerythronic acid 4-DEA X
3-hydroxyisovalerate 3-HV X
Lactate Lac X
Alanine Ala X
Acetate AcO X
Pyruvate Pyr X
Succinate Suc X
Citrate Cit X
Dimethylamine DMA X
Trimethylamine TMA X
Dimethylglycine DMG X
Creatine Crea X
Creatinine Creat X
Proline betaine PB X
P-cresol sulphate PCS X
Phenylacetylglutamine PAG X
Hippurate Hip X
N-methyl-nicotinic acid NMNA X
Trimethylamine oxide TMAO X
Glycine Gly X
Urea Urea X
Formate For X
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Figure A.1: A flowchart for NFBC data analysis
Appendix B
Statistical methods for GWAS
Table B.1: Results from the multi-SNP analysis of serum metabolic
traits
Metabolic T Markers Chr Pos Al1/Al2 P Genes
XXL-VLDL-L rs780094 2 27652888 C/T 4.98E-5 GCKR
rs6472088 8 64381899 G/T 1.38E-5 YTHDF3
rs12542080 8 88775120 A/G 1.71E-3 DCAFAL2
XL-VLDL-L rs1260326 2 27642591 C/T 1.98E-7 GCKR
rs6472088 8 64381899 G/T 7.38E-6 YTHDF3
rs12542080 8 88775120 A/G 5.24E-4 DCAFAL2
rs2248141 15 51959844 A/G 3.16E-4 UNC13C
rs4985124 16 15032942 G/T 2.50E-5 PDXDC1
rs7289448 22 31913986 A/G 2.00E-3 LARGE
L-VLDL-L rs1260326 2 27642591 C/T 1.87E-9 GCKR
rs10096633 8 19875201 C/T 1.11E-7 LPL
rs4985124 16 15032942 G/T 4.74E-6 PDXDC1
M-VLDL-L rs673548 2 21149196 A/G 7.75E-10 APOB
rs780094 2 27652888 C/T 3.89E-9 GCKR
rs2054046 2 70028725 C/T 3.09E-2 GMCL1
rs10096633 8 19875201 C/T 1.78E-9 LPL
rs2304821 12 69249886 A/G 3.42E-3 PTPR3
S-VLDL-L rs6728178 2 21105581 A/G 1.83E-12 APOB
rs1260326 2 27642591 C/T 5.45E-8 GCKR
rs2054046 2 70028725 C/T 1.82E-2 GMCL1
rs1328925 4 159547895 C/T 1.05E-3 TMEM144
rs10096633 8 19875201 C/T 3.18E-8 LPL
rs10984096 9 118418644 A/G 1.40E-4
rs2000571 11 116090743 A/G 1.12E-5 APOcluster
rs2248141 15 51959844 A/G 2.40E-4 UNC13C
rs4243298 18 62688709 G/T 1.11E-3 CDH19
rs2303180 19 8401765 A/G 3.02E-6 MARCH
XS-VLDL-L rs6728178 2 21105581 A/G 1.45E-12 APOB
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Metabolic T Markers Chr Pos Al1/Al2 P Gene
rs2054046 2 70028725 C/T 2.18E-2 GMCL1
rs1264542 6 30494975 A/G 1.00E-3 TRIM39
rs4986947 6 52957189 A/G 6.29E-3 GSTA4
rs6937974 6 133682141 C/T 5.01E-4 EYA4
rs11793564 9 108613870 A/G 1.70E-4 ACTL7B
rs1904683 10 52619168 G/T 3.75E-4 PRKG1
rs10498404 14 48015708 A/G 5.64E-4
rs1532085 15 56470658 A/G 5.53E-10 LIPC
rs261336 15 56529710 A/G 8.34E-7 LIPC
rs4436850 18 25841455 A/G 1.58E-3
rs157580 19 50087106 A/G 1.22E-8 TOMM40, APOE
IDL-L rs646776 1 109530572 C/T 4.00E-6 CELSR2
rs6754295 2 21117835 G/T 3.07E-8 APOB
rs693 2 21143847 A/G 3.68E-9 APOB
rs2464698 2 70394102 C/T 4.45E-2 PCYOX1
rs4384906 3 33215318 G/T 5.86E-4 SUSD5
rs7655585 4 181174294 A/G 4.18E-4
rs1264542 6 30494975 A/G 1.12E-3 TRIM39
rs3011286 9 132923544 C/T 6.61E-4 GSTA4
rs1904694 10 52575500 A/G 1.52E-4 PRKG1
rs6575501 14 94710082 A/C 9.48E-6 DICER1-AS1
rs1532085 15 56470658 A/G 2.10E-7 LIPC
rs12904245 15 77303043 C/T 1.16E-2 ANKRD34C
rs11877591 18 26069966 A/G 1.16E-3
rs157580 19 50087106 A/G 1.29E-8 TOMM40, APOE
rs405509 19 50100676 G/T 2.95E-1 APOE
rs4821240 22 32947519 C/T 2.09E-2 LARGE
L-LDL-L rs646776 1 109530572 C/T 2.55E-7 CELSR2
rs693 2 21143847 A/G 1.56E-8 APOB
rs4384906 3 33215318 G/T 1.63E-3 SUSD5
rs7655585 4 181174294 A/G 2.87E-4
rs1264542 6 30494975 A/G 3.33E-3 TRIM39
rs1904683 10 52619168 G/T 1.92E-4 GSTA4
rs7159503 14 88458634 A/G 2.53E-3 TTC8
rs10409243 19 10193988 C/T 2.79E-5 DNMT1
rs157580 19 50087106 A/G 2.55E-7 TOMM40, APOE
rs405509 19 50100676 G/T 1.92E-2 APOE
rs5767585 22 45923688 A/C 2.13E-3 TBC1D22A
M-LDL-L rs646776 1 109530572 C/T 1.42E-7 CELSR2
rs693 2 21143847 A/G 5.06E-8 APOB
rs1904683 10 52619168 G/T 2.39E-4 PRKG1
rs2965101 19 49929652 C/T 1.14E-5 BCL3
S-LDL-L rs646776 1 109530572 C/T 2.78E-7 CELSR2
rs693 2 21143847 A/G 2.53E-7 APOB
rs1904683 10 52619168 G/T 2.88E-4 PRKG1
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Metabolic T Markers Chr Pos Al1/Al2 P Gene
rs2965101 19 49929652 C/T 5.30E-6 BCL3
XL-HDL-L rs7650071 3 137460003 A/G 9.36E-3 PCCB
rs13156109 5 40941833 C/T 7.72E-5 C7
rs1935420 6 82745959 A/G 5.60E-3 IBTK
rs9285492 6 140837328 C/T 2.85E-4
rs11005804 10 58887377 C/T 8.21E-3
rs1532085 15 56470658 A/G 4.00E-16 LIPC
rs261336 15 56529710 A/G 1.94E-10 LIPC
rs7178362 15 56634555 C/T 3.09E-8 LIPC
rs1532624 16 55562980 A/C 1.16E-6 CETP
rs7499892 16 55564091 C/T 4.87E-7 CETP
rs6065906 20 43987422 C/T 3.18E-11 PLTP
L-HDL-L rs6697783 1 221934995 A/G 4.25E-2 LBR
rs4654103 1 242851660 G/T 2.55E-3 SMYD3
rs17148957 5 121551075 C/T 7.74E-4 ZNF474
rs11154522 6 130483157 A/G 5.15E-4 L3MBTL3
rs9397900 6 150757866 A/G 2.26E-2 IYD
rs2977469 8 141618473 A/G 1.19E-2 EFI2C2
rs4836625 9 128596392 C/T 6.68E-3 ZER1
rs766606 13 94452168 A/C 5.95E-2 ABCC4
rs1532085 15 56470658 A/G 2.27E-18 LIPC
rs473224 15 56524633 G/T 5.10E-6 LIPC
rs3764261 16 55550825 A/C 9.32E-18 CETP
rs8054916 16 56089134 A/G 9.48E-4 CCDC102A
rs1121985 16 77920580 A/C 1.88E-4 WWOX
rs1800961 20 42475778 C/T 4.38E-9 HNF4A
rs4810479 20 43978455 C/T 2.03E-7 PLTP
M-HDL-L rs12547884 8 10032925 A/G 1.05E-5 MSRA
rs2047554 12 24945476 C/T 1.45E-2 BCAT1
rs3764261 16 55550825 A/C 4.89E-11 CETP
rs1799281 19 53640582 A/G 7.88E-4 GRIN2D
S-HDL-L rs4453935 4 13585054 C/T 9.16E-7 BOD1L1
rs1390498 6 140586160 A/G 9.07E-4
rs3739942 9 137052237 C/T 2.78E-5 TRAF2
rs4917911 10 102549411 A/G 1.11E-3 PAX2
rs17152324 10 126547196 A/G 4.65E-4 FAM175B
rs6065906 20 43987422 C/T 7.34E-9 PLTP
ApoA1 rs6697783 1 221934995 A/G 4.90E-4 LBR
rs10495736 2 23131509 A/G 1.53E-4 KLHL29
rs1940309 4 116444565 C/T 1.15E-3 NDST4
rs425974 4 189752867 A/C 3.44E-6 RP11-219G10
rs652888 6 31959213 A/G 8.96E-4 EHMT2
rs10499028 6 100459334 A/G 9.12E-5 MCHR2
rs2171981 6 168344796 C/T 1.85E-6 FRMD1
rs2350842 7 9207348 A/C 1.52E-2
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rs174570 11 61353788 C/T 7.07E-5 FADS2-3
rs1532085 15 56470658 A/G 5.30E-7 LIPC
rs3764261 16 55550825 A/C 2.10E-15 CETP
rs1465354 17 50789174 C/T 1.64E-3 HLF
rs1948557 19 36410329 A/G 1.92E-4 TSHZ3
rs8110189 19 61522069 A/C 7.99E-3 ZSCAN5A
ApoB rs6728178 2 21105581 A/G 1.79E-10 APOB
rs693 2 21143847 A/G 2.43E-9 APOB
rs1260326 2 27642591 C/T 6.53E-5 GCKR
rs2054046 2 70028725 C/T 3.03E-3 GMCL1
rs1904683 10 52619168 G/T 3.29E-5 PRKG1
rs2717440 12 69245373 C/T 5.31E-4 PTPRB
rs7186194 16 82183721 G/T 1.68E-4 CDH13
rs10409243 19 10193988 C/T 6.73E-6 DNMT1
rs157580 19 50087106 A/G 3.21E-7 TOMM40, APOE
3-hydroxybutyrate rs10510515 3 21695378 A/G 2.11E-3 ZNF385D
rs2328943 13 74918850 C/T 1.62E-3 TBC1D4
rs2242629 14 76403716 C/T 1.77E-3 C14orf166B
Acetate rs848792 3 126057032 C/T 6.84E-2 ITGB5
rs2968505 7 71339280 C/T 6.13E-3 CALN1
rs10765031 10 132754466 C/T 6.51E-2 TCERG1L
rs1564580 17 30587907 C/T 2.20E-2 SLFN5
Acetoacetate rs4778908 15 79632208 A/G 9.97E-3 TMC3
rs2328559 20 20726180 A/G 1.98E-4 RALGAPA2
Alanine rs1260326 2 27642591 C/T 5.72E-7 GCKR
rs492272 3 162947528 G/T 2.65E-3 OTOL1
rs6829634 4 45453629 A/G 3.79E-4 GABRG1
rs4415952 14 72258906 C/T 7.03E-4 DPF3
Citrate rs6677954 1 172445619 A/G 1.75E-2 TNR
rs701157 1 226981561 C/T 2.91E-2 LOC729257
rs1437313 2 139659908 A/G 2.58E-6 NXPH2
rs4667819 2 166113483 C/T 5.50E-2 CSRNP3
rs12485763 3 27558321 A/G 1.62E-1 SLC4A7
rs10236225 7 9999670 C/T 1.08E-4 NA
rs8074277 17 78382917 C/T 1.39E-2 TBCD
rs712964 22 17530671 C/T 1.84E-11 CLTCL1
Creatinine rs1113958 2 148314711 A/G 6.97E-4 ACVR2A
rs12506374 4 8272605 C/T 1.00E-3 ABLIM2
rs11751605 6 160933641 C/T 1.67E-3 LPA
rs2078980 7 28350789 A/G 3.26E-3 CREB5
rs1939470 11 95485565 A/G 6.75E-3 MAML2
rs10777233 12 89109577 A/G 9.26E-4
rs9573940 13 34916882 A/C 2.02E-3 NBEA
rs2239990 15 89624441 A/G 2.80E-5 SV2B
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rs7505939 18 7987833 C/T 1.87E-3 PTPRM
rs565798 18 8125770 A/G 1.39E-3 UQCRFS1
rs6022671 20 51743446 A/G 9.25E-4 ZNF217
Glucose rs4666204 2 29457029 C/T 8.95E-4 ALK
rs7623833 3 64314296 C/T 2.53E-4 PRICKLE2
rs4831130 3 117522532 G/T 3.30E-4 LSAMP
rs11714053 3 133332108 C/T 1.54E-3 CPNE4
rs6788064 3 144959109 A/G 1.16E-3 SLC9A9
rs1864372 4 147501177 A/G 8.91E-5 LSM6
rs2069297 5 93609173 C/T 1.17E-2 KIAA825
rs9275495 6 32781552 A/T 4.21E-3 HLA-DQB1
rs1373130 9 99233349 C/T 5.12E-4 SEC61B
rs17267324 10 14805582 C/G 1.48E-4 FAM107B
rs543970 11 125421262 C/T 9.66E-7 CDON
rs6574591 14 80152153 C/T 7.14E-2 CEP128
rs6022671 20 51743446 A/G 1.21E-5 ZNF217
rs768832 21 27843561 A/C 3.18E-3
Glutamine rs1000226 4 63199692 C/T 2.88E-3 LPHN3
rs3802037 7 90161256 A/G 9.70E-4 CDK14
rs7845972 8 69683092 A/G 5.25E-3 C8orf34
rs7015712 8 75643058 C/T 1.18E-2 GDAP1
rs2620636 8 145748936 C/T 2.27E-3 ARHGAP39
rs11817730 10 99348501 A/G 1.18E-4 PI4K2A
rs4919305 10 101123989 G/T 9.53E-4 CNNM1
rs1366906 11 44454928 G/T 7.56E-2 CD82
rs774211 12 55207206 C/T 4.02E-8 RBMS2
rs4778464 15 20537129 G/T 1.81E-5 CYFIP1
rs1194463 15 53060288 C/T 2.27E-2 RSL24D1
Glycerol rs3737593 1 3719693 A/G 1.43E-2 LRRC47
rs213473 1 54642991 A/G 5.13E-1 SSBP3
rs17016934 1 106573537 C/T 7.00E-3
rs7538977 1 108465875 A/G 1.98E-1 NBPF4
rs12060029 1 208959970 C/T 1.28E-1 TMEM206
rs9288032 2 180143698 G/T 2.45E-3 ZNF385B
rs7639655 3 99853530 C/T 5.67E-1 CPOX
rs4422306 3 108282550 G/T 6.22E-1 RP11-280F2
rs1242064 3 144854964 C/T 1.02E-3 SLC9A9
rs3843376 3 198302734 C/T 8.26E-3 DLG1
rs13125250 4 8128183 C/T 9.15E-2 ABMIM2
rs11734226 4 178536007 C/T 3.66E-2 NEIL3
rs2102575 4 187506653 A/G 5.89E-4 CYP4V2
rs29560 5 123116099 A/G 2.39E-2 CSNK1G3
rs17067004 5 165847033 C/T 2.28E-1
rs9354652 6 68738367 C/T 3.09E-2
rs3793227 7 158385404 A/G 3.86E-4 VIPR2
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rs4260902 8 23426356 A/G 5.58E-2 SLC25A37
rs11774796 8 25094151 A/C 3.48E-2 DOCK5
rs1535658 9 10361281 A/G 2.73E-1 PTPRD
rs4509708 10 41934567 A/G 4.25E-2 CCNYL2
rs3844492 10 49492807 A/G 4.34E-4 ARHGAP22
rs7075347 10 76203313 C/T 3.52E-1 KAT6B
rs7911910 10 126021464 A/G 2.42E-2 OAT
rs1792549 11 15182234 A/G 2.74E-2 INSC
rs2306365 11 65183922 A/G 2.16E-2 RELA
rs10743621 12 28636597 A/G 3.78E-1 CCDC91
rs4293188 12 38522359 A/C 6.01E-4 SLC2A13
rs2044747 14 42393956 A/C 6.58E-3
rs6573242 14 58623902 A/G 1.27E-2 DAAM1
rs922178 15 62056463 C/T 3.52E-3 RSL24D1
rs7237794 18 9941304 C/T 2.03E-1 VAPA
rs2287671 19 11469931 A/C 1.14E-2 ZNF653
rs6068407 20 51013811 A/G 9.16E-1 TSHZ2
rs394484 21 19299986 A/G 2.87E-1 PP1AP22
rs457779 21 27790008 A/G 1.62E-2
rs2092331 22 33956098 C/T 1.22E-1 HMGXB4
rs2267341 22 35301475 C/T 1.07E-3 CACNG2
Histine rs2731672 5 176775080 A/G 3.86E-2 GRK6
rs7800178 7 1400873 C/T 5.06E-5 PSMG3
rs10486100 7 10599434 C/T 2.25E-4 NDUFA4
rs190925 10 70990949 A/G 1.00E-4 NEUROG3
Isoleucine rs1334336 1 88104461 C/T 1.78E-3
rs9287724 2 10939186 A/C 7.96E-3
rs1260326 2 27642591 C/T 1.47E-7 GCKR
rs1399627 2 226908916 A/G 1.58E-2
rs2943641 2 226919250 C/T 1.59E-2 IRS1
rs2943645 2 226924685 C/T 1.48E-2
rs908265 2 239998541 C/T 4.47E-6 HDAC4
rs688136 6 153172175 C/T 3.55E-3 YIP
rs4719934 7 28261492 A/G 1.34E-6 CREB5
rs1421320 7 154801369 A/C 5.04E-3 CNPY1
rs7839522 8 94909310 A/G 4.73E-5 TMEM67
rs4905214 14 94067248 A/G 8.28E-4 SERPINA12
rs12460985 19 50382729 C/T 1.83E-3 MARK4
Lactate rs12069195 1 202947755 A/G 1.75E-1 SRGAP2
rs3008206 1 210334156 C/T 4.76E-2 PROX1
rs17047306 1 214632092 C/T 3.66E-1 RRP15
rs3795367 1 229052855 C/T 2.42E-5 SIPA1L2
rs6709502 2 30922575 C/T 3.11E-4 CAPN13
rs7593405 2 78240187 C/T 1.00E-1
rs1511199 2 167729549 G/T 5.91E-3 XIRP2
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rs4667173 2 188258463 A/G 4.87E-2 TFP1
rs6782432 3 58786097 A/G 4.09E-1 C3orf67
rs2968671 4 5092742 A/C 6.58E-3 CYTL1
rs6447091 4 41392741 A/G 4.44E-2 LIMCH1
rs2331548 4 170337334 A/G 2.38E-1 SH3RF1
rs10520847 5 16956718 A/C 9.02E-3 MYO10
rs6458287 6 12580242 C/T 3.59E-2 RPL15P3
rs1782449 6 91206909 C/T 2.47E-1 MAP3K7
rs9487754 6 112343990 C/T 2.22E-3 FYN
rs4398772 6 115869717 A/G 8.17E-1
rs7803071 7 83104559 C/T 6.83E-2 SEMA3A
rs7796348 7 157098551 C/T 7.00E-3 PTPRN2
rs10105819 8 19272477 C/T 1.33E-1 SH2D4A
rs7863972 9 3334203 C/T 1.19E-1 RFX3
rs875295 12 26232155 A/C 5.09E-4 SSPN
rs17631397 13 29351522 A/G 1.51E-1 UBL3
rs1929753 13 75709051 C/T 2.32E-1 LMO7
rs171603 16 9375312 A/G 1.16E-3 RPL21P119
rs4455065 18 5064049 A/G 2.03E-2 C18orf42
rs10483243 22 47390986 A/C 7.84E-4 FAM19A5
Leucine rs3784191 14 31993041 C/T 5.71E-4 AKAP6
rs3784759 15 87184048 C/T 5.81E-4 ACAN
Phenylalanine rs2731672 5 176775080 A/G 4.59E-4 GRK6
Pyruvate rs360102 1 222374597 A/G 1.07E-4 TMEM63A
rs10802397 1 242860493 A/G 3.00E-5 SYD3
rs1260326 2 27642591 C/T 2.85E-5 GCKR
rs1356609 3 34278287 A/G 2.54E-4 PDCD6IP
rs6899062 5 25646520 A/C 1.42E-2
rs1039693 6 54705257 A/G 2.35E-2 FAM83B
rs2798976 6 78314890 C/T 2.46E-2 HTR1B
rs7091933 10 9477937 A/G 9.46E-5
rs12367514 12 68311754 C/T 4.56E-3 BEST3
rs2717417 12 69315698 C/T 6.40E-3 PTPRR
rs189247 15 95387634 A/G 3.04E-3 SATA8
rs1061273 19 5093817 C/T 1.83E-4 KDM4B
rs4805339 19 34365730 G/T 5.97E-4
rs2423967 20 15529484 A/G 4.73E-3 MACROD2
Tyrosine rs6664203 1 104328358 A/G 6.42E-4 AMY1C
rs4696687 4 8057265 C/T 2.94E-3 AFAP1
rs1947372 4 124781096 A/G 2.02E-4 SPRY1
rs7451051 6 111851511 A/G 4.07E-8 REV3L
rs517684 11 78721866 A/G 4.21E-5 TENM4
rs4346460 20 23517400 C/T 1.27E-5 CST9
Urea rs7545292 1 208667453 G/T 7.32E-3 DTL
rs901666 1 241418873 A/G 1.91E-2 EFCAB2
Continued on next page
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rs4420731 2 22910802 A/C 4.56E-2
rs3732191 2 47951936 A/C 4.16E-2 FBXO11
rs6781602 3 81497660 C/T 3.44E-1 GBE1
rs4234851 4 81429574 C/T 2.65E-1
rs7655290 4 141543207 A/G 3.04E-1 SCOC
rs17476583 5 85958923 A/C 1.10E-2
rs10040945 5 96442155 C/T 5.26E-2 LIX1
rs11738868 5 169880846 A/G 7.32E-3 KCNIP1
rs4718709 7 67011579 A/G 1.37E-2
rs7830040 8 83079508 C/T 1.90E-2 SNX16
rs1180628 8 116500037 A/C 8.59E-2 TRPS1
rs1132743 9 131401844 A/G 4.59E-2 PRRC2B
rs1926559 10 114042907 C/T 1.79E-4 TECTB
rs2238023 12 2072798 C/T 3.77E-1 CACNA1C
rs2046932 12 38866707 A/G 7.21E-2
rs17538030 14 32639991 C/T 1.01E-1 NPAS3
rs7497239 15 22459149 A/G 2.24E-1 NPAP1
rs6502246 17 13124626 A/C 3.58E-2 HS3ST3A1
rs2614996 18 40534091 A/G 2.30E-1 SETBP1
rs1469580 18 64802946 A/G 2.65E-1 CCDC102B
rs4471960 20 8398247 A/G 7.20E-2 PLCB1
rs6031225 20 41981244 A/C 5.48E-2 TOX2
Valine rs958325 4 89566860 A/G 2.92E-6 RP11-10L7.1
rs454282 19 35291623 A/G 2.23E-3 URI1
EstC rs646776 1 109530572 C/T 2.81E-6 CELSR2
rs693 2 21143847 A/G 4.05E-6 APOB
rs4384906 3 33215318 G/T 4.20E-4 SUSD5
rs7655585 4 181174294 A/G 1.74E-4
rs2474152 6 144054752 C/T 6.88E-4 PHACTR2
rs1904683 10 52619168 G/T 2.22E-4 PRKG1
rs7186194 16 82183721 G/T 4.86E-4 CDH13
rs878971 18 31300672 A/G 8.14E-3 INO80C
FreeC rs693 2 21143847 A/G 2.35E-8 APOB
rs4852500 2 70461429 A/C 2.07E-2 DFAM136A
rs1904683 10 52619168 G/T 2.90E-4 PRKG1
rs7159503 14 88458634 A/G 2.46E-4 TTC8
rs1532085 15 56470658 A/G 8.95E-9 LIPC
rs897587 17 74907220 C/T 2.55E-3 RBFOX3
rs878971 18 31300672 A/G 1.10E-2 INO80C
FAw3 rs3934285 1 104310962 A/G 6.09E-3
rs2143109 1 167504689 A/G 7.37E-4 PRRX1
rs11582261 1 178141143 G/T 2.29E-4 CACNA1E
rs7603546 2 240455954 C/T 7.90E-4
rs6868240 5 4991915 A/C 5.39E-4 ADAMTS16
rs2474152 6 144054752 C/T 2.63E-4 PHACTR2
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rs11592435 10 67332087 A/G 9.52E-7 CTNNA3
rs444323 10 109904338 A/G 3.41E-3
rs1898354 10 118818194 C/T 2.25E-4 KIAA1598
rs102275 11 61314379 C/T 2.48E-7 FADS1-3
rs4936947 11 124003995 C/T 8.74E-4 TBRG1
rs12146774 12 118136223 C/T 6.46E-4 HSPB8
rs3786394 18 31313063 A/C 3.43E-3 INO80C
rs2304130 19 19650528 A/G 5.57E-6 ZNF101
FAw6 rs693 2 21143847 A/G 7.63E-6 APOB
rs10185680 2 24186957 A/G 6.88E-5 APOB
rs4616468 2 64015783 C/T 1.62E-4 UGP2
rs1900741 2 135836232 C/T 1.57E-6 ZRANB3
rs4384906 3 33215318 G/T 3.27E-4 SUSD5
rs7653056 3 177272705 A/G 1.73E-2 NAALADL2
rs6818812 4 164995577 C/T 4.11E-3 MARCH
rs7655585 4 181174294 A/G 2.33E-4
rs17492381 5 152429608 C/T 4.73E-3 GRIA1
rs10807218 6 40057564 C/T 4.44E-4 MOCS1
rs2474152 6 144054752 C/T 1.45E-3 PHACTR2
rs6969660 7 7619666 A/C 4.17E-5 AC006465.3
rs1904683 10 52619168 G/T 4.03E-4 PRKG1
rs9595132 13 43946832 A/G 2.65E-4 TSC22D1
rs9634510 13 97572905 C/T 2.51E-5 FARP1
rs1927384 13 101943751 A/G 1.37E-2 TPP2
rs7193689 16 7474240 A/G 2.97E-3 RBFOX1
rs7186194 16 82183721 G/T 5.23E-4 CDH13
rs133903 22 24490565 A/C 1.02E-3 MYO18B
FAw79S rs6728178 2 21105581 A/G 4.70E-5 APOB
rs1260326 2 27642591 C/T 2.25E-8 GCKR
rs10495936 2 46819850 C/T 7.41E-5 SOCS5
rs2474152 6 144054752 C/T 1.69E-3 PHACTR2
rs17152855 7 25692400 A/C 1.65E-3 NFE2L3
rs9634510 13 97572905 C/T 1.49E-4 FARP1
rs878971 18 31300672 A/G 2.26E-3 INO80C
TotFA rs6728178 2 21105581 A/G 1.96E-5 APOB
rs10185680 2 24186957 A/G 2.79E-4 APOB
rs1260326 2 27642591 C/T 2.05E-7 GCKR
rs2474152 6 144054752 C/T 7.09E-4 PHACTR2
rs4722537 7 25700068 G/T 2.51E-4 NFE2L3
rs2339732 10 52597248 G/T 4.29E-4 PRKG1
rs9634510 13 97572905 C/T 5.00E-5 FARP1
rs878971 18 31300672 A/G 2.28E-3 INO80C
LA rs956796 1 146999164 A/G 2.85E-3 ANP32E
rs693 2 21143847 A/G 8.01E-7 APOB
rs10185680 2 24186957 A/G 3.52E-4 APOB
Continued on next page
APPENDIX B. STATISTICAL METHODS FOR GWAS 182
Table B.1 – continued from previous page
Metabolic T Markers Chr Pos Al1/Al2 P Gene
rs2464698 2 70394102 C/T 9.64E-2 PCYOX1
rs968051 2 103911743 A/G 4.99E-4
rs1900741 2 135836232 C/T 2.08E-6
rs4691101 4 165010531 C/T 3.37E-3 MARCH
rs9368699 6 31910520 C/T 2.19E-2 SNORD52
rs10947842 6 40023327 C/T 6.67E-4 MOCS1
rs2474152 6 144054752 C/T 3.67E-3 PHACTR2
rs6969660 7 7619666 A/C 7.87E-6 AC006465.3
rs1904683 10 52619168 G/T 4.30E-4 PRKG1
rs174546 11 61326406 C/T 2.46E-10 FADS1-3
rs9634510 13 97572905 C/T 5.59E-5 FARP1
rs7186194 16 82183721 G/T 2.93E-3 CDH13
rs2410062 21 39150790 A/G 1.70E-3 ETS2
TotPUFA rs2031373 1 62795310 A/C 1.00E-3 DOCK7
rs3934285 1 104310962 A/G 1.58E-3
rs10924989 1 243826691 A/G 7.54E-4 ZNF496
rs11682343 2 85580646 A/G 1.02E-2 SH2D6
rs4384906 3 33215318 G/T 9.91E-4 SUSD5
rs1866929 3 73997737 C/T 1.57E-2
rs10511248 3 107260259 G/T 6.20E-4 CBLB
rs6830724 4 90550905 C/T 4.99E-5 GPRIN3
rs2389925 4 121237670 A/G 3.93E-4 MAD2L1
rs12659587 5 50305167 C/T 4.91E-3 PARP8
rs9790855 5 77634610 C/T 8.53E-3 AP3B1
rs11746854 5 78864910 A/G 3.75E-4 HOMER1
rs17492381 5 152429608 C/T 2.01E-2 KCTD16
rs2474152 6 144054752 C/T 9.94E-4 PHACTR2
rs7780859 7 20540830 C/T 2.05E-2 ABCB5
rs1881726 7 147371266 C/T 3.81E-3 CNTNAP2
rs2978521 8 62279233 A/G 1.28E-3 CLVS1
rs6982636 8 126548497 A/G 5.88E-4 TRIB1
rs10808546 8 126565000 C/T 2.41E-4 TRIB1
rs2150197 9 116782172 A/G 2.00E-3
rs12685378 9 128827265 A/G 3.48E-4 NUP188
rs790661 10 106779870 A/G 3.31E-4 SORCS3
rs1898354 10 118818194 C/T 4.06E-3 KIAA1598
rs174556 11 61337211 C/T 1.01E-51 FADS1
rs174570 11 61353788 C/T 6.41E-34 FADS2-3
rs1149593 11 76141588 A/G 4.92E-4 TSKU
rs4936947 11 124003995 C/T 1.04E-3
rs11046207 12 21887312 C/T 1.64E-3 ABCC9
rs10843712 12 30339528 C/T 5.16E-4 IPO8
rs7159503 14 88458634 A/G 3.65E-3 TTC8
rs3786394 18 31313063 A/C 1.53E-3 INO80C
rs7247764 19 50367713 C/T 1.39E-2 MARK4
rs363452 21 29901558 A/G 9.76E-4 GRIK1
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rs412519 21 42916410 A/G 7.35E-3 AP0011626.1
rs761336 22 36333741 A/C 2.59E-5 GGA1
DHA rs4970405 1 1088878 A/G 1.16E-4 C1orf159
rs4573267 8 64168117 A/G 7.93E-3 TTPA
rs1898354 10 118818194 C/T 1.18E-3 KIAA1598
rs174537 11 61309256 G/T 7.88E-6 PURAQTL1
rs3786394 18 31313063 A/C 5.48E-3 INO80C
rs2304130 19 19650528 A/G 2.93E-5 ZNF101
rs761336 22 36333741 A/C 8.43E-6 GGA1
MUFA rs6728178 2 21105581 A/G 1.14E-6 APOB
rs1260326 2 27642591 C/T 1.41E-9 GCKR
rs10495936 2 46819850 C/T 2.38E-4 SOCS5
rs9683662 4 62577150 C/T 2.65E-2 LPHN3
rs17152855 7 25692400 A/C 4.11E-3 NFE2L3
rs9634510 13 97572905 C/T 2.73E-4 FARP1
rs4243298 18 62688709 G/T 6.09E-4 CDH19
TotPG rs10185680 2 24186957 A/G 2.93E-5 APOB
rs2474152 6 144054752 C/T 8.90E-4 PHACTR2
rs6969660 7 7619666 A/C 7.91E-5 AC006465.3
rs1904683 10 52619168 G/T 4.50E-4 PRKG1
rs9634510 13 97572905 C/T 3.09E-4 FARP1
rs1532085 15 56470658 A/G 5.58E-8 LIPC
rs878971 18 31300672 A/G 2.24E-3 INO80C
rs1948557 19 36410329 A/G 2.27E-3 TSHZ3
PC rs10185680 2 24186957 A/G 7.18E-4 APOB
rs1866852 2 191066692 C/T 7.50E-4
rs425974 4 189752867 A/C 5.21E-4 RP11-219G10
rs16871677 5 3448061 C/T 2.24E-3 IRX1
rs2474152 6 144054752 C/T 2.85E-4 PHACTR2
rs6969660 7 7619666 A/C 6.98E-5 AC006465.3
rs2270214 7 140276302 A/G 1.34E-2 MRPS33
rs1904683 10 52619168 G/T 8.30E-4 PRKG1
rs7122481 11 132467431 A/G 1.62E-4 OPCML
rs9634510 13 97572905 C/T 1.04E-3 FARP1
rs3649 15 43696596 C/T 8.78E-3 BLOC1S6
rs1532085 15 56470658 A/G 8.69E-9 LIPC
rs878971 18 31300672 A/G 1.76E-3 INO80C
rs1948557 19 36410329 A/G 1.03E-3 TSHZ3
rs3804019 21 38568806 A/C 2.15E-3 CBLB
SM rs991694 3 30677144 A/G 2.10E-3 TGFBR2
rs10511248 3 107260259 G/T 1.07E-3 CBLB
rs4723497 7 36046214 C/T 8.99E-5 EEPD1
rs878971 18 31300672 A/G 2.50E-3 INO80C
FAw3toFA rs2056387 1 234250153 A/C 6.79E-5 RYR2
rs4555301 2 29551330 A/G 6.01E-3 ALK
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rs25440 2 34413857 C/T 6.38E-3
rs614281 2 45778107 C/T 9.37E-5 PRKCE
rs2203586 2 164707177 A/G 4.85E-4 FIGN
rs1532191 3 164888628 G/T 1.43E-4
rs7628387 3 178046264 A/C 1.70E-3 TBL1XR1
rs1373947 5 13677894 A/C 4.59E-3 DNAH5
rs319003 5 41399645 C/T 1.18E-4 PLCXD3
rs3816024 5 108463913 A/G 1.49E-3 FER
rs4583918 5 144279029 A/C 5.72E-4
rs9295553 6 22650885 A/G 3.83E-5 HDGFL1
rs9373409 6 144328911 C/T 2.33E-3 PLAGL1
rs2072184 7 19522123 A/G 1.55E-5 TMEM196
rs2289496 8 98357340 A/C 3.65E-4 TSPYL5
rs11166643 8 135723522 C/T 2.14E-4 ZAAT
rs7856857 9 101529148 A/C 1.77E-2 GRIN3A
rs174546 11 61326406 C/T 1.18E-17 FADS1-3
rs10771468 12 29089014 A/G 8.62E-3 FAR2
rs1679802 14 55563670 A/G 2.64E-5 PEL12
rs3743398 15 87199411 C/T 8.16E-5 ACAN
rs30988 16 2214301 C/T 1.08E-3 E4F1
rs485018 17 72626322 A/G 1.20E-2 SEC14L1
rs2000778 18 56271952 A/G 8.63E-4 MC4R
rs736950 22 26043329 A/G 5.02E-6 MN1
FAw79StoFA rs6662607 1 67733523 C/T 1.04E-4 GADD45A
rs1260326 2 27642591 C/T 2.01E-6 GCKR
rs319003 5 41399645 C/T 1.69E-4 PLCXD3
rs2072184 7 19522123 A/G 4.74E-5 TMEM196
rs6094373 20 35402488 C/T 5.51E-4 SRC
TGtoPG rs673548 2 21149196 A/G 8.45E-1 APOB
rs1260326 2 27642591 C/T 2.00E-2 GCKR
rs4724206 7 43263377 A/G 6.73E-1 HECW1
rs10096633 8 19875201 C/T 4.61E-1 LPL
rs1044531 9 114178204 C/T 6.63E-2 CRM1
rs4573621 10 113977538 A/G 9.36E-1 GPAM
rs2543356 14 75658039 C/T 2.59E-1 GPATCH2L
rs7149330 14 89705959 A/G 1.13E-1 KCNK13
Metabolic T, each of the fifty one serum metabolites included in the analysis, Markers,
SNPs included in the best-fitting models found for each of the NMR serum metabolites
for type I error α = 10−5 and shape parameter λ = 1; Chr, Chromosome; Pos, SNPs
position at the corresponding chromosome; A1/A2, listed are 1st major allele, 2nd minor
allele; P, p-value obtained in the single-SNP analysis for each trait; Gene, the plausible
candidate gene in the locus or the nearest annotated gene to the lead SNP.
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Figure B.1: The Manhattan plots of P-values for the leading traits
obtained in the single-SNP association analysis.
(a) Total lipids in medium
VLDL
(b) Total lipids in small
VLDL
(c) Total lipids in very small
VLDL
(d) Total lipids in very large
HDL
(e) Total lipids in large HDL (f) Apolipoprotein A1
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Figure B.1: The Manhattan plots of P-values for the leading traits
obtained in the single-SNP association analysis.
(g) Apolipoprotein B (h) Citrate
(i) Creatinine (j) Total PUFA
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Figure B.2: Heatmaps displaying linkage disequilibrium (r) between
SNPs identified by the single-SNP analysis.
a) Total lipids in medium
VLDL
b) Total lipids in small
VLDL
c) Total lipids in very small
VLDL
d) Total lipids in very large
HDL
e) Total lipids in large HDL f) Apolipoprotein A1
The colour intensity reflects the amount of LD. Results are only shown for the
leading traits.
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Figure B.2: Heatmaps displaying linkage disequilibrium (r) between
SNPs identified by the single-SNP analysis.
g) Apolipoprotein B h) Citrate
i) Creatinine j) Total PUFA
The colour intensity reflects the amount of LD. Results are only shown for the
leading traits.
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Figure B.3: Heatmaps displaying linkage disequilibrium (r) between
SNPs identified by the HyperLasso regression analysis.
a) Total lipids in medium
VLDL
b) Total lipids in small
VLDL
c) Total lipids in very small
VLDL
d) Total lipids in very large
HDL
e) Total lipids in large HDL f) Apolipoprotein A1
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Figure B.3: Heatmaps displaying linkage disequilibrium (r) between
SNPs identified by the HyperLasso regression analysis.
g) Apolipoprotein B h) Citrate
i) Creatinine j) Total PUFA
The colour intensity reflects the amount of LD. Results are only shown for the
leading traits.
APPENDIX B. STATISTICAL METHODS FOR GWAS 191
Table B.2: Results of the SUR analysis of VLDL system
rs3923037 rs6728178 rs6754295 rs676210 rs673548 rs1260326 rs10096633 rs1532085
XXL-VLDL-L 0.8 0.2 0.1 0.9 1 7.50E-6 6.50E-4 0.8
XL-VLDL-L 0.4 0.2 0.2 0.8 0.7 2.50E-8 6.50E-5 0.2
L-VLDL-L 0.5 0.2 0.1 0.8 0.6 3.50E-10 1.50E-5 0.1
M-VLDL-L 0.5 0.09 0.1 0.7 0.5 2.50E-10 6.50E-7 0.2
S-VLDL-L 0.5 0.06 0.2 0.2 0.2 1.50E-6 9.50E-7 0.9
XS-VLDL-L 0.9 0.2 0.7 0.6 0.7 0.03 0.01 7.50E-8
A P-value given in bold indicates a statistically significant association between a SNP and
a metabolite measure with a threshold P < 0.05/k where k = 8 is the total n umber of
tested SNPs
Table B.3: Results of the SUR analysis of HDL system
rs166358 rs1532085 rs415799 rs16940213 rs261336 rs3764261 rs1532624 rs6065906
XL-HDL-L 0.3 6.50E-3 0.7 0.1 1.50E-6 0.5 0.01 3.50E-7
L-HDL-L 0.4 1.50E-4 0.4 0.09 7.50E-3 6.50E-4 0.1 2.50E-3
M-HDL-L 0.3 0.2 0.3 0.05 0.8 4.50E-5 0.7 4.00E-3
S-HDL-L 0.1 0.7 0.2 0.02 0.02 8.50E-3 0.5 9.50E-8
A P-value given in bold indicates a statistically significant association between a SNP and
a metabolite measure with a threshold P < 0.05/k where k = 8 is the total n umber of
tested SNPs
Table B.4: Results of the SUR analysis of metabolites involved in the
citric acid cycle
rs712964 rs1061325 rs2073740 rs885978 rs1340958
Cit 0.07 0.4 0.03 0.2 0.03
bOHBut 1 0.6 0.2 0.8 0.1
Ace 0.7 0.5 0.5 0.7 0.5
AcAce 0.8 0.4 0.2 1 0.1
A P-value given in bold indicates a statistically significant association between a SNP and
a metabolite measure with a threshold P < 0.05/k where k = 5 is the total n umber of
tested SNPs
Table B.5: Results of the SUR analysis of metabolites involved in the
urea cycle
rs16921974 rs7217872
Crea 0.2 0.06
Urea 1 0.04
A P-value given in bold indicates a statistically significant association between a SNP and
a metabolite measure with a threshold P < 0.05/k where k = 2 is the total n umber of
tested SNPs
Appendix C
Differential Networks
Table C.1: Clinical characteristic of the NFBC1966 study participants.
Clinical Traits Male
1NFG 1IFG 2P-value
Fasting glucose, mmol/L 5.01 (0.31) 5.84 (0.27) < 2.20E-16
Fasting insulin, IU/L 8.20 (3.41) 10.89 (6.71) < 2.20E-16
Body mass index, kg/m2 24.96 (3.28) 26.09 (3.92) 3.73E-7
Waist circumference, cm 88.21 (9.06) 91.33 (10.75) 4.60E-7
Hip circumference, cm 97.08 (6.17) 99.02 (6.99) 7.58E-7
Waist-to-hip ratio 0.91 (0.06) 0.92 (0.06) 1.06E-4
Systolic blood pressure, mm Hg 129.40 (12.16) 133.16 (13.55) 1.65E-6
Diastolic blood pressure, mm Hg 79.47 (11.09) 83.01 (12.18) 6.27E-8
Total cholesterol, mmol/l 5.34 (1.05) 5.52 (1.13) 8.03E-3
Triglycerides, mmol/l 1.01 (0.47) 1.09 (0.52) 9.77E-3
Low density lipoprotein cholesterol, mmol/l 2.21 (0.63) 2.30 (0.64) 8.03E-3
High density lipoprotein cholesterol, mmol/l 1.50 (0.33) 1.52 (0.33) 0.43
Clinical Traits Female
1NFG 1IFG 2P-value
Fasting glucose, mmol/L 4.83 (0.36) 5.83 (0.28) < 2.20E-16
Fasting insulin, IU/L 8.00 (3.35) 11.38 (6.73) 9.57E-14
Body mass index, kg/m2 24.07 (4.44) 27.09 (6.53) 3.29E-9
Waist circumference, cm 78.57 (11.48) 86.31 (15.53) 4.91E-11
Hip circumference, cm 97.05 (8.50) 102.08 (11.61) 7.39E-9
Waist-to-hip ratio 0.81 (0.08) 0.84 (0.10) 6.13E-8
Systolic blood pressure, mm Hg 119.27 (11.88) 125.27 (13.59) 1.22E-7
Diastolic blood pressure, mm Hg 74.44 (10.54) 78.76 (11.87) 2.13E-6
Total cholesterol, mmol/l 5.10 (1.03) 5.15 (1.10) 0.64
Triglycerides, mmol/l 0.87 (0.39) 0.97 (0.45) 0.012
Low density lipoprotein cholesterol, mmol/l 1.91 (0.57) 1.99 (0.64) 0.19
High density lipoprotein cholesterol, mmol/l 1.74 (0.36) 1.66 (0.36) 0.026
1 Data are means ± SD; 2 P-value obtained from Mann-Whitney test.
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Table C.2: Lipoprotein subclass measures and their mean concentra-
tions for normal (NFG) and impaired fasting glucose (IFG).
Lipoproteins subclass fractions Abbreviation 1NFG 2IFG 3P
Phospholipids in extremely large VLDL XXL-VLDL-PL 2.2E-3 2.7E-3 5.5E-4
Concentration in extremely large VLDL particles XXL-VLDL-P 7.3E-11 8.7E-11 0.011
Phospholipids in very large VLDL XL-VLDL-PL 0.011 0.013 2.1E-3
Triglycerides in very large VLDL XL-VLDL-TG 0.042 0.046 0.021
Concentration of very large VLDL particles XL-VLDL-P 6.6E-10 7.3E-10 9.2E-3
Cholesterol in large VLDL L-VLDL-C 0.063 0.067 0.06
Free cholesterol in large L-VLDL-FC 0.03 0.033 0.048
Phospholipids in large VLDL L-VLDL-PL 0.047 0.05 0.072
Triglycerides in large VLDL L-VLDL-TG 0.16 0.16 0.19
Cholesterol esters in large VLDL L-VLDL-CE 0.032 0.034 0.089
Concentration of large VLDL particles L-VLDL-P 4.3E-9 4.6E-9 0.12
Cholesterol in medium VLDL M-VLDL-C 0.18 0.18 0.098
Free cholesterol in medium VLDL M-VLDL-FC 0.074 0.077 0.2
Phospholipids in medium VLDL M-VLDL-PL 0.12 0.12 0.23
Triglycerides in medium VLDL M-VLDL-TG 0.28 0.29 0.52
Cholesterol esters in medium VLDL M-VLDL-CE 0.1 0.11 0.074
Concentration of medium VLDL particles M-VLDL-P 1.6E-8 1.6E-8 0.36
Cholesterol in small VLDL S-VLDL-C 0.3 0.31 0.023
Free cholesterol in small VLDL S-VLDL-FC 0.11 0.11 0.055
Phospholipids in small VLDL S-VLDL-PL 0.16 0.17 0.059
Triglycerides in small VLDL S-VLDL-TG 0.26 0.27 0.15
Concentration of small VLDL particles S-VLDL-P 3.2E-8 3.3E-8 0.072
Phospholipids in very small VLDL XS-VLDL-PL 0.15 0.16 0.072
Triglycerides in very small VLDL XS-VLDL-TG 0.12 0.12 0.044
Concentration of very small VLDL particles XS-VLDL-P 3.6E-8 3.7E-8 0.034
Free cholesterol in IDL IDL-FC 0.22 0.23 0.056
Phospholipids in IDL IDL-PL 0.32 0.33 0.034
Concentration of IDL particles IDL-P 9.7E-8 1.0E-7 0.017
Cholesterol in large LDL L-LDL-C 1.12 1.17 0.012
Free cholesterol in large LDL L-LDL-FC 0.29 0.3 0.017
Phospholipids in large LDL L-LDL-PL 0.37 0.39 9.4E-3
Cholesterol esters in large LDL L-LDL-CE 0.83 0.86 0.012
Concentration of large LDL particles L-LDL-P 1.7E-7 1.8E-7 7.3E-3
Cholesterol in medium LDL M-LDL-C 0.68 0.71 7.4E-3
Phospholipids in medium LDL M-LDL-PL 0.24 0.25 3.3E-3
Cholesterol esters in medium LDL M-LDL-CE 0.5 0.55 0.011
Concentration of medium LDL particles M-LDL-P 1.4E-7 1.5E-7 3.3E-3
Cholesterol in small LDL S-LDL-C 0.41 0.43 3.4E-3
Concentration of small LDL particles S-LDL-P 1.6E-7 1.7E-7 1.4E-3
Cholesterol in very large HDL XL-HDL-C 0.2 0.21 0.22
Continued on next page
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Table C.2 – continued from previous page
Lipoproteins subclass fractions Abbreviation 1NFG 2IFG 3P
Free cholesterol in very large HDL XL-HDL-FC 0.051 0.052 0.04
Phospholipids in very large HDL XL-HDL-PL 0.17 0.17 0.82
Triglycerides in very large HDL XL-HDL-TG 0.011 0.012 0.46
Cholesterol esters in very large HDL XL-HDL-CE 0.15 0.16 0.21
Concentration of very large HDL particles XL-HDL-P 3.0E-7 3.1E-7 0.5
Cholesterol in large HDL L-HDL-C 0.34 0.33 0.66
Free cholesterol in large HDL L-HDL-FC 0.066 0.066 0.77
Phospholipids in large HDL L-HDL-PL 0.3 0.31 0.76
Cholesterol esters in large HDL L-HDL-CE 0.27 0.27 0.63
Concentration of large HDL particles L-HDL-P 8.2E-7 8.2E-7 0.67
Cholesterol in medium HDL M-HDL-C 0.44 0.45 0.66
Free cholesterol in medium HDL M-HDL-FC 0.08 0.081 0.52
Phospholipids in medium HDL M-HDL-PL 0.37 0.38 0.48
Cholesterol esters in medium HDL M-HDL-CE 0.37 0.37 0.69
Concentration of medium HDL particles M-HDL-P 1.5E-6 1.6E-6 0.55
Triglycerides in small HDL S-HDL-TG 0.04 0.041 0.19
Concentration of small HDL particle S-HDL-P 4.4E-6 4.5E-6 0.093
Apolipoprotein A-I ApoA.I. 1.64 1.67 0.1
Apolipoprotein B ApoB. 1.04 1.08 9.8E-3
Apolipoprotein B / Apolipoprotein A-I ApoB.ApoA.I 0.64 0.65 0.12
1 Mean concentration for each 1H lipoprotein measure in males with normal fasting glucose.
2 Mean concentration for each 1H lipoprotein measure in males with impaired fasting glucose.
3 P-values obtained from Mann-Whitney test. Bold indicates significant differences in mean concentration
between the two groups for the non-corrected threshold (P < 0.01).
APPENDIX C. DIFFERENTIAL NETWORKS 195
Correlation maps using Pearson’s correlation
Figure C.1: The colour key gives the R value for the correlation between the
lipoproteins subclass components calculated for males with (a) normal fasting glu-
cose (NFG) and males with (b) impaired fasting glucose (IFG).
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Correlation maps using standard partial correlation
Figure C.2: The colour key gives the R value for the correlation between the
lipoproteins subclass components calculated for males with (a) normal fasting glu-
cose (NFG) and males with (b) impaired fasting glucose (IFG).
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Correlation maps using shrinkage partial correlation
Figure C.3: The colour key gives the R value for the correlation between the
lipoproteins subclass components calculated for males with (a) normal fasting glu-
cose (NFG) and males with (b) impaired fasting glucose (IFG).
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Differential Network:
NFG-IFG
Figure C.4: The differential network inferred from females with normal fast-
ing glucose (NFG) and impaired fasting glucose (IFG). Each of the connections
indicates a significant change in partial correlation between two lipoprotein mea-
sures across the physiological conditions. Edge colours represent how the partial
correlation between two measures has changed across the two groups.
Appendix D
GEMINi
Table D.1: Linear regression analysis in the NFBC1966 between body
mass index (BMI) and the serum metabolite measures
Metabolic measure Abbreviation Estimate (β) P
Total lipids in chylomicrons XXL-VLDL-L 38.1 3.99E-50
Total lipids in very largeVLDL XL-VLDL-L 15.4 6.39E-50
Total lipids in large VLDL L-VLDL-L 4.7 4.01E-55
Total lipids in medium VLDL M-VLDL-L 3.6 1.02E-62
Total lipids in small VLDL S-VLDL-L 5.2 3.08E-73
Total lipids in very small VLDL XS-VLDL-L 6.8 3.38E-50
Total lipids in IDL IDL-L 2.7 1.28E-37
Total lipids in large LDL L-LDL-L 2.2 3.74E-41
Total lipids in medium LDL M-LDL-L 3.8 2.24E-49
Total lipids in small LDL S-LDL-L 6.7 4.80E-64
Total lipids in very large HDL XL-HDL-L -2.6 5.37E-14
Total lipids in large HDL L-HDL-L -2.9 5.80E-53
Total lipids in medium HDL M-HDL-L -1.3 3.03E-7
Total lipids in small HDL S-HDL-L 1.6 3.26E-5
Apolipoprotein A-I ApoA1 -1 6.83E-4
Apolipoprotein B ApoB 5.4 1.04E-63
Mean diameter for VLDL particles VLDL-D 0.8 4.13E-47
Mean diameter for LDL particles LDL-D -3.2 7.92E-14
Mean diameter for HDL particles HDL-D -5.2 1.04E-58
3-hydroxybutyrate bOHBut -1 0.1
Acetate Ace -7.1 0.03
Acetoacetate AcAce -0.8 0.62
Alanine Ala 8.5 9.29E-21
Citrate Cit -11.1 2.84E-3
Creatinine Crea -6.6 0.16
Glucose Glc 0.5 7.12E-10
Glutamine Gln -2.9 8.67E-5
Glycerol Glol 30.8 4.70E-52
Glycoprotein acetyls Gp 4.5 2.19E-60
Histidine His 18.9 5.99E-4
Continued on next page
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Table D.1 – continued from previous page
Metabolic measure Abbreviation Estimate (β) P
Isoleucine Ile 89 2.61E-82
Lactate Lac 1 4.30E-12
Leucine Leu 64.9 2.76E-67
Phenylalanine Phe 96.5 5.27E-93
Pyruvate Pyr 17.4 5.57E-11
Tyrosine Tyr 90.4 6.87E-54
Urea Urea 1.8 0.5
Valine Val 24.7 6.38E-54
A P-value given in bold indicates a statistically significant association between BMI and a metabolite
measure with a Bonferroni corrected threshold, p < 0.01/M , where M = 38 is the total number of
metabolites included in the analyses. Estimate (β), estimate BMI effect size.
Table D.2: Linear regression analysis in the NFBC1986 between body
mass index (BMI) and the serum metabolite measures
Metabolic measure Abbreviation Estimate (β) P
Total lipids in chylomicrons XXL-VLDL-L 51.22 1.58E-79
Total lipids in very large VLDL XL-VLDL-L 20.21 4.58E-88
Total lipids in large VLDL L-VLDL-L 6.02 2.58E-93
Total lipids in medium VLDL M-VLDL-L 4.44 1.72E-100
Total lipids in small VLDL S-VLDL-L 6.09 1.89E-102
Total lipids in very small VLDL XS-VLDL-L 7.01 2.01E-53
Total lipids in IDL IDL-L 2.78 9.22E-38
Total lipids in large LDL L-LDL-L 2.36 4.28E-44
Total lipids in medium LDL M-LDL-L 4.16 1.36E-52
Total lipids in small LDL S-LDL-L 6.96 1.99E-63
Total lipids in very large HDL XL-HDL-L -4.46 3.73E-57
Total lipids in large HDL L-HDL-L -3.13 5.21E-69
Total lipids in medium HDL M-HDL-L 0.55 0.046
Total lipids in small HDL S-HDL-L 4.42 5.13E-30
Apolipoprotein A-I ApoA1 -0.91 3.16E-4
Apolipoprotein B ApoB 5.88 2.15E-87
Mean diameter for VLDL particles VLDL-D 0.56 1.22E-45
Mean diameter for LDL particles LDL-D -1.66 5.74E-9
Mean diameter for HDL particles HDL-D -4.84 1.41E-94
3-hydroxybutyrate bOHBut -7.30E-6 1.05E-6
Acetate Ace -6.86E-5 1.29E-5
Acetoacetate AcAce -1.17E-5 1.31E-3
Alanine Ala 1.79E-5 2.68E-12
Citrate Cit -6.18E-5 1.15E-23
Creatinine Crea 7.11E-5 2.62E-5
Glucose Glc 1.69E-6 0.024
Glutamine Gln -1.26E-5 8.36E-8
Glycerol Glol 4.09E-5 8.24E-13
Glycoprotein acetyls Gp 1.46E-5 9.63E-82
Continued on next page
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Table D.2 – continued from previous page
Metabolic measure Abbreviation Estimate (β) P
Histidine His 1.16E-4 1.02E-11
Isoleucine Ile 2.16E-4 9.12E-65
Lactate Lac -2.17E-6 8.56E-4
Leucine Leu 1.67E-4 1.74E-60
Phenylalanine Phe 2.88E-4 2.43E-85
Pyruvate Pyr 3.44E-5 5.38E-5
Tyrosine Tyr 2.24E-4 5.24E-51
Urea Urea -9.39E-6 0.18
Valine Val 5.17E-5 5.84E-32
A P-value given in bold indicates a statistically significant association between BMI and a metabolite
measure with a Bonferroni corrected threshold, p < 0.01/M , where M = 38 is the total number of
metabolites included in the analyses. Estimate (β), estimate BMI effect size.
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Figure D.1: Differential network analysis for serum metabolites inferred
from normal and obese individuals. (a) Differential Network inferred from
NFBC1966; (b) differential network inferred from NFBC1986; (c) Replicated dif-
ferential connection between NFBC1966 and NFBC1986 differential networks. In-
dividuals are classified using body mass index (BMI) definitions.
Appendix E
Variance and Covariance Regres-
sion
Table E.1: Connectivity of the correlation networks.
Metabolites k0.2 k0.3 k0.4 k0.5 k0.6 k0.7 k0.8
4-deoxyerythronic.acid 3 5 5 5 5 5 4
3-hydroxyisovalerate 6 9 8 7 6 6 6
lactate 3 7 7 6 5 4 4
alanine 4 6 6 8 10 10 9
acetate 3 5 5 4 2 0 0
pyruvate 4 4 4 3 3 3 3
succinate 5 5 3 3 3 2 2
citrate 5 4 4 3 4 4 3
dimethylamine 6 8 8 8 8 6 5
trimethylamine 1 4 4 3 3 3 3
dimethylgycine 7 7 6 3 3 3 2
creatine 1 0 0 0 1 1 1
creatinine 5 4 4 4 4 4 5
Proline.betaine 3 2 3 6 6 6 6
P.cresol.sulphate 5 4 3 4 4 3 3
phenylacetylglutamine 4 5 5 5 5 4 4
hippurate 6 7 8 3 1 2 2
N.methyl.nicotinic.acid 4 4 2 3 3 3 2
TMAO 3 6 6 5 5 5 4
glycine 6 8 7 5 5 4 4
urea 5 7 7 5 5 1 1
formate 5 3 1 3 3 3 3
Total Connectivity 94 114 106 96 94 82 76
k; connectivity for each of correlation networks under seven different concentrations of
urinary cadmium (U-Cd (nmol/mmol creatinine)= 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8)
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